hERG K⁺ CHANNELS: STRUCTURE, FUNCTION, AND CLINICAL SIGNIFICANCE

Jamie I. Vandenberg, Matthew D. Perry, Mark J. Perrin, Stefan A. Mann, Ying Ke, and Adam P. Hill

Mark Cowley Lidwill Research Programme in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia; St Vincent’s Clinical School, University of New South Wales, New South Wales, Australia; and University of Ottawa Heart Institute, Ottawa, Canada

I. INTRODUCTION

A. The Kv11.1 Channel

The human ether-a-go-go related gene (hERG) encodes the pore-forming subunit of a delayed rectifier voltage-gated K⁺ (VGK) channel. These channels are variously referred to as Iₖᵣ, hERG, or Kv11.1 (233). In this review, KCNH2, the official name for the human ether-a-go-go related gene, is used when referring to the gene, KCNH2 when referring to the mRNA, hERG when referring to the channel protein, Kv11.1 when referring to the fully assembled channels studied in heterologous expression systems, and Iₖᵣ when discussing the native channel. HERG is a member of one of the three subfamilies of the ether-a-go-go family of VGK channels (ether-a-go-go, Kv10.x; ether-a-go-go related, Kv11.x; and ether-a-go-go like, Kv12.x). Within the family of Kv11.x, there are three members, Kv11.1 (hERG), Kv11.2 (hERG2), and Kv11.3 (hERG3), but only Kv11.1 is discussed in this review.

The family name “ether-á-go-go” was coined by Kaplan and Trout in 1969 (314) and was intended as a humorous reference to how the legs of mutant flies shake under ether anesthesia like the go-go dancers of the 1960s (Ganetzky, personal communication). It should be pointed out though, that hERG itself is the human ortholog of a different protein, which is encoded by the sei (seizure) locus (636, 673).

KCNH2 was first cloned in 1994, by Warmke and Ganetzky, by screening a human hippocampal cDNA library with a mouse homolog of the Drosophila “ether-à-go-go” (EAG) K⁺ channel gene (678). KCNH2 was shown to be located on chromosome 7, and analysis of the sequence revealed that it shared features with both VGK channels as well as cyclic nucleotide-gated (CNG) channels. Shortly thereafter, the Keating laboratory identified mutations in KCNH2 as the basis of chromosome 7-associated long QT syndrome (now referred to as LQTS type 2) (132). Later in that year, Trudeau et al. (643) and Sanguinetti et al. (547) showed that Kv11.1 channels pass the rapid compo
ment of the delayed rectified K\(^+\) current \(I_{Kr}\) and that these channels were the molecular target for class III antiarrhythmic drugs.

**B. Historical Overview**

Just over 40 years ago, in back-to-back papers in the Journal of Physiology, Tsien and Noble (448, 449) demonstrated that there were two kinetically distinct components of the delayed rectifier K\(^+\) current in cardiac myocytes, which they termed \(I_{x1}\) (now referred to as the rapid delayed rectifier, \(I_{Kr}\)) and \(I_{x2}\) (now referred to as the slow delayed rectifier, \(I_{Ks}\)). In the original description, the currents \(I_{x1}\) and \(I_{x2}\) were shown to be carried largely by K\(^+\), but as the reversal potentials were more positive than \(E_{K}\), the authors concluded that they may also have a small conductance for other ions and hence used the term \(x\), rather than K. This work was controversial at the time (442) and was not fully accepted until identification of the genes encoding these separate conductances were discovered in the mid 1990s (51, 546, 547, 643, 678). It is salient to review the key features of \(I_{Kr}\) as identified by Tsien and Noble over 40 years ago. The two components of \(I_{Kr}\) were separated on the basis of kinetic properties using an envelope of tails protocol (448), which is still a key protocol used for measuring rates of activation of \(I_{Kr}/Kv11.1\) channels (see sect. IVD). Second, they showed that the rapid component exhibited inward rectification (discussed in detail in sect. IV). Third, they suggested that these two current components were sufficient to account for cardiac repolarization (449).

In the subsequent two decades, numerous groups confirmed the presence of the rapid component of the delayed rectifier K\(^+\) conductance in a range of cardiac preparations (145, 271, 450, 460, 572). The most notable finding among these studies was that of Shibasaki (572) who observed an initial “hook” during deactivation current recordings of the rabbit sinoatrial node cell. He correctly surmised that “a fraction of \(I_{Kr}\) is partially inactivated during the depolarization, and on hyperpolarization this inactivation is removed with a fast time course, which gives rise to a ‘hook’.” This hook current is one of the most characteristic features of \(I_{Kr}\) and \(Kv11.1\) channels and was subsequently shown to be due to a rapid voltage-dependent inactivation process (see sect. IVC).

In the early 1990s, Sanguinetti and Jurkiewicz (548) showed that the two delayed rectifier K\(^+\) currents could be separated pharmacologically. In particular, they noted that class III antiarrhythmic drugs (which were being vigorously pursued in the pharmaceutical industry at the time) acted on the rapid component, which they termed \(I_{Kr}\). Subsequently, a wide range of drugs, from every therapeutic class, have been shown to inhibit \(I_{Kr}\) channels (see sect. V). Sanguinetti and Jurkiewicz also showed that whereas the slow component, \(I_{Ks}\), was highly sensitive to activation by \(\beta\)-adrenergic stimulation, the \(I_{Kr}\) component appeared to be insensitive to \(\beta\)-adrenergic stimulation (549). This has profound implications for the differences in arrhythmogenic triggers in patients with defects in \(I_{Kr}\) versus \(I_{Ks}\) (see sect. VII).

The cloning of \(KCNH2\) in 1994 (678), and demonstration that it underlies chromosome 7-associated long QT syndrome (LQTS type 2) (132) and that its gene product, the \(Kv11.1\) channel, is the molecular target for the vast majority of drugs that cause drug-induced arrhythmias (547), led to a huge increase in interest in \(Kv11.1\) channels. In the last 16 years, a plethora of studies investigating the biogenesis (see sect. III), molecular and structural basis of gating (see sect. IV), pharmacology (see sect. V), and regulation (see sect. VI) have contributed to a better understanding of the clinical importance of inherited mutations in \(KCNH2\) (see sects. VII and IX) as well as the molecular basis of drug-induced QT prolongation (sect. VIII). Whilst the role of \(Kv11.1\) channels has been most extensively investigated in the heart, they are also expressed in numerous other tissues (see sect. X) and recently have been implicated in the pathogenesis of schizophrenia (279).

**II. GENOMIC AND PROTEIN STRUCTURE**

**A. KCNH2 gene**

The human \(KCNH2\) gene spans ~33 kb of region q36.1 on chromosome 7 (accession no. NG_008916). It is read in the reverse strand, and the major transcript \(KCNH2\)–1a (accession no. NM_000238.3) contains 15 exons (see FIGURE 2) (285). The gene contains two additional transcription start

![Figure 1](http://physrev.physiology.org/)

**FIGURE 1.** First recording of hooked tail currents recorded from rabbit sinoatrial nodal cell. Top panel: voltage protocol. Bottom panel: current traces. An expanded version of the tail current recorded at -73 mV (in presence of symmetrical 150 mM K\(^+\)) is shown in the inset at the bottom and clearly illustrates the “hooked” appearance characteristic of \(I_{Kr}/Kv11.1\) currents. [From Shibasaki (572), copyright John Wiley and Sons Ltd.]
sites. KCNH2–1b (accession no. NM_172057) has a transcription start site in intron 5, resulting in a transcript missing the first five exons of KCNH2–1a and containing an alternative exon 5b (358, 383). KCNH2–1b is identical to KCNH2–1a from exon 6 onwards. KCNH2–1c (accession no. FJ938021; sometimes referred to as KCNH2–3.1) has a transcription start site in intron 2 of KCNH2–1a. It is missing the first two exons of KCNH2–1a and has an additional six amino acids at the 5′ end of exon 3 but thereafter is identical to KCNH2–1a (279). In addition to the stop codon in exon 15 of KCNH2–1a, exon 9 may be translated for an additional 88 unique amino acids followed by a 3′ UTR within intron 9 of the KCNH2–1a transcript. Transcripts with this premature COOH-terminal truncation are sometimes referred to as hERGUSO (338).

The dbSNP build 132 of the human genome on the UCSC genome browser (http://genome.ucsc.edu) lists 251 single nucleotide polymorphisms (SNPs; where the minor allele frequency is ≥1%). This includes 32 SNPs in coding regions (15 synonymous and 17 nonsynonymous), 9 SNPs in untranslated regions, and the remainder in introns. The two SNPs that appear to have the strongest connection to (patho)physiological phenotypes are rs1805123 in exon 11 and rs1036145 in intron 2. The minor allele in rs1805123 results in residue 897 changing from lysine to threonine (K897T) and has been identified in genome-wide association studies as a significant determinant of QT interval duration (126, 374, 397, 444, 496). The minor allele in SNP rs1036145 is significantly correlated with expression of the KCNH2–1c isoform, which is correlated with development of schizophrenia (279).

**B. hERG Protein**

The KCNH2–1a transcript gives rise to a 1,159-amino acid protein (hERG) that is a member of the superfamily of VGK channels (678). It contains six transmembrane segments (S1–S6) with S1–S4 contributing to the voltage sensor domain (VSD) and S5–S6 along with the intervening pore loop contributing to the pore domain (see **FIGURE 3**). The functional channel is a tetramer with the pore domain from each of the four subunits lining the central ion conduction pathway. In addition to the membrane-spanning region, the hERG protein contains large cytoplasmic NH2-terminal and COOH-terminal domains. The NH2 terminus contains a Per-Arnt-Sim (PAS) domain (425) that defines the *ether-a-go-go* subfamily of VGK channels (678). The COOH terminus contains a cyclic nucleotide binding domain (cNBD), which shares homology with the cNBD of CNG channels and hyperpolarization activated channels (HCN). Overall, hERG channels share a greater degree of homology with CNG and HCN channels than with other VGK channels (even when just the pore regions are considered; see **FIGURE 4**) (678).

In vertebrate genomes there is a significant correlation between exon boundaries and protein domains (379). Within the KCNH2 gene, exon 1 encodes the 5′ UTR and first 26 residues, which play a significant role in regulating deactivation kinetics of the channel (see sect. IV F). Exons 2 and 3 encompass the PAS domain. Exon 6 encodes the last portion of the cytoplasmic NH2 terminus and first three TM segments. Exon 7 encodes the fourth TM segment, i.e., the segment containing the positive charges that are thought to act as the principal voltage-sensing region within the VSD (see sect. IV E), along with the majority of the pore domain. It is notable that the exon 7/8 boundary occurs at a glycine residue (Gly648 in hERG) that is one of the most highly conserved residues in all K+ channels (296) and defines the boundary between the upper and lower halves of the pore cavity. Exons 8–10 encode the c-linker and cNBD domains, while the remaining five exons encode the distal COOH-terminal domain.
Based on sequence homology to potassium and cyclic nucleotide-gated channels with known structures, numerous homology models of the Kv11.1 channel have been constructed (304, 343, 591, 603, 628, 646, 705). The homology models have usually included only the pore domain regions, with the focus being on structural basis of ion permeation or drug binding. Invariably, these models have left out the extracellular S5P linker, as this linker is considerably longer in Kv11.1 channels (~40 amino acids) than it is in other K⁺ channels (typically 12–15 amino acids; Refs. 378, 641), so there is no good template to use for constructing homology models in this region. In addition, some models have not included the outer helix, S5 (591), as the homology between Kv11.1 and other VGK channels is so low in this domain (304). Of course, the other major omission from published homology models are the cytoplasmic domains. There are atomic resolution structures available for the cytoplasmic NH₂-terminal PAS domain of Kv11.1 channels (residues 1–135; Refs. 367, 425, 431, 445). In addition, there is sufficient sequence homology between Kv11.1 and the murine HCN2 channel (707) and the zebrafish ELK channel (75) in the c-linker and cNBD domains for us to be confident that Kv11.1 will have a similar structure to that for mHCN2 and zELK in this region (11, 431). It should be noted though that the functional roles of the domains are likely to be very different between Kv11.1 and HCN channels (see sect. VI B). As with the pore domain models, it is very likely that the central core of the cytoplasmic assembly will resemble that of the HCN2 channel, but the precise relationship between the PAS domain and C-linker/cNBD remains to be determined. Furthermore, there is no information available with regard to the structure of the proximal NH₂-terminal and distal COOH-terminal domains of Kv11.1 channels. While it is very likely that the structure of Kv11.1 will be broadly similar to that of other VGK and CNG channels, it is the subtle differences that distinguish Kv11.1 from other VGK channel structures that will be most illuminating with respect to understanding the unique properties of Kv11.1, and in this regard, there is very little known.

C. Kv11.1 Channels

KCNH2 encodes the pore-forming subunit of a K⁺-selective voltage-gated ion channel, Kv11.1, which passes the rapid component of the delayed rectifier K⁺ current, I_{Kr} (547, 643). Within the critical five central residues of the selectivity filter region, Kv11.1 channels are highly homologous to canonical K⁺ channels, and Kv11.1 channels have high selectivity for K⁺ over Na⁺ (p_{KNa} > 100:1) (547, 643), comparable to that observed in a range of other K⁺ channels (257). In contrast, CNG and HCN channels do not contain the consensus sequence for K⁺-selective channels (T/S-V/I/L-G/F/Y-G) and so are not K⁺ selective, making them functionally quite different from Kv11.1 channels.
Kv11.1 channels can exist in closed, open, or inactivated states (see FIGURE 5). Like other voltage-gated K\(^+\) channels, they contain multiple positive charges in the S4 domain and this acts as the primary voltage sensor for channel opening (500, 601, 720). The inactivation process of Kv11.1 channels, however, exhibits a number of unusual features. Most notably, the kinetics of inactivation are much more rapid than the kinetics of activation (558, 583, 588), and second, the inactivation process is voltage-dependent (547, 583, 643), although whether inactivation is intrinsically voltage-dependent or derives its voltage-dependence from coupling to activation is unresolved (see sect. IVG). This unique combination of properties underlies the physiological role \(I_{Kr}\) plays in cardiac repolarization (see below). The molecular and structural bases of the unusual gating kinetics of Kv11.1 channels are discussed in detail in section IV.

D. Physiological Role of \(I_{Kr}\)

\(I_{Kr}\) channels are expressed in a wide range of tissues, but their physiological function is best characterized in cardiac cells. The slow activation and deactivation kinetics, coupled to rapid voltage-dependent inactivation and recovery from inactivation (see sect. IV for more detail of gating), makes the current passed through \(I_{Kr}\) channels ideally suited for determining the duration of the plateau phase of the action potential (AP) in atrial and ventricular myocytes (550, 583). Maintenance of this plateau is crucial for ensuring there is sufficient time for calcium release from the sarcoplasmic reticulum to enable cardiac contraction. As repolarization begins, \(I_{Kr}\) channels recover from inactivation, thereby passing more current and hastening repolarization, leading to greater recovery from inactivation (see FIGURE 5C). This positive feedback loop ensures that repolarization is relatively rapid and robust. During terminal repolarization, \(I_{Kr}\) channels close slowly and so remain open for a substantial period after the membrane potential has returned to the resting (diastolic) level. As the resting membrane potential is close to the potassium reversal potential, there is little current flow through Kv11.1 channels in the early diastolic period, but they still contribute to the relative refractoriness of cardiac cells immediately following completion of repolarization. If a premature beat occurs during the early diastolic interval, there will be a large increase in \(I_{Kr}\) that will antagonize the depolarization of the cell (390, 583) (see FIGURE 5C). Conversely, in clinical scenarios where \(I_{Kr}\) is reduced, due to loss-of-function mutations (sect. VII) or drug block (sect. VIII), patients are more prone to arrhythmias initiated by premature beats (58) (see FIGURE 6).

\(I_{Kr}\) also contributes to pacemaking activity in sinoatrial (SA) and atrioventricular node cells (109, 191, 421, 652, 692). In SA node cells, \(I_{Kr}\) reaches maximum levels approximately midway through the repolarization phase (421). The slow deactivation and decay of \(I_{Kr}\) after the AP also contributes to diastolic depolarization. Thus inhibition of \(I_{Kr}\) leads to slowing of SA node cell firing. This has been demonstrated in isolated cells (109, 361, 462), intact nodes (652), and whole hearts (191). Whilst \(I_{Kr}\) is not classically considered a “pacemaker” current, Kurata et al. (341) have aptly described it as an oscillation amplifier and frequency stabilizer.

**FIGURE 4.** Cladogram of voltage-gated K\(^+\) channel superfamily. Sequences were aligned on the pore domain region, using ClustalW. Canonical voltage-gated K\(^+\) channels are shown in red, EAG family in black, and CNG/HCN family in blue.
Extra-cardiac roles for $I_{Kr}$ include spike-frequency adaptation and regulation of burst duration in neurons (see sect. XB) as well as regulation of resting membrane potential and AP firing frequency in smooth muscle (sect. XC) and endocrine cells (see sect. XD). $I_{Kr}$ channels are also upregulated in a number of tumor cell lines where they are postulated to contribute to cell proliferation (sect. XD).

III. BIOGENESIS AND TRAFFICKING OF Kv11.1 CHANNELS

As with other polytopic membrane proteins, the vast majority of mutations in KCNH2 result in defects in biogenesis (544). Consequently, there has been considerable interest in understanding the biogenesis of Kv11.1 channels. Defects in biogenesis may occur at the level of mRNA processing (716), mRNA stability (218), or protein folding and trafficking (19, 176, 733). Indeed, only a small proportion of the over 459 putative mutants identified to date result in channels that have normal biogenesis but then have abnormal function. There has been a particular focus on understanding channel trafficking with the hope that in some cases at least the defective trafficking properties of mutant channels can be rescued by pharmacological chaperones (522).

Like other proteins destined for the plasma membrane, KCNH2 mRNA is processed in the nucleus and the channel subunits then synthesized in the endoplasmic reticulum (ER). The nascent polypeptide chains fold and assemble into a tetramer within the ER before being exported to the Golgi apparatus where the channels undergo complex glycosylation before being trafficked to the plasma membrane. Mature channels are transported to the plasma membrane in COPII coated vesicles (140) and remain at the plasma membrane with a half-life of ~10 h (176, 216, 656) (see FIGURE 7). Whilst there is less known about the degradation of hERG, mature tetrameric channels are likely internalized in endocytic vesicles, tagged with ubiquitin and then degraded in lysosomes (227). In addition to degradation of the mature protein, any protein subunits that do not fold prop-
Many of the studies of hERG protein trafficking have leaned very heavily on what has been learned from the very extensive studies of trafficking of CFTR (332, 520). There is, however, one very important difference between Kv11.1 and CFTR channels. Kv11.1 channel subunits must coassemble as tetramers to function, whereas CFTR functions as a monomer. This adds a very important clinical dimension as mutations in Kv11.1 can result in haploinsufficiency (loss of 50% of channel function) or a dominant negative phenotype if the presence of any abnormal subunits in a tetrameric channel results in abnormal trafficking of the entire channel and hence degradation of both the normal and abnormal subunits (175, 310, 728).

**FIGURE 6.** Holter recording from a patient with congenital long QT syndrome during an episode of ventricular arrhythmia that spontaneously reverted. The highlighted regions show (i) the bifid or notched T-wave (*), characteristic of patients with long QT syndrome type 2, and (ii) the arrhythmia episode is initiated by a premature beat (†). [From Benhorin and Medina (58), copyright The Massachusetts Medical Society.]
There are numerous comprehensive reviews of general mechanisms of protein biogenesis (see, e.g., Refs. 142, 287, 537). Here, the focus is on those aspects of biogenesis as they relate to Kv11.1 channels and the mechanisms by which mutations in KCNH2 result in channels not reaching the plasma membrane.

### A. mRNA Biogenesis

#### 1. mRNA transcription

There are at least three alternative transcription start sites for KCNH2 (see sect. II.A). These encode transcripts referred to as KCNH2–1a (the predominant transcript expressed in the heart), KCNH2–1b (also expressed in the heart), and KCNH2–3.1 (more highly expressed in neuronal tissues). Relatively little is known about how KCNH2 transcription is regulated, but clearly it must be, as levels of KCNH2 transcripts are spatially and temporally distinct (see sect. III.F).

#### 2. mRNA splicing

The mature KCNH2–1a isoform contains 15 exons. KCNH2–1b lacks the first five exons of KCNH2–1a but contains the final 10 exons along with an additional exon 1b. KCNH2–3.1 lacks exons 1 and 2 and has an extended exon 3 (at the 5’ end), resulting in a total of 13 exons (see FIGURE 2). At least 12 KCNH2 mutations that are predicted...
to have an effect on splice acceptor or donor sites have been identified (315), (http://www.fsm.it/cardmoc/). In four cases, in vitro studies have confirmed that the mutations result in abnormally spliced mRNA (125, 217, 598, 716). Such splice site mutations invariably lead to frameshifts and/or premature termination. These findings also highlight the importance of screening the 5’ and 3’ ends of introns as well as exons when screening for mutations in clinical populations. An additional trap to be aware of when designing primers for detecting mutations is that the presence of intronic polymorphisms in the sites covered by primers can result in failure of the primers to bind, leading to allelic dropout and failure to detect mutations in the affected exon (626).

3. mRNA decay

The steady-state level of KCNH2 mRNA is influenced by rates of transcription and stability. From a clinical perspective, the major interest in KCNH2 mRNA stability relates to the role of nonsense mediated mRNA decay (NMD) in patients with mutations that result in premature termination codons, which is almost always the case with frameshift mutations as well as with deletions and insertions (68). Proteins involved in the exon junction complex that determine splicing also play a critical role in quality control of mRNA transcripts including detection of premature termination codons. A premature termination codon that occurs more than ~50 nucleotides upstream of an exon-exon boundary will undergo NMD. The exon junction protein complex cannot accurately scan the last 50 nucleotides of an exon (629, 713, 714) so premature termination codons in the last 50 bp of an exon may escape NMD. NMD protects the cell from production of proteins that would either be nonfunctional or, worse still, cause dominant negative effects. In the case of KCNH2, NMD of mutant transcripts would result in 50% loss of function, which is, however, still sufficient to reduce \( I_{Ks} \) function and hence cause clinical LQTS. NMD has been documented for a number of KCNH2 mutations including Q1078X (67), Y652X (609), W1001X and R1014X (218), and P926AfsX14 (708), but it is likely to occur in ~30% of mutations in this gene (see sect. VII).

B. Protein Biogenesis

1. Protein synthesis

When the mRNA reaches the cytosol, it associates with ribosomes where translation is initiated. Once a transmembrane signal sequence is recognized, the RNA/ribosome/polypeptide complex is targeted to the ER where it engages the translocation machinery and the transmembrane segment is translocated across the ER membrane (see FIGURE 7). The specific steps involved have been much more extensively studied for canonical VGK channels (142), but it is likely that the same processes are involved in biogenesis of Kv11.1 channels.

2. Protein folding and trafficking

Folding of the nascent hERG polypeptide is assisted by molecular chaperones (176, 439, 655, 656) that reside in the ER or cytoplasm (see TABLE 1). Folding intermediates are recognized and associated with chaperones, which prevent protein misfolding by binding to exposed hydrophobic residues that typically become buried in the correctly folded structure. Chaperones will remain bound until the channel achieves its native structure. The corollary of this is that mutant channels that do not fold correctly will remain bound to chaperones for much longer and this is indeed the case for trafficking defective hERG mutant proteins (176, 674).

Protein trafficking through the ER is tightly regulated (651). In general, proteins contain motifs that promote export, as well as motifs that if exposed are indicative of misfolded proteins and result in the misfolded protein being retained in the ER or returned to the ER if it manages to escape. Thus trafficking undergoes both positive and negative regulation. The best characterized motif for ER retention is the Arg-X-Arg (RXR) motif (710) and for ER export is the diacidic export motif (413). HERG contains multiple RXR motifs. Not all of the hERG RXR motifs have been characterized, but those that have [including the RXR motif at residues 1005–1007 in hERG-1a (340) and the RXR motif at residues 15–17 in hERG-1b (301, 495)] play classical roles in ER retention. From this, one can presume that these motifs are normally hidden in correctly folded proteins but provide a quality checkpoint for detecting locally misfolded protein structure. There are no specific studies of the role of the numerous diacidic motifs in hERG, but it is reasonable to presume that they will contribute to ensuring that only correctly folded proteins are exported from the ER.

3. Glycosylation

Once the proteins are correctly folded, the chaperones dissociate and the channels can be trafficked to the Golgi apparatus where they undergo higher order glycosylation before being trafficked to the plasma membrane. The core-glycosylated hERG protein has a molecular mass of ~135 kDa and is sensitive to deglycosylation by Endo H (214, 733). An additional ~20 kDa of complex glycosylation is added in the Golgi resulting in an ~155 kDa band, which is sensitive to PNGase treatment (10, 216). HERG contains two putative N-linked glycosylation sites in the extracellular region, Asn598 and Asn629 (492). Further studies using site-directed mutagenesis revealed that Asn598 is the only site required for N-linked glyco-
Abolishing glycosylation does not prevent trafficking to the cell membrane, but it decreases the stability of hERG protein at the plasma membrane (214). Conversely, mutation of Asn629 causes a trafficking defect, and the mutant protein is retained in the ER (214). The molecular weight difference between the fully glycosylated mature protein and core-glycosylated immature protein provides a very convenient assay for determining whether mutations result in misfolding, i.e., misfolded proteins do not reach the Golgi and so only give rise to the smaller 135-kDa band (192, 733). Simple western blot assays also provide a convenient means of determining whether mutant channels exhibit a dominant negative effect on wild-type channels (175, 310, 728). By including separate antibody epitopes on the wild-type and mutant channels, one can detect individual subunits separately after coexpression experiments, to determine whether wild-type channels get trapped in the ER and/or whether mutant channels can be rescued. The majority of KCNH2 missense mutations that have been studied to date result in defective trafficking (19). The study from Anderson and colleagues (19) predominantly involved mutants occurring in the transmembrane regions (28 of the 34 mutants studied). There are, however, numerous studies of mutations in

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsp70</td>
<td>Cytosolic</td>
<td>Promoter trafficking WT hERG, retain mutants 176, 366</td>
<td></td>
</tr>
<tr>
<td>Hsc70</td>
<td>Cytosolic</td>
<td>176, 655</td>
<td></td>
</tr>
<tr>
<td>Hsp90</td>
<td>Cytosolic</td>
<td>Increase trafficking of WT hERG, retain mutants 176, 655</td>
<td></td>
</tr>
<tr>
<td>Calnexin</td>
<td>ER membrane</td>
<td>Retention of misfolded hERG 215, 655</td>
<td></td>
</tr>
<tr>
<td>Grp78</td>
<td>ER membrane</td>
<td>ER stress/unfolded protein response 319</td>
<td></td>
</tr>
<tr>
<td>Grp94</td>
<td>ER membrane</td>
<td>ER stress/unfolded protein response 319</td>
<td></td>
</tr>
<tr>
<td>Calrecticulin</td>
<td>ER membrane</td>
<td>ER stress/unfolded protein response 319</td>
<td></td>
</tr>
<tr>
<td>Hsp-organizing protein</td>
<td>Cytosolic</td>
<td>655</td>
<td></td>
</tr>
<tr>
<td>Sigma 1 receptor</td>
<td>ER membrane</td>
<td>Enhance herg maturation and stability 124</td>
<td></td>
</tr>
<tr>
<td>Bag-2</td>
<td>Cytosolic</td>
<td>Binds and inhibits Hsc70 ATPase domain 655</td>
<td></td>
</tr>
</tbody>
</table>

### Chaperones

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsp70</td>
<td>Cytosolic</td>
<td>Promoter trafficking WT hERG, retain mutants 176, 366</td>
<td></td>
</tr>
<tr>
<td>Hsc70</td>
<td>Cytosolic</td>
<td>176, 655</td>
<td></td>
</tr>
<tr>
<td>Hsp90</td>
<td>Cytosolic</td>
<td>Increase trafficking of WT hERG, retain mutants 176, 655</td>
<td></td>
</tr>
<tr>
<td>Calnexin</td>
<td>ER membrane</td>
<td>Retention of misfolded hERG 215, 655</td>
<td></td>
</tr>
<tr>
<td>Grp78</td>
<td>ER membrane</td>
<td>ER stress/unfolded protein response 319</td>
<td></td>
</tr>
<tr>
<td>Grp94</td>
<td>ER membrane</td>
<td>ER stress/unfolded protein response 319</td>
<td></td>
</tr>
<tr>
<td>Calrecticulin</td>
<td>ER membrane</td>
<td>ER stress/unfolded protein response 319</td>
<td></td>
</tr>
<tr>
<td>Hsp-organizing protein</td>
<td>Cytosolic</td>
<td>655</td>
<td></td>
</tr>
<tr>
<td>Sigma 1 receptor</td>
<td>ER membrane</td>
<td>Enhance herg maturation and stability 124</td>
<td></td>
</tr>
<tr>
<td>Bag-2</td>
<td>Cytosolic</td>
<td>Binds and inhibits Hsc70 ATPase domain 655</td>
<td></td>
</tr>
</tbody>
</table>

### Cochaperones

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>DnaJA-1/2/4</td>
<td>Cytosolic</td>
<td>Quality control, modulates herg degradation 655, 656</td>
<td></td>
</tr>
<tr>
<td>FKBP38</td>
<td>ER membrane</td>
<td>Quality control, folding and export 655</td>
<td></td>
</tr>
<tr>
<td>KCNE1</td>
<td>ER/plasma membrane</td>
<td>Modulates Kv11.1 current 405</td>
<td></td>
</tr>
<tr>
<td>KCNE2</td>
<td>ER/plasma membrane</td>
<td>Modulates Kv11.1 current 1</td>
<td></td>
</tr>
<tr>
<td>KCNQ1</td>
<td>ER/plasma membrane</td>
<td>Modulates Kv11.1 current 161, 250, 516</td>
<td></td>
</tr>
</tbody>
</table>

### ER export/endosomal recycling

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sar1</td>
<td>ER, cytosolic, plasma membrane</td>
<td>Regulates ER export of hERG 140</td>
<td></td>
</tr>
<tr>
<td>Rab11B</td>
<td>ER, Golgi, plasma membrane</td>
<td>Golgi processing of herg 140</td>
<td></td>
</tr>
</tbody>
</table>

### Ubiquitination/deubiquitinylation

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHIP</td>
<td>ER membrane</td>
<td>Ubiquitinate chaperone bound herg 656</td>
<td></td>
</tr>
<tr>
<td>Nedd4-2</td>
<td>ER plasma membrane</td>
<td>Reduces cell surface expression of herg 13</td>
<td></td>
</tr>
<tr>
<td>STAMBP</td>
<td>ER membrane</td>
<td>hERG endocytosis from plasma membrane 607</td>
<td></td>
</tr>
</tbody>
</table>

### Retrotranslocation

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vps24</td>
<td>MVBs</td>
<td>Accelerate degradation of mature herg 607</td>
<td></td>
</tr>
<tr>
<td>Caveolin-1, -3</td>
<td>Plasma membrane, endosomes</td>
<td>Endocytosis of mature herg 402</td>
<td></td>
</tr>
<tr>
<td>Dynamin-2</td>
<td>Plasma membrane, endosomes</td>
<td>Endocytosis of mature herg 402</td>
<td></td>
</tr>
</tbody>
</table>

### Others

<table>
<thead>
<tr>
<th>Protein</th>
<th>Location</th>
<th>Function</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDEM</td>
<td>ER membrane</td>
<td>Degradation of misfolded glycoprotein 218</td>
<td></td>
</tr>
<tr>
<td>ARHGAP6</td>
<td>Cytosolic</td>
<td>Acts on PLC to reduce herg current 505</td>
<td></td>
</tr>
<tr>
<td>GM130 (Golgin-95)</td>
<td>Golgi</td>
<td>Vesicle trafficking to cis-Golgi 532</td>
<td></td>
</tr>
<tr>
<td>14-3-3ε</td>
<td>Cytosolic</td>
<td>Regulate PKA modulation of Kv11.1 308</td>
<td></td>
</tr>
<tr>
<td>KCR1</td>
<td>Plasma membrane</td>
<td>Reduce the sensitivity of herg to drug blockers 339</td>
<td></td>
</tr>
</tbody>
</table>
both the NH$_2$-terminal (209, 478, 531) and COOH-terminal (9, 129, 181, 437, 733) cytoplasmic domains that have trafficking defects as well.

4. Degradation

Mature wild-type hERG has a half-life of $\sim$10 h when expressed in heterologous systems (176, 310, 366). Degradation of hERG can occur via both polyubiquitination-proteasomal degradation (216) as well as ubiquitin-dependent lysosomal degradation (94). Exposure of cells to reduced extracellular K$^+$ also promotes degradation via ubiquitination and caveolin-dependent endocytosis (227, 401, 402, 607) (see sect. IIII). Misfolded hERG proteins remain associated with chaperones and are tagged by CHIP (COOH terminus of Hsc70-interacting protein), an E3 ubiquitin ligase that contacts Hsc70 and ubiquitylates chaperone-bound proteins (656). The channels are then degraded in the proteasome via ER-associated degradation (ERAD) (533, 651), a process involving recognition and active removal of misfolded protein from the ER.

Immature (core glycosylated) wild-type hERG disappears during pulse chase experiments with a half-life of $\sim$4 h (216). However, a large portion of the immature hERG is converted into the mature form during a 24-h chase period (216). On the contrary, trafficking defective hERG channels do not undergo maturation and are completely degraded within 24 h (216, 733). Coexpression of the dominant negative trafficking mutant A561V also results in accelerated degradation of wild-type hERG subunits that are retained in the ER as a result of assembling with the mutant subunits (310).

C. Assembly

1. Tetramerization

Individual hERG isoforms can form homotetramers or coassemble to form heterotetramers (301, 383, 494). The assembly of the tetrameric channel also occurs within the ER. This can be deduced from observations that many misfolded mutant channels that are retained in the ER bind to wild-type subunits and exert a dominant negative effect on channel expression (175, 310, 728).

In canonical VGK channels, subunit assembly is facilitated by the cotranslational interactions of the NH$_2$-terminal T1 domain (365, 570). In Kv11.1 channels however, deletion of most of the NH$_2$ terminus does not prevent normal trafficking (661). Nevertheless, it has been suggested that the NH$_2$ terminus may still contribute to tetramerization, as purified recombinant NH$_2$-terminal constructs containing the PAS domain can form tetramers in solution (369).

With the early studies suggesting that the NH$_2$ terminus may not be essential for tetramerization, many workers switched their attention to the COOH-terminal domain. By using a deletion and rescue strategy, Kupershmidt et al. (338) showed that ligation of a region of the distal COOH terminus (residues 1018–1122) into channels lacking the entire COOH terminus (hERG-ΔC), rescued the trafficking of the hERG-ΔC channels. Furthermore, the rescued channels produced typical Kv11.1 currents (338). A conserved coiled-coil domain (residues 1036–1074, termed TCC) within this region was later shown to form a tetramer in vitro (289). However, the role of residues 1018–1122 in channel assembly has been questioned by other workers. For example, Akhavan and colleagues (9, 10) have shown that this sequence is dispensable for the formation of functional tetramers. It may be that, like the PAS domain, the distal COOH terminus is not essential but does contribute to stabilization of tetrameric channels. More recently, attention has shifted to the role of the cNBD domain located in the proximal end of the cytoplasmic COOH-terminal domain. Numerous missense mutations and partial deletions within the cNBD cause trafficking defects (9, 10, 598). More recently, Gustina and Trudeau (231) have also provided evidence for intersubunit interactions between the PAS domain and the cNBD. Whether these interactions are important for assembly and/or are involved in regulating gating remains to be determined.

Overall, there appear to be multiple cytosolic domains that can contribute to assembly and tetramerization of hERG proteins. However, none of them appears to be essential; rather, a model is emerging of multiple interacting domains, in which the absence of one can be at least partially compensated for by other domains.

2. hERG 1a/1b heterotetramers

The hERG-1b isoform lacks the first 373 amino acids of the 1a isoform but contains a unique 36-amino acid sequence at its NH$_2$ terminus. It was initially thought that hERG 1b isoform was not expressed at very high levels in human cardiac tissue (504). However, with the aid of improved antibody reagents, expression of hERG-1b protein has been detected in human cardiac tissue (301). Subsequently, Robertson et al. (494) showed that 1a and 1b subunits preferentially coassemble with each other mediated via a cotranslational interaction between the NH$_2$-termini of 1a and 1b during biogenesis. The NH$_2$-terminal interaction between the two isoforms promotes ER exit of the 1b containing channel complex by masking an RXR ER retention signal that is present in the NH$_2$ terminus of the 1b isoform (495). Recently, mutations have also been found in the 1b specific exon strongly suggesting that the 1b isoform is indeed clinically important (542). Thus it is likely that the native I$_Ks$ in human tissue is composed of 1a/1b heterotetramers (301, 542). The presence of hERG 1b subunits in Kv11.1 channels also alters responses to thyrotropin releasing hormone (328), acidosis (153), oxidative stress (331), and cGMP...
with KCNEs modulating drug-induced QT prolongation (1, 565), which is consistent long QT syndrome (LQTS) (3, 72, 441, 589) as well as the bridge between hERG and KCNE1 (see below).

In addition to the KCNE family of accessory subunits, KCNQ1 and KCNE2 are single transmembrane domain proteins that interact with the pore-forming subunits of KCNQ1 and hERG proteins (1, 2, 18, 405). Whereas KCNE1 subunits are essential components of the \( I_{Ks} \) channel complex (51, 546), the role of KCNEs in regulating Kv11.1 function is still a topic of debate (2). Both KCNE1 and KCNE2 have been shown to associate with hERG (1, 405) and alter gating kinetics of Kv11.1 both in oocytes and mammalian cell lines (403). KCNE1 antisense oligos also reduce \( I_{Kr} \) density in the atrial tumor cell line (AT1 cell) (695). A study in horse heart has provided additional evidence that KCNE1 can coimmunoprecipitate with hERG in native tissue (184). However, it is not clear whether these observed interactions are direct or via an undetermined adaptor protein. One possibility is that KCNQ1 acts as the bridge between hERG and KCNE1 (see below).

Mutations in KCNEs are associated with both inherited long QT syndrome (LQTS) (3, 72, 441, 589) as well as drug-induced QT prolongation (1, 565), which is consistent with KCNEs modulating \( I_{Kr} \) in native tissue. Conversely, some workers have found that coexpression of KCNE2 has no effect on Kv11.1 kinetics (679). This apparent discrepancy may though be resolved by a recent report from Zhang et al. showing that KCNE2 may modulate Kv11.1 by accelerating the degradation of hERG protein (722). In addition, KCNE2 has been shown to modulate the activity of many other cardiac ion channels (2) including HCN channels (704), Kv4.x channels (717), and Kv2.x channels (404). Thus it is also possible that mutations in KCNE2 could alter cardiac repolarization via effects on channels other than Kv11.1.

4. Other interacting partners

In addition to the KCNE family of \( \beta \)-subunits, KCNQ1 has been shown to alter hERG function. Ehrlich et al. (161) showed that coexpression of KCNQ1 with hERG in CHO cells (transient transfection) resulted in a significant acceleration of Kv11.1 channel deactivation that more closely resembled native \( I_{Kr} \). Furthermore, they showed that coexpression with KCNQ1 resulted in an approximately twofold increase in plasma membrane expression of hERG (161). They also showed that the interaction between hERG and KCNQ1 was mediated by the COOH-terminal domain. Hayashi et al. (250) subsequently showed that the positive influence of KCNQ1 coexpression on Kv11.1 current density was not observed with trafficking defective KCNQ1 mutants. In contrast to this, Brunner et al. (81) showed that transgenic overexpression of dominant negative pore-mutants of hERG or KCNQ1 in rabbit hearts resulted in a downregulation of \( I_{Ks} \) or \( I_{Kr} \), respectively, without altering the steady-state levels of the native polypeptides. They followed this up with studies in CHO cells showing that coexpression of KCNQ1 caused downregulation of Kv11.1 current (516). The origin of the discrepancy between the studies of Ren et al. (516) and the studies from Ehrlich et al. (161), and Hayashi et al. (250), is not immediately obvious, although Ren and colleagues suggest that it could be related to the transfection technique (a combination of stable and transient expression in their study compared with double transient transfection in the Erlich et al. and Hayashi et al. studies).

The \( K^+ \) channel regulator KCR1 is a 12 transmembrane domain protein that associates with hERG and rat EAG channels (273, 339). When coexpressed in heterologous systems, KCR1 associates with hERG at the plasma membrane and renders it less sensitive to classic hERG blockers, including dofetilide, quinidine, and sotalol (339). In addition, a gain of function polymorphism in KCR1, which enhances KCR1 protection against drug block of hERG, has been linked to a reduced risk of drug-induced QT prolongation (491). The protective action of KCR1 against drug-induced QT prolongation is linked to its \( \alpha \)-1,2-gluco-syltransferase activity, which was discovered after it was noticed that it had high sequence homology to yeast \( \alpha \)-1,2-gluco-syltransferase ALG10 (436). Subsequently, a loss of function variant of KCR1 was linked with an increased susceptibility to drug-induced prolongation of the QT interval (249).

4. Other interacting partners

In addition to glycosylation, hERG channels have been shown to be phosphorylated via numerous signaling pathways. Phosphorylation of hERG has important roles in biogenesis (see sect. IIIG), as well as acute regulation of gating under a variety of physiological and pathophysiological conditions (see sect. VIE). HHERG contains multiple putative consensus phosphorylation sites for protein kinase A (PKA), protein kinase C (PKC), and protein tyrosine kinases. Other kinases, including PKB and PKG, have also been implicated in regulating hERG function. In this section, the focus is on signaling/phosphorylation pathways that regulate hERG and how these alter assembly and trafficking. The effects of phosphorylation on gating are discussed in section VI.

1. PKA

PKA is activated by increases in cAMP concentration, which in the heart typically occurs following stimulation of the \( \beta \)-adrenergic pathway (524). HHERG contains four consensus phosphorylation sites for PKA: Ser283 in the NH\(_2\) terminus as well as Ser890, Thr895, and Ser1137 in the COOH terminus. All four sites can be phosphorylated in

(411) as well as altering the sensitivity and kinetics of drug binding (542) and modulation by agonists (351).
vitro (130). In addition to these four sites, there is a common SNP (RS1805123) that introduces another phosphorylation site, K897T (204).

A number of accessory proteins are involved in PKA-dependent substrate phosphorylation. For example, the A-kinase adaptor protein (AKAP) Yotiao plays an essential role in mediating adrenergic regulation of KCNQ1 activity (398). A peptide that specifically disrupts interactions between PKA and AKAPs has been shown to diminish phosphorylation of hERG by PKA (370). AKAPs have also been shown to cosediment with hERG in subcellular fractionation experiments from both HEK293 cells and porcine ventricular tissue, although a direct interaction between hERG and an AKAP has not been detected (370).

The family of 14–3-3 proteins are highly conserved regulatory molecules expressed in all eukaryotic cells (188). 14–3-3ε is the most abundant isoform expressed in cardiac tissue, and it has been shown to associate with hERG to potentiate effects of cAMP/PKA stimulation (309). Binding of 14–3-3ε to hERG requires intact PKA phosphorylation sites at Ser283 in the NH2 terminus and at Ser1137 in the COOH terminus. Binding of 14–3-3ε prolongs the adenergic effects on Kv11.1 gating possibly by shielding phosphorylated Ser283 and Ser1137 from cellular phosphatases (308). Mutations that impair 14–3-3ε-hERG binding have also been implicated in pathogenesis of LQTS type 2. A series of frameshift or truncation mutations in the distal COOH terminus that remove Ser1137 exhibit normal gating kinetics but do not exhibit the hyperpolarizing shift in voltage dependence of activation when coexpressed with 14–3-3ε (104).

2. Protein kinase B and phosphatidylinositol 3-kinase signaling

Kv11.1 channels are regulated through a signaling cascade involving phosphatidylinositol 3 (PI3) and phosphoinositide-dependent kinases, which subsequently activates downstream serum and glucocorticoid inducible kinase (SGK) and protein kinase B (PKB) (393). Both SGK and PKB are members of the AGC protein kinase superfamily. Kinases in this superfamily share a high degree of homology in their protein sequences especially within the catalytic kinase domain (480). SGK and PKB also share many common upstream effectors as well as downstream targets in their signal cascades (14, 330, 355, 585). Maier et al. (393) reported that coexpression of SGK3, but not SGK1, with hERG in Xenopus oocytes enhanced steady-state current and cell membrane protein abundance, without altering gating kinetics. This effect was not abolished by mutating the consensus sites for SGK phosphorylation, suggesting that the SGK3 effects were independent of direct channel phosphorylation. Similarly, the expression of constitutively active PKB also increases Kv11.1 current in HEK293 cells (725), although it is unclear whether this requires direct channel phosphorylation. Conversely, direct phosphorylation by PKB may have a role in downregulating hERG protein in which a PKB site is generated through the K897T polymorphism (204). Furthermore, in pituitary cells, thyroid hormone T3 stimulates hERG via activation of PI3 kinase, which reduces phosphorylation at residue Thr895 (203, 204).

The downstream targets of SGK3 and PKB that regulate Kv11.1 are not known. However, given what is known about how SGK3 and PKB regulate other ion channels, including, e.g., the epithelial sodium channels (533), it is likely that they will act through other proteins, such as the E3 ubiquitin ligase Nedd4–2. Nedd4–2 is expressed in cardiac tissue, and a possible role of Nedd4–2 in regulating plasma membrane expression of hERG protein has started to emerge (13), although disparity in opinion exists regarding a direct interaction between hERG and Nedd4–2 (535).

3. PKC

The acute effects of PKC activation have been examined in several different experimental systems, using either activators of PKC such as diacylglycerol (DAG)/1-Oleoyl-2-acetyl-sn-glycerol (OAG) and phorbol 12-myristate 13-acetate (PMA) (53, 113, 633) or by studying G protein-coupled receptors linked to PKC activation, including TRH receptor (213), angiotensin II receptor AT1 (676), α-adrenergic receptors (631, 671), and muscarinic receptors (113, 260, 407). Acute activation of PKC typically results in reduced Kv11.1 current in oocytes (53, 630, 633) and HEK293 cells (113, 513, 676), as well as isolated guinea pig ventricular myocytes (671). These changes are mediated in part by changes in gating properties as well as increased endocytosis (513).

The major controversy regarding PKC regulation of Kv11.1 channels is whether the channel is directly phosphorylated. Thomas et al. (633) identified 18 consensus sites for PKC phosphorylation in hERG using PROSITE software (Ser26, Thr74, Thr162, Thr174, Thr179, Ser250, Ser278, Ser354, Thr371, Thr526, Ser606, Ser636, Thr670, Ser890, Thr895, Ser918, Ser960, and Thr1133). Mutating each of these sites to alanine (with the exception of Thr74, as the alanine mutation prevented correct folding and assembly) did not abrogate acute regulation by PKC, suggesting that direct phosphorylation of hERG protein is not required. Cockrell et al. (113) confirmed that Kv11.1 channels with all the PKC consensus phosphorylation sites mutated to alanine are still regulated by PKC. Furthermore, they showed that PKC activation resulted in an increased level of phosphorylation of hERG protein (113). Whilst they were not able to identify the specific phosphorylation sites they showed that deletion of the NH2 terminus (Δ2–354) prevented the PKC-stimulated increase in phosphoprotein levels and prevented the acute effects on Kv11.1 function, which suggests that residues in the NH2 terminus are directly phosphorylated by PKC. One possibility could be that there is an atypical
PKC site in the NH₂ terminus of the hERG protein. Subsequently, Chen et al. (96) showed that intact PKC phosphorylation sites were required for the enhanced rates of synthesis seen with chronic stimulation of PKC. Together, these studies suggest that PKC-mediated phosphorylation of hERG protein can occur, but to what extent it contributes to the functional effects observed remains to be defined. Furthermore, the specific sites phosphorylated by PKC remain to be determined.

4. cGMP/ANP, BNP/PKG

Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are two hormones secreted by the atria in response to atrial stretch/dilatation and increased levels are hallmarks of heart failure (406). ANP, signaling via cGMP, has been shown to modulate Kv11.1 function, in particular channels containing the hERG-1b isoform. In heterologous cell lines, cGMP or ANP has no effect on Kv11.1 channels composed entirely of hERG-1a subunits (130, 411, 613), but cGMP potently suppresses Kv11.1 channels composed of ERG1b or ERG1a/1b subunits in a PKG-dependent manner (130, 411, 613). In the mouse heart, cGMP exhibits a striking regional difference by suppressing IKr in atrial but not ventricular myocytes, suggesting that cGMP and its physiological activators ANP and BNP may have significant roles in arrhythmogenesis under pathophysiological conditions such as heart failure (130, 411, 613).

5. Tyrosine kinases/Src/EGFR

Stimulation of the tyrosine kinase Src increased Kv11.1 current in the rat microglial cell line MLS-9 (732). Cayabayab and Schlichter (90) subsequently showed that hERG and Src can be coimmunoprecipitated and may form a multimeric regulatory complex. Zhang et al. (711) also showed that Kv11.1 current amplitude was reduced following inhibition of EGFR kinase and the Src family of kinases. They suggested that the effects of the inhibitors occurred through decreased phosphorylation of Tyr475 and/or Tyr611. Given that Tyr475 is located on the intracellular S2-S3 loop, whereas Tyr611 is potentially buried within the membrane and has been suggested to point towards the membrane interior (359), it would seem that Ty475 is the more likely candidate.

E. Regulation of Biogenesis

1. Developmental changes in KCNH2 expression

The levels of KCNH2 mRNA expression change during development. In rodents, IKr current density (665) as well as KCNH2 mRNA (45) and ERG protein levels (672) decrease from fetal to neonatal and to adult levels. This is consistent with numerous studies showing that IKr blockers have minimal or no effect on QT interval duration in adult mice (45). There are no comparable studies in higher mammals. However, it is clear that KCNH2 expression is important for development in both mice and humans as genetic ablation of KCNH2 mRNA, either in knockout mice (622) or homozygous loss of function in humans (67), results in embryonic lethality. Furthermore, in mice, there is evidence to suggest that mERG function contributes to early embryo development with IKr specific blockers resulting in reduced incidence of blastocyst formation (685). Wang et al. (672) have also shown that the subunit composition of IKr changes during development with levels of mERG1b expression high in neonates but not detectable in adults, whereas mERG1a expression is higher in adults compared with neonates.

Despite the importance of IKr for cardiac function and the multiple studies highlighting significant IKr expression changes during development, there are few studies that have investigated the molecular basis of these changes. Wang and colleagues (158) have shown that treating young mice (10–15 day) with dexamethasone (a synthetic glucocorticoid) prevents the normal loss of IKr function and dofetilide binding sites during this time period in mice. The specific mechanisms by which glucocorticoids regulate IKr expression, however, remain to be determined. In adults, IKr current density as well as KCNH2 transcript levels also vary between males and females (194), which suggests regulation by sex hormones, with the strongest evidence indicating that there is a positive influence of testosterone (381, 519, 688) resulting in higher KCNH2 levels and in turn shorter QT intervals in men.

2. Regulation of mRNA biogenesis

Mammalian gene promoters are typically either GC rich or contain canonical TATA box or CCAAT box motifs that bind components of the RNA polymerase complex of proteins required for initiation of transcription (581). DNA sequences immediately upstream of the transcription initiation sites for KCNH2–1a and -1b lack canonical TATA and CCAAT boxes but are GC rich (64–68% GC content). The KCNH2–3.1 promoter lacks canonical TATA and CCAAT boxes and is not particularly GC rich. The level of KCNH2–3.1 expression, however, is considerably lower than the 1a or 1b transcripts in most tissues, with the exception of hippocampal and prefrontal cortical regions of the brain where KCNH2–3.1 and 1a are expressed at similar levels (279).

Recently, Lin et al. (373) showed that the length of a TG repeat polymorphism ~1 kb upstream of the KCNH2–1a transcription start site is inversely correlated with the level of KCNH2 transcription and QT prolongation. Given that the levels of functional hERG protein expression can have a marked influence on cardiac electrical activity, further study of the regulation of transcription of KCNH2 is clearly warranted.
3. Regulation of protein biogenesis

Sustained elevation of cAMP increases hERG biogenesis (98). A 24-h exposure to CPT-cAMP (a direct activator of PKA) resulted in a two- to fourfold increase in steady-state levels of protein expression in HEK293 cells and ~25–40% in isolated rabbit cardiomyocytes (98). This increase in hERG synthesis is due to an increase in translation, as demonstrated by increased incorporation of 35S-methionine, which was blocked by treating cells with cycloheximide, an inhibitor of translation. The stability of hERG at the plasma membrane however remained unaltered. At least in HEK293 cells, the increase in Kv11.1 current density was delayed relative to the increase in synthesis in the ER, suggesting that trafficking of hERG through the ER and Golgi apparatus is the rate-limiting step of forward trafficking (98). More recently, McDonald et al. (590) have shown, using a FRET-based PKA biosensor, that PKA located at the ER membrane surface, as opposed to the plasma membrane, is responsible for the changes in protein synthesis. In addition to the direct effects of PKA on KV11.1 channels, one has to take into account the fact that chronic β-adrenergic stimulation eventually results in downregulation of many components of the signaling pathway (171), so the overall effect may be much more modest than that seen in relatively short term (order of days) tissue culture experiments. Thus the pathophysiological relevance of the chronic effects of PKA stimulation on Kv11.1 remain to be fully determined (see sect. VI).

Acute PKC activation (15–60 min) results in increased endocytosis and reduced plasma membrane expression of hERG (513). Conversely, chronic stimulation of α1-adrenergic receptors leading to chronic stimulation of PKC causes an increase in hERG biogenesis in HEK293 cells (96). Although smaller, this effect is also observed in neonatal rat cardiomyocytes (96). Stimulation of the NH2-terminal truncated isoform of the androgen receptor has also been shown to stabilize hERG protein half-life (688). This effect is mediated by phosphorylation of ERK1/2 and is observed both in CHO cells and in isolated rabbit cardiac myocytes.

In contrast to the upregulation of hERG synthesis observed with chronic PKA/PKC phosphorylation, Nanduri and colleagues (439, 440) have shown that rates of protein synthesis are reduced by chronic hypoxia. They subsequently showed that hypoxia inhibited the interaction of hERG with Hsp90, a chaperone required for maturation. Furthermore, they showed that this effect could be reversed by reactive oxygen species scavengers (439).

4. Regulation of protein degradation

Until recently, there has been relatively little known about the regulation of hERG channel degradation. Ceramide has been shown to cause ubiquitin-dependent lysosomal degradation of hERG (94), and more recently, Ramstrom et al. (513) have also shown that acute stimulation of PKC can increase endocytosis of hERG channels thereby reducing levels at the plasma membrane. In the last few years, a series of elegant studies from Zhang and colleagues has highlighted an important role played by hypokalemia in regulating hERG turnover at the plasma membrane (227, 401, 402, 607). Furthermore, this effect of hypokalemia occurred at pathophysiologically relevant levels (227, 401, 402, 607). Exposure to reduced extracellular K+ results in the channels entering a long-lived nonconducting state that promotes ubiquitination, caveolin-dependent endocytosis, and degradation (227, 401, 402, 607). Changes in extracellular K+, however, have no effect on the stability of the intracellular pool of hERG (227, 401, 402, 607). The E3 ubiquitin ligase that mediates this process has not been identified.

IV. GATING OF IKR/Kv11.1

A. Principles of Gating

Like other VGK channels, Kv11.1 channels can exist in closed, open, and inactivated states. Kv11.1 channels, however, have some unusual gating kinetics. For instance, transitions between open and closed states are usually slow, whereas transitions between the open and inactivated states are both very fast and voltage dependent (see FIGURE 5). The unusual kinetics result in some distinctive features, such as hooked tail currents, but also cause some difficulties in accurately quantifying gating kinetics. Here, the properties of IKr in cardiac cells are compared with the properties of Kv11.1 channels expressed in heterologous expression systems. This is followed by a review of the protocols used and pitfalls to be aware of in the experimental determination of the kinetics of gating before discussing what is known about the molecular and structural basis of gating.

B. Gating of IKr in Cardiac Myocytes

Between 1969 and the mid 1980s, there were numerous reports of a rectifying K+ current contributing to repolarization of the cardiac action potential (79, 145, 448, 449). But it was not until 1987 that Shibasaki, using the then recently developed patch-clamp technique (237) to study both the macroscopic and single-channel IK from rabbit sinoatrial node cells (572), provided the first insights into the gating properties of what is now known as the rapid component of the delayed rectifying current (IKr). In macroscopic current recordings he noted the presence of a “hook” following repolarization and correctly surmised that the hook was caused by “a quick removal of inactivation of IKr which had occurred during the depolarizing pulse” (see FIGURE 1). Furthermore, he demonstrated that the current had a voltage-dependent activation gate and the voltage at which half-maximal activation occurred (V0.5)
was \(-25\) mV. He also noted that the voltage dependence of activation was insensitive to the concentration of K\(^+\) at the extracellular face of the channel, as were the rates of current deactivation. Shibasaki also examined the microscopic basis of \(I_{Kr}\) gating, using the cell-attached configuration to record single-channel currents. He noted that no channels appeared to open at stronger depolarized potentials, while channels opened during the subsequent repolarizing step. He also noted that the open burst duration decreased as the holding potential was made more negative. Ensemble averages of single-channel records mirrored the rates of \(I_{Kr}\) activation and deactivation obtained from direct fitting to the time course of macroscopic current, indicating that these single channels were the microscopic basis of \(I_{Kr}\). Lifetime analysis of single-channel activity revealed the presence of one open lifetime with a time constant of 2.5 ms and two closed lifetimes with time constants of 0.7 and 17.6 ms at \(-90\) mV. Shibasaki also noted that the lifetime of the open state was shorter than what would be expected from the decay of the macroscopic tail current and also got shorter with more positive potentials, the opposite to what would be predicted for a channel whose gating is just controlled by a single activation/deactivation gate. Based on this, Shibasaki suggested the presence of a second gating process, inactivation, and proposed that this might be the basis of the observed rectification of \(I_{Kr}\).

Three years later, Horie et al. (271) noted that the \(I_{Kr}\) from guinea pig atrial cells could be separated into two components based on single-channel conductance, with one of these components sharing many characteristics with the \(I_{Kr}\) reported by Shibasaki (572). Notable among these features were a single-channel conductance of 10 pS in 150 mM K\(^+\) (compared with 11.1 pS reported by Shibasaki), the presence of 1 open lifetime (\(\tau_o = 9\) ms) and 2 closed lifetimes (\(\tau_{c1} = 1.2\) ms and \(\tau_{c2} = 37\) ms at \(-100\) mV) similar to those reported by Shibasaki, and a \(V_{0.5}\) of \(-15\) mV, compared with \(-25\) mV reported by Shibasaki. Horie et al. also noted a similar hook, rectification, and voltage-dependent deactivation. Sanguinetti and Jurkiewicz subsequently used E-4031, a drug now known to be a highly selective \(I_{Kr}\) channel blocker, to pharmacologically isolate a component of the guinea pig ventricular myocyte \(I_{Kr}\) (548) that had very similar characteristics to those described by Shibasaki and Horie et al., including the hook, rectification, and \(V_{0.5}\) for activation of \(-21.5\) mV. Sanguinetti and Jurkiewicz performed a more extensive analysis of the voltage dependence of gating and showed that the time constants of activation and deactivation followed a bell-shaped distribution peaking between \(-30\) and \(-40\) mV. However, the activation time constants were derived by fitting a single exponential function to the current recorded during a simple depolarization step, a method that is now accepted as inaccurate, due to the coincident nature of activation and inactivation (see sect. IVD). They also presented the first approximation of the voltage dependence of the rectification process by measuring the degree of rectification relative to the maximal conductance of a fully activated \(I-V\) plot. The reported \(V_{0.5}\) of \(-9\) mV for rectification is right shifted compared with subsequent characterizations of \(I_{Kr}\) and Kv11.1 (380, 547), most likely due to the fact that the \(I-V\) relationship was only measured down to \(-100\) mV, meaning the maximal conductance and therefore the degree of rectification was underestimated (see sect. IVD). Based on these experiments, Sanguinetti and Jurkiewicz coined the term \(I_{Kr}\) (rapid component of the delayed rectifier current) to describe this component of the repolarizing \(I_{Kr}\).

Subsequently, Liu et al. (380) used the pharmacological isolation method to characterize fully the voltage-dependent kinetics of \(I_{Kr}\). Most notably they used a modified envelope of tails protocol (448) to separate the activation and inactivation processes, which permitted the first measurement of the rates of \(I_{Kr}\) activation at depolarized voltages (see sect. IVD). Their data indicated that activation of \(I_{Kr}\) must involve multiple steps, similar to what had been reported for other voltage-gated K\(^+\) currents (263, 275), and had recently been shown for the cloned Kv11.1 channel (643; see below). They also showed that the rates of activation saturated at highly depolarized voltages, which suggested the presence of a voltage-independent step in the activation pathway.

There have been very few studies of \(I_{Kr}\) in human ventricular myocytes (302, 454). O’Hara and colleagues performed a partial characterization of \(I_{Kr}\) in undiseased human ventricular myocytes including steady-state activation and rates of activation and deactivation (454). Although it should be noted that rates of activation were measured from a holding potential of \(-40\) mV (which will result in faster apparent rates of activation as the channels will not have to transit through all closed states, see sect. IVD for more details). In addition, the inactivation characteristics of human \(I_{Kr}\) remain to be determined.

C. Gating of Kv11.1 Channels

1. Macroscopic currents

The properties of Kv11.1 channels, expressed in Xenopus oocytes, were first described in 1995 (547, 643). These papers showed that the biophysical properties of Kv11.1 were very similar to those of \(I_{Kr}\) in cardiac myocytes (271, 380, 572). The \(V_{0.5}\) for Kv11.1 activation was \(-15.1\) mV compared with \(-22\) mV (548), \(-25\) mV (572), and \(-18\) mV (271) for \(I_{Kr}\) in native myocytes. It should be noted that the value for \(V_{0.5}\) will depend on the length of the depolarization steps (see sect. IVD). Also in common with \(I_{Kr}\), Kv11.1 showed a time course of deactivation best described by two exponential components, inward rectification of the current and paradoxical “activation” of the current by external K\(^+\). This last characteristic is in contrast to what would be ex-
pected for a K⁺ conducting channel as the outward driving force is reduced. In hindsight, this is now known to be due to the effect of extracellular K⁺ on inactivation (668).

The two studies differed with respect to their explanations for the current rectification at depolarized potentials. Sanguinetti et al. (547) investigated the hypothesis originally proposed by Shibasaki, that the current rectification was due to fast voltage-dependent inactivation. Although they were unable to directly measure inactivation, they reasoned they should be able to measure its recovery as a way of interrogating the process. The authors measured recovery from inactivation at a range of holding potentials and noted that the V₀.5 for the voltage dependence of recovery from inactivation was very similar to the V₀.5 for the rectification process of Iᵦᵢ in rabbit nodal cells (572), with a slope factor identical to that in guinea pig (548). Although these data are consistent with the hypothesis that rectification is caused by a soluble cytoplasmic moiety such as Mg²⁺ or polyamines (643). Their conclusion was based on sequence homology within the core channel region as well as similar profiles for Kv11.1 and inward rectifier block by Cs⁺ and Ba²⁺ (235, 236). Like Sanguinetti et al. though, they could not rule out other mechanisms such as C- or N-type inactivation.

In 1996, three groups independently identified the mechanism of inward rectification (558, 583, 588). Each of these groups ruled out so-called ball and chain or N-type inactivation (274, 706) since the process was insensitive to both internal application of TEA (583) and to deletion of the cytoplasmic NH₂ terminus (558, 588). Channel block by intracellular Mg²⁺ (as reported for inward rectifiers) was also discounted (583, 584, 588). Instead, they concluded it was more analogous to “C-type” (106, 276). Like C-type inactivation in Shaker, Kv11.1 inactivation is sensitive to external application of TEA and ion occupancy of the selectivity filter (558, 583), both of which were thought to physically prevent “collapse” of the selectivity filter. In addition to this, mutation of the serine at position 631 to alanine markedly affected inactivation. Ser631 is equivalent to Thr449 in Shaker, a residue critical for C-type inactivation (388, 700). However, while bearing features analogous to C-type inactivation, Kv11.1 inactivation clearly has features that are unique. Most notably, the rates of inactivation and recovery from inactivation are both fast and voltage-dependent (583, 588). In contrast, C-type inactivation as reported in Shaker channels is slow and voltage insensitive (276). Wang et al. (668) later reasoned that the voltage sensitivity of Kv11.1 inactivation could not be explained by coupling to activation since: 1) Kv11.1 inactivation continues to show voltage dependence at voltages where activation is complete, 2) the slopes of the equilibrium activation and inactivation curves are markedly different (compare FIGURES 9 and 14 below), and 3) inactivation is sensitive to changes in external K⁺ while activation is insensitive to changes in extracellular K⁺ (668).

In 1997, Wang et al. (668) provided the first full quantitative description of all the kinetic parameters of Kv11.1 gating based on experiments in Xenopus oocytes, consolidating much of the previous data. Among other features, they recapitulated the bell-shaped distribution of the forward and reverse rates of inactivation reported by Spector et al. (588), the potassium sensitivity of inactivation, and the saturation effect of voltage on the rate of activation (380). This compilation of kinetic descriptions allowed the authors to develop the first fully characterized model for simulation of Kv11.1 current, discussed below in section IVH.

Each of the descriptions of Kv11.1 gating outlined above was based on expression of the hERG1a isoform in heterologous systems. However, some recent studies have suggested that native Iᵦᵢ is a heterotetrameric assembly of hERG1a and hERG1b subunits (358, 383). The hERG1a and 1b isoforms are identical in their transmembrane and cytoplasmic regions, but the 1b isoform is significantly truncated in the NH₂-terminal cytoplasmic region, being 340 amino acids shorter. In heterologous expression systems, heterotetramers of hERG1a and hERG1b show faster activation, deactivation, and recovery from inactivation than Kv11.1 channels composed of hERG1a subunits alone (542). These differences in kinetics are not surprising given the role of the NH₂-terminal domain in regulating Kv11.1 gating (see sect. IVF). These characteristics of the heterotramer, particularly the faster deactivation, potentially explain the observed differences between the gating kinetics of Iᵦᵢ in myocytes compared with Kv11.1 channels composed only of hERG1a subunits (421, 679).

2. Single-channel recordings of Kv11.1 channels

In 1996, Kiehn et al. (324) presented the first single-channel recordings from recombinant Kv11.1 channels expressed in Xenopus oocytes. As with single-channel recording from Iᵦᵢ (572), Kv11.1 channel activity was only apparent during repolarization, and ensemble averages of multiple single-channel records recapitulated the typical hooked Kv11.1 tail current (323) (see FIGURE 8). Analysis of single-channel lifetimes revealed the presence of a single open state with a mean open time of 3.2 ms and two closed states with time constants of 1.0 and 23 ms (at −100 mV in the presence of 100 mM K⁺ at the external face of the channel). Zou et al. (738) carried out parallel experiments and reported similar closed state kinetics: two closed states with lifetimes of 0.54 and 14.5 ms. However, they reported two open states with lifetimes of 2.9 and 11.8 ms at −90 mV. This was the first suggestion of multiple open states for the Kv11.1 channel, which the authors ascribe to simply acquiring more events for analysis. A potentially important methodological differ-
ence between the Zou and Kiehn studies is that Zou used a cell attached configuration compared with excised patches used by Kiehn; it is possible that the presence of accessory proteins and/or scaffold proteins that are lost upon excision of the patch could alter the gating kinetics. The time constants for the closed states reported for Kv11.1 in the above two studies are very similar to those reported for $I_{Kr}$ in nodal (572) and atrial cells (271). The data from Zou also suggests a possible explanation for the discrepancy in mean open times between the Zou and Kiehn studies is that Zou used a high concentration of extracellular K$^\mp$, in 24% of recordings there were early openings, with a mean latency of 12 ms and in the remainder of recordings there were late openings with a mean latency of 122 ms. Kiehn et al. suggested that the lack of openings in the majority of sweeps at depolarized potentials was due to closed-state inactivation, as initially suggested by Shibasaki in 1987 (572). Based on this observation, they suggested that the openings with the shortest latency are the bursts responsible for the transient peak during depolarization, while those with longest latency contribute to the small steady-state current at depolarized potentials. This theory was supported by experimental recordings of ensemble averages from macropatches that showed that the magnitude of the transient peak was dependent on the holding potential from which depolarization occurred; that is, cells depolarized from more negative potentials showed a greater peak magnitude, as fewer channels were resident in the closed-inactivated state at more negative potentials there were more channels available to open (323). The authors also reported that a five-state kinetic model incorporating closed to inactive transitions provided the best fit to their macroscopic data (discussed in sect. IVH).

The differences in mean open times between different studies, together with the finding that the minimal number of states required in a Markov state model to reproduce both macroscopic and single-channel data was more than the number of states that could be directly observed in Kv11.1 single-channel recordings (323), highlight the technical difficulties in studying Kv11.1 at the single-channel level. Most notably, the channel inactivates very quickly and has very small unitary conductance, particularly at physiological extracellular K$^\mp$ concentrations, estimated at $\sim$1 pS using noise analysis (256, 324). This has meant that each of the above studies has used a high concentration of extracellular potassium to slow inactivation and increase unitary conductance (323, 324, 738) or used inactivation deficient mutants (739). Because of these difficulties, the vast majority of work relating to Kv11.1 channels, and a corresponding majority of the functional insight into the structural and molecular basis of Kv11.1 gating as discussed below, has come from studies of macroscopic currents.

The kinetics of Kv11.1 gating, in particular the temporal and electrical coincidence of activation and inactivation, mean that it is not straightforward to measure these characteristics. However, there are now well-established and routinely used protocols. This section outlines the protocols, as well as potential difficulties associated with them. It is also important to note that while the protocols below are discussed in the context of the wild-type channel, the individual experimental parameters, such as the voltages and durations of particular pulses, may need to be adjusted based on the particular mutant or experimental conditions of the study.

1. Steady-state activation

The voltage-dependence of Kv11.1 activation is assessed using tail current analysis (FIGURE 9A). From a holding potential of −90 mV, channels are activated with a series of depolarizing P1 pulses (typically from −80 mV to +60 mV for wild-type Kv11.1), and tail currents are recorded during a repolarizing P2 pulse (typically −60 mV). Inactivation of Kv11.1 at depolarized potentials means significant rectification is seen during the P1 pulse, while fast recovery from inactivation relative to deactivation ensures that the magnitude of the tail current during P2 is an accurate representation of the proportion of channels activated during the preceding P1 pulse (FIGURE 9A). A fit of the Boltzmann equation to the peak tail current measured during P2 allows an assessment of the V_{0.5} of activation as well as a slope factor that approximates the activation gating charge.

As a consequence of the slow kinetics of Kv11.1 activation, it is important to ensure the P1 pulse is of sufficient duration to allow activation to reach as close as possible to steady state. Indeed, the data obtained from a tail pulse protocol should really be referred to as isochronal activation data with specific mention of the duration of the P1 pulse duration. As illustrated in FIGURE 8C, the apparent V_{0.5} of “steady-state activation” varies by over 20 mV as the P1 duration is increased from 0.5 to 16 s. The duration of the P1 pulse is particularly important when characterizing mutants that alter the activation process, as mutants that slow activation may result in an apparent depolarizing shift in the V_{0.5} of “steady-state activation” and mutants that increase the rate of activation may result in a hyperpolarizing shift of steady-state activation. Another point to consider when comparing results from different studies is the composition of the perfusion solutions. Divalent and trivalent cations have a profound effect on gating properties including the voltage dependence of activation (261, 262, 300, 543, 547). While these effects are most pronounced for trivalent ions, such as La^{3+} and Co^{3+} (543), significant effects are also observed with Ca^{2+} (300) and Mg^{2+} (503) in the low millimolar range. For example, going from 1.8 to 10 mM Ca^{2+} results in a +22 mV shift in the voltage dependence of activation as measured from 2 s isochronal activation curves (300).

In regard to estimating the gating charge, the fit of a simple Boltzmann distribution to activation data can lead to underestimation of the effective number of charges moved. A more accurate estimation of gating charge can be made using the limiting slope method (16, 65, 577). In this case, the natural logarithm of the open probability (P_o), the peak

**FIGURE 9.** Measurement of steady-state activation of Kv11.1 channels. A: voltage protocol and typical example of current traces recorded from a Xenopus laevis oocyte injected with KCNH2-1a mRNA. Cells are depolarized from a holding potential of −90 mV to voltages in the range −80 to +40 mV (P1 pulse), then stepped back to −60 mV (P2 pulse) to allow channels to recover from inactivation back to the open state and so reveal the relative proportion of channels that had been activated during the P1 pulse. B: plot of current at the end of the 4 s P1 voltage step (closed circles, shows a typical n-shaped curve) and peak tail currents during the P2 pulse (closed squares, shows typical sigmoidal shaped curve). C: isochronal activation curves where duration of the P1 voltage step was 0.5, 1, 2, 4, 8, and 16 s. This highlights the leftward shift in the voltage dependence of activation with longer P1 voltage steps.
尾电流在 P2 期间测量，并且拟合为 Boltzmann 方程

\[ P_o = \frac{1}{1 + e^{-z_g \Phi_e \frac{V - V_{1/2}}{k_B T}}} \]  

(1)

其中 \( z_g \) 是电位差，\( q_e \) 是元电荷，\( V \) 是膜电压，\( k_B \) 是玻耳兹曼常数，而 \( T \) 是绝对温度。在较低的开放概率时，\( P_o \) 的电压关系在半对数图中是线性的。因此，当将数据在半对数图中绘制时，需要在接近零的膜电压处取样（每 2–5 mV 为例），电压范围更负。图 B (图 10) 显示了在最超极化情况下对数据的线性拟合，因此电位差 \( z_g \) 可以计算为

\[ z_g = \frac{k_B T}{q_e} \times \text{Slope} \]  

(2)

图 10 说明了一种可用于估算欧姆克等温线图的方法的准确性。图 B (图 10) 中展示的这种方法的一个缺点是，在更负的测试电压（至少为 -60 mV 对野生型 Kv11.1，图 10）时，可能得到的速率较低。

2. 激活速率

由于激活过程的临时和电性质，激活与失活过程，特别是当电压超过阈值范围时，通常被当作是单分子的整体。更好的方法是使用复极化协议，P1 脉冲通常设置为典型的 40 mV 对 500 ms，然后是 P2 脉冲，脉冲宽度和测试电压范围可扩展到 -50 至 -160 mV 对野生型 Kv11.1 通道（见图 12）。在 P2 脉冲期间，电流快速恢复，而尾电流在失活前迅速恢复。从而使得估计时间常数为所有其他步骤。对于能够单独改变的通道，采用单指数函数（446, 601, 668, 670）。在文献中，存在多种报告，这些报告表示其在失活过程中，快速恢复的尾电流在 P1 脉冲后，一个尖锐的电流增加，观察到通道在失活前快速恢复。尾电流随着时间的推移而逐渐衰减，而且通常为 P1 脉冲的两倍。

3. 失活速率

失活速率的 Kv11.1 通道使用两步电压协议和尾电流测量。两个指数函数。脉冲与 P1 脉冲（典型地 +40 mV 对 500 ms）后，由一系列的 P2 脉冲（电压范围 -50 至 -160 mV 对野生型 Kv11.1 通道）（见图 12）。在 P2 脉冲期间，一个尖锐的电流增加，观察到通道在失活前快速恢复。尾电流在失活前迅速恢复。将这种失活过程的时间常数与 P1 脉冲的时间常数进行比较，可以判断通道是否失活。失活过程通常是一个单指数函数（390, 659, 735），或者更常见的是一个双指数函数（446, 601, 668, 670）。在文献中，存在多种报告，这些报告表示其在失活过程中，可以单独通过突变或药物（487, 648）来改变两个成分。图 12 中展示了这种成分的失活。
and that the fits be extrapolated back to the start of the P2 pulse to allow correct estimation of the relative proportions of the fast and slow components.

4. Rates of inactivation

Since inactivation in Kv11.1 occurs so quickly and is concurrent with or even precedes channel opening (323), it is necessary to use more complex voltage protocols to electrically manipulate the state occupancy of the channel to enable measurement of the kinetics of inactivation. To determine the rate of channel inactivation, a triple pulse protocol, first employed by Smith and Yellen (583), is now routinely used (FIGURE 13). Cells are depolarized using a P1 pulse (typically +40 mV for 500 ms) to ensure channels are fully inactivated. A short P2 pulse (−90 mV for 25 ms) is then used to allow channels to recover from inactivation into the open state. The duration of the P2 pulse may need to be modified for mutants or specific experimental conditions (e.g., using different temperatures) and the extent to which channels undergo deactivation during the P2 pulse needs to be corrected for (see below). The membrane potential is then stepped to a series of P3 test pulses, typically between +60 and −80 mV. Since the channels are in the open state at the end of P2, the rate of inactivation at each potential can be measured directly by fitting a single exponential function to the decay of the current during P3 (FIGURE 13A).

To measure the rate of recovery from inactivation, a two-step voltage protocol is used (FIGURE 13Aii). A depolarizing P1 pulse (typically +40 mV for 500 ms) drives all the channels to an inactivated state. The membrane is then repolarized to a series of increasingly negative P2 test pulses (typically +40 mV to −160 mV for 500 ms). During repolarization a transient increase in current is observed as channels quickly recover from inactivation, before the current slowly decays as channels deactivate. The current profile during P2 is therefore a sum of recovery from inactivation and deactivation which is fit with a double exponential to extract the individual components (see FIGURE 13Aii).

It is important to note that the observed rate constants for inactivation and recovery from inactivation are actually the sum of the unidirectional rate constants at that voltage. This gives rise to the typical “bell-shaped” curve for plots of time constants of inactivation and recovery from inactivation (FIGURE 13B). If, instead of plotting time constants, the observed rate constants are plotted on a logarithmic axis, then the observed rates show a typical chevron shape (see FIGURE 13C) indicative of a reaction that is dominated by a single transition state between the two end states (open and inactivated in this case) (658). The chevron plot can be fitted with the equation

\[ k_{\text{obs},V} = k_{\text{inact},V} + k_{\text{rec},V} \]  

where \( k_{\text{obs},V} \) is the measured rate constant at voltage \( V \), and \( k_{\text{inact},V} \) and \( k_{\text{rec},V} \) are the unidirectional forward (inactivation) and reverse (recovery) rate constants. It is clear from FIGURE 13C that at more negative voltages, the observed rate tends towards the true unidirectional rate of recovery, while at more positive potentials, the observed rate tends to the unidirectional rate of inactivation.
It should be noted that when measuring the kinetics of any fast process such as the rate of inactivation in Kv11.1 channels, particular attention should be paid to experimental technique. Inactivation occurs on a millisecond timescale that can often be coincident with experimental artefacts. For example, in two electrode voltage-clamp recordings from Xenopus oocytes, at extreme voltages (>40 mV) it can be difficult to differentiate current inactivation from decay of capacitive currents. In addition, care should be taken to ensure good voltage control, since a combination of large currents and high electrode resistance can mean the membrane is not clamped to the desired voltage until well after most of the inactivation process has occurred. Likewise, in whole cell patch-clamp experiments, proper compensation of series resistance as well as selection of cells expressing appropriately sized currents can help ensure a faithful voltage clamp and allow proper measurement of fast kinetics.

6. Steady-state inactivation

Several different approaches are routinely used in the literature to measure the voltage dependence of steady-state inactivation. Examples of each of these protocols are shown in FIGURE 14. The first two, the “rectification method” (547, 548) and the “extrapolation method” (649) both use the same two-step protocol described above for measuring the rate of recovery from inactivation, but with different approaches to extracting the relevant data. In each of these two cases, the proportion of channels that recover from inactivation, a reflection of the steady state, is assessed during the P2 test pulse. For the rectification method, the peak current during P2 is plotted against voltage and the degree of inactivation is determined by the extent of deviation of the \( \mathcal{I-V} \) relationship from a linear fit to the most extreme negative voltages where no inactivation occurs (FIGURE 14A). This rectification factor is then fitted with the Boltzmann function to give a \( V_{0.5} \) for inactivation (FIGURE 14C). The “extrapolation method” takes a different approach. In this case, the deactivation phase of the current during P2 is extrapolated back to the point where the membrane voltage is stepped from P1 to P2. This method aims to get a better representation of the degree of recovery from inactivation at each test potential by taking into account the small amount of deactivation that has already occurred before the current reaches its peak. The contaminating effect of deactivation is most prominent at more negative potentials where deactivation is faster (compare \( \mathcal{I-V} \) relationships in FIGURE 14A).
A third method uses a triple pulse voltage protocol. Cells are depolarized to (+40 mV for 500 ms) to ensure all channels are inactivated. The channels are then allowed to relax to a steady state of inactivation during a series of short P2 pulses (typically +20 mV to −300 mV for 30 ms). The peak current is then measured at the start of a P3 “revelatory step” (+20 mV) to assess the extent to which channels are inactivated at each P2 voltage (FIGURE 14B) (583). Analysis of inactivation using this protocol necessitates the use of an extra step. At more negative voltages, a proportion of the channels also deactivate during the P2 pulse, leading to the observed decrease in the peak current at negative potentials (FIGURE 14B). Before fitting of the Boltzmann equation, this deactivation must be corrected for. Since the duration of P2 is too short to fit and acquire an accurate reflection of the rate of deactivation, a separate protocol such as that shown in FIGURE 12 must also be analyzed to obtain the rates of deactivation at each P2 voltage. In our experience, using a two-exponential function to correct for deactivation gives more reproducible sigmoidal steady-state inactivation relationships that can then be well-fitted with a Boltzmann function (see Eq. 1).

Each method gives a different value for the $V_{0.5}$ of steady-state inactivation. These discrepancies are due in part to methodology differences, such as underestimation of recovery during the P2 pulse in the triple pulse protocol and inconsistent extrapolation or correction for the deactivation in the different protocols. It is also possible that some of the difference may also be due to the fact that there may be multiple open and multiple inactivated states, and that the voltage-dependent occupancy of these different states may be interrogated differently by each protocol. In any case, each of the methods provides an equally good means of comparison for the effects of system perturbations on the steady state of inactivation so long as a single method is used throughout a particular set of experiments. When comparing different studies though, it is important to be aware that if different methods have been used these will contribute to any apparent differences.

A fourth method that has been used to estimate the equilibrium constant for inactivation, $K_{\text{inact},V}$, that is of measuring the ratio of the forward and reverse rate constants, i.e.

$$K_{\text{inact},V} = k_{\text{inact},V} / k_{\text{rec},V}$$ (4)

For this method, the $V_{0.5}$ can then be calculated as the voltage at which $k_{\text{inact},V} = k_{\text{rec},V}$, which corresponds to the minimum on the chevron plot depicted in FIGURE 13C. This method invariably gives more positive values for $V_{0.5}$ than those obtained with the triple pulse and two pulse extrapolation methods (but not too dissimilar to that obtained using the rectification method). It has been argued that the $V_{0.5}$ measured using the rates method reflects inactivation occurring from the open state, i.e., inactivation that occurs whilst the voltage sensors are in the up conformation (658).

As mentioned in the previous section, expression of overly large membrane currents has consequences for good voltage control in electrophysiological experiments. In Xenopus oocyte recordings, large currents coupled with the heavily invaginated surface membrane can also result in local accumulation of $K^+$, which is particularly problematic as...
Kv11.1 inactivation is very sensitive to changes in extracellular \([\text{K}^+]/\text{H}^+\) (668). FIGURE 14D shows the relationship between the \(V_{0.5}\) for inactivation (assessed by the “rectification method”) and the magnitude of peak outward current, showing a depolarized shift in the \(V_{0.5}\) with increasing current magnitude. This phenomenon most likely occurs as a result of an accumulation of \(\text{K}^+\) which inhibits the inactivation process and so shifts the equilibrium to more positive potentials (see FIGURE 14D).

E. Molecular Basis of Activation

The process of opening and closing of voltage-dependent ion channels, in particular VGK channels, has been the subject of a plethora of studies over the past 60 years (65, 640). Broadly speaking, changes in the transmembrane electric field result in an outward displacement of the voltage-sensing domain (VSD) that is comprised of the first four transmembrane helices, S1-S4 (see FIGURE 3 above), and this movement is electromechanically coupled to opening of an activation gate at the cytoplasmic entrance of the ion conducting pore. It is generally accepted that the structural rearrangements that occur in the VSD are transferred to the pore domain via a physical interaction of the S4-S5 linkers with the cytoplasmic terminals of the S6 helices, which acts to open and close the activation gate (385, 642). However, there is less agreement in regard to the exact structural rearrangements that occur between the “up” and “down”
states of the voltage sensor domain, and more specifically the magnitude of movement of the voltage sensor between these states (640). These general principals of activation gating also apply to Kv11.1 with regards to the role of the VSD (601, 602, 720); S455 (173, 642, 648); S6 activation gate (245, 417, 689). The discussion below will therefore focus on what distinguishes Kv11.1 activation gating from that of other VGK channels.

1. The activation gate

Comparison of the crystal structures of several different potassium channels in either the open [e.g., MthK (296), KvAP (297), Kv1.2 (384), KirBac3.1 (57)] or closed state [KcsA (150), KirBac3.1 (337)] shows that the COOH-terminal part of the inner helices are tightly packed in the closed state but splayed apart in the open state, thus allowing passage of ions. The extent of this splaying probably varies between families (57, 111, 128), and the specific details of the hinge site and extent of hinge motion probably vary between channels. Two putative hinge points have been identified. First there is a highly conserved glycine residue (corresponding to Gly99 in KcsA, Gly466 in Shaker and Gly648 in hERG; see FIGURE 15). Mutations of this glycine to alanine or proline (392) have confirmed its importance as a hinge residue in multiple potassium channels. Second, in canonical voltage-gated K⁺ channels, there is a Pro-X-Pro motif just COOH terminal to the conserved glycine discussed above that has also been demonstrated to play an important role in opening and closing of the activation gate (137, 234, 345, 346). HERG, however, lacks the Pro-X-Pro motif, but instead contains a second glycine (Gly657) in a position corresponding to the second proline (see FIGURE 15).

In a scan of the S6 transmembrane helix, Mitcheson et al. (417) found that substitution of either Gly648 or Gly657 with alanine did not prevent channel opening in Kv11.1. More recently the same group showed that when both hERG S6 glycine residues were mutated to alanine, this did not substantially alter the voltage dependence or the rates of Kv11.1 activation, and did not affect block of Kv11.1 by terfenadine (a 10 Å diameter molecule which requires open-K⁺ channels, there is a Pro-X-Pro motif just COOH terminal to the conserved glycine discussed above that has also been demonstrated to play an important role in opening and closing of the activation gate (137, 234, 345, 346). HERG, however, lacks the Pro-X-Pro motif, but instead contains a second glycine (Gly657) in a position corresponding to the second proline (see FIGURE 15).

These data suggest that unlike other potassium channels, flexibility in these hinge regions is not a prerequisite for channel opening in Kv11.1. Conversely, replacing these glycine residues with proline, or larger hydrophobic residues, destabilizes the closed conformation and shifted the equilibrium toward the open state of the channel (245). Hardman et al. (245) also used molecular dynamics simulation techniques to examine the conformational dynamics of the S6 helices of G648A, G657A, G648A/G657A, compared with wild-type Kv11.1 channels. These simulations showed that regardless of the presence of alanine at position 648 or 657 there was inherent flexibility in the Kv11.1 S6 linker close to position Gly648 that was comparable in degree of swivel and kink to the open state of the KvAP

![Residue conservation](http://physrev.physiology.org/DownloadedFrom/10.2203.32.247)
channel (297). The authors concluded that the Kv11.1 pore, in contrast to other VGK channels, is more stable in the open conformation, and that the presence of glycine at positions 648 and 657 was important for helical packing rather than as a hinge.

Further differences in the COOH-terminal region of S6 between hERG and other voltage-sensitive channels were highlighted by Wynia-Smith et al. (689) using cysteine-scanning mutagenesis to investigate the role of the COOH-terminal end of the S6 helices in Kv11.1 gating. They found that the most important residues clustered into two S6 microdomains. The innermost of these, containing residues Gln664, Tyr667, and Ser668 (see Figure 15), formed a ringed domain, with the side chain of Gln664 occluding the conduction pathway in the closed state. Critically, this is more than a full helical turn away from the predicted gate, as determined through alignment with Shaker residue Val478 (382). Moreover, amino acid substitutions at the position corresponding to the Shaker gate (Ser660 in hERG) had little effect on gating, suggesting that the molecular location of the S6 activation gate is different in Kv11.1 channels. The second microdomain contained the residue Val659, which was sensitive to a wide range of substitutions. Their structural modeling showed this side chain buried in a pocket formed by the S5, S6, and S455 linker in the closed state, and interpreted the reduced slope in the voltage dependence of current activation for many mutants at this position to be indicative of a disruption of coupling between the voltage sensor and the activation gate. Overall, both the study by Hardman et al. and Wynia-Smith et al. highlight that mutagenesis in the S6 primarily disrupts the closed state of Kv11.1, suggesting specific interactions are necessary to stabilize Kv11.1 in the closed state (245).

2. The voltage sensing domain

It has been shown in a wide range of VGK channels that the first three or four positively charged residues in the S4 domain are predominantly responsible for sensing changes in the transmembrane electrical field (6, 372, 471, 483, 564). The first comprehensive study of the S4 region in Kv11.1 involved mutating each of the S4 charged residues, Lys525, Arg528, Arg531, Arg534 and Arg537, to glutamine (601). Neutralization of any of these charges shifted the voltage dependence of activation gating. A thermodynamic analysis of the shifts in activation equilibrium showed that of the two positions where mutants caused the largest perturbation of activation, Arg531Q shifted the equilibrium towards the closed state, while Lys525Q shifted the equilibrium toward the open state compared with wild-type channels. These data suggest that Lys525 stabilizes the closed and Arg531 stabilizes the open state in wild-type Kv11.1 channels. The mutations at position Arg531 also highlighted some clear differences with the activation process in Shaker channels. R531Q caused a depolarizing shift in the V0.5 of activation, whereas the equivalent mutation in Shaker (R371Q) causes a hyperpolarizing shift (6, 564). It is also worth noting that in all voltage-gated ion channels the vast majority of S4 charged residues are arginine but in the case of the outermost S4 charge in Kv11.1 it is lysine. By mutating Lys525 to cysteine and assessing the effects of different MTS reagents, Subbiah et al. (601) also showed that replacing the lysine with other positively charged residues did not restore the wild-type phenotype, suggesting that the specific lysine side chain rather than charge per se was important at this residue.

Soon after this initial characterization, Zhang and Tseng (720) used a Boltzmann analysis of the voltage dependence of current activation, coupled with cysteine scanning accessibility mutagenesis, to examine the contribution to the gating charge of each of the charged residues in the Kv11.1 S4 domain (720). They showed that only the three outermost charged residues contributed to activation gating charge, and this was supported by the state dependence of MTS accessibility of these three residues during activation. Piper et al. (500) subsequently used gating current measurements to show that Arg531 likely contributes to activation gating charge whilst residues Arg534, Arg537, and Lys538 do not. Unfortunately, the level of expression for K525A and R528A was too low to permit recording of gating currents (500). Nevertheless, the results of Piper et al. are consistent with those of Zhang and Tseng (720).

These initial characterizations suggested that in a broad sense, the overall contribution of the voltage-sensing domain to Kv11.1 activation is similar to other VGKs. But why then is the activation of ionic current so much slower in Kv11.1? Experiments on Shaker channels have shown that the S4 region moves rapidly in response to voltage and that channel activation quickly follows this movement (91, 353, 395). Slow activation gating in Kv11.1 could therefore be due to slower movement of the VSD, less efficient coupling between VSD movement, and opening of the S6 activation gate, or a combination of both factors. Smith and Yellen (584) addressed this question, using voltage clamp fluorometry. They attached a fluorescent probe to the extracellular end of the S4 domain to monitor conformational changes in this region in response to changes in membrane voltage, whilst simultaneously monitoring changes in ionic currents. In this study, the kinetics of the changes in fluorescence were slow and very similar to the kinetics of current activation. These data strongly supports the hypothesis that the slow kinetics of Kv11.1 activation, relative to other VGK channels, can be attributed to slow VSD movement rather than poor coupling between the VSD and the intracellular activation gate. The following year, these data were corroborated by the first measurement of gating currents in Kv11.1 channels. Using the cut open oocyte technique (65), Piper et al. (500) showed that the bulk (>95%) of charge movement associated with the Kv11.1 voltage sensor movement was slow (see Figure 16).
These data raise the question as to the origin of the slow movement of the voltage sensor. Is it an intrinsic property of the domain, and/or due to additional constraints placed on the voltage sensor limiting its movement? Subbiah et al. (602) investigated whether the environment surrounding S4 could have a significant impact on the rate at which the S4 domain can traverse the transmembrane electrical field. They hypothesized that if the Kv11.1 S4 helix was tightly abutted against surrounding protein domains, then its motion would be limited through steric hindrance. The authors examined this hypothesis using tryptophan-scanning mutagenesis, reasoning that the side chain of the tryptophan residue, being 1) bulky and 2) hydrophobic, should be poorly tolerated if there is close packing around the helix or there are tight protein-protein interactions. Surprisingly, mutation to tryptophan was tolerated in the entire region studied, from Leu524 to Leu539, suggesting the entire domain is loosely packed and not consistent with especially close interactions with other domains in the voltage sensor.

Zhang et al. (719) also investigated whether internal constraints, specifically whether a network of internal salt bridges between the positively charged residues in S4 and negative charges in the S1-S3 transmembrane helices, affected voltage sensor movement. In Shaker, and related VGKs, three conserved negative charges in the VSD,

![FIGURE 16. Comparison of gating current recordings for Kv11.1 (HERG) and Kv10.1 (EAG) channels. A: typical examples of Kv10.1 ionic currents. B: examples of Kv11.1 ionic currents during step depolarizations to potentials in the range −40 to +40 mV. C: plot of normalized ionic currents for Kv10.1 (black) and Kv11.1 (red). Typical examples of Kv10.1 (D) and Kv11.1 (E) gating currents for step depolarization to 0 mV and return to −120 mV. q_{on} (F) and q_{off} (G) for Kv10.1 (black) and Kv11.1 (red) plotted on the same time scale. Note the two very distinct components for Kv11.1 gating charge movement. [From Piper et al. (502), copyright National Academy of Sciences.]](http://physrev.physiology.org/
Glu283 and Glu293 in S2 and Asp316 in S3, are involved in proper folding of the voltage sensor (637) as well as contributing to gating charge movement (564). In Kv11.1, the equivalent residues are Asp456 and Asp466 in S2 and Asp501 in S3. In addition, there are three negative charges unique to the EAG family of VGK channels, Asp411 in S1, Asp460 in S2, and Asp509 in S3 (see FIGURE 17). Neutralization of Asp466 (377, 719) or Asp501 (377) by mutation to cysteine resulted in a change in the slope of the Boltzmann equation fitted to the steady-state activation curves, indicating that there may be a change in the gating charge of these channels. Mutation of Asp460 and Asp509 shifted the \( V_{0.5} \) for activation in the depolarizing direction as well as slowing the rate of activation, i.e., shifted the equilibrium toward the closed state, suggesting these residues stabilize the open state in wild-type channels. Conversely, D411C shifted the \( V_{0.5} \) of activation in the hyperpolarizing direction and accelerated activation, suggesting this residue was involved in stabilizing the closed state in the wild-type channel. Together with previous data showing that Lys525 stabilizes the closed state and Arg531 the open state (601), Lys525-Asp411 and Arg531-Asp460/Asp509 were suggested as possible salt bridge pairings in the closed and open states, respectively (501, 719). An alternative pairing for Asp411 in the closed state would be with Lys538, as mutations to Lys538 also cause significant hyperpolarizing shifts in steady-state activation (500, 602).

In addition to the internal constraints described above, multiple studies have shown that external factors also limit VSD movement in Kv11.1 channels. Van Slyke et al. (648) showed, using voltage clamp fluorometry, that mutants in the S4S5 linker, which they proposed to reduce the constraint on VSD movement, increased the rate and shifted the voltage dependence of both S4 movement and ionic current activation. These data again indicate that VSD movement limits the rate of current activation in Kv11.1, but that in turn, the movement of the VSD is constrained by other factors, in this case the S4S5 linker. Saenen et al. (538) reported that deletion of a charge cluster, KIKER, beginning at position 362 in the proximal NH2-terminal domain, immediately prior to the S1 transmembrane helix, resulted in a hyperpolarizing shift in the voltage-dependence of activation and increased the rate of the voltage-independent transition in the activation gating sequence. They proposed that the local electric field within this region modulates activation gating via electrostatic interactions with the gating machinery. The specific sites of interaction, however, remain to be identified.

3. Coupling of VSD to activation gate

The voltage-dependent rearrangements of the voltage-sensing domain are transmitted to the activation gate via a physical interaction of the S4S5 linkers with the cytoplasmic terminals of the S6 helices (385, 642). In Kv11.1, multiple mutations at two acidic positions in this linker, Asp540 and Glu544, have been shown to alter both activation and deactivation gating (551). The most dramatic of these, D540K, showed a U-shaped dependence of activation on voltage; that is opening at both depolarized and hyperpolarized potentials (420). Tristani-Firouzi et al. (642) used this novel background to probe the interaction between the S4S5 and the S6 helices and found that a single residue, Arg665 at the distal end of S6, was involved in the unique activation gating of D540K. The authors suggest that the activation at hyperpolarized potentials is mediated via charge repulsion between these sites, while in the wild-type channel, an electrostatic interaction between Asp540 and Arg665 provides a direct interaction between S4S5 and S6 which mediates coupling between the VSD and the S6 activation gate to stabilize the closed state. Interestingly, though, more subtle mutations to Asp540 (551) and Arg665 (689) do not have dramatic effects on steady-state activation, but instead affect only the rates of activation and deactivation. This suggests that these residues may not necessarily be involved in stabilizing the closed or open end states but rather may be important for stabilizing intermediate states in the activation process.

F. Molecular Basis of Slow Deactivation in Kv11.1 Channels

While the molecular basis of Kv11.1 activation gating is understood in a broad sense, this is in large part due to the similarities between Kv11.1 and other VGK channels. The mechanism of slow closure of Kv11.1 channels, however, cannot be explained by slow movement of the VSD alone. The Kv11.1 channel has unique cytosolic domains, compared with other VGK channels, and many of these domains have been shown to modulate deactivation kinetics.

1. Role of the NH2 terminus in slow deactivation of Kv11.1

Shortly after Kv11.1 was discovered, two groups independently reported that deletion of the NH2-terminal cytoplasmic domain resulted in acceleration of deactivation (558, 588). Initially it was thought that the PAS domain in the NH2 terminus (see FIGURE 3) was responsible for slow deactivation gating (425). Morais-Cabral et al. (425) showed that the fast deactivation phenotype of D2–373 channels could be substantially slowed by the addition of a recombinant protein corresponding to the PAS domain (residues 1–135). In addition to the deletion studies, several groups have shown that point mutations within the PAS domain result in an acceleration of the deactivation kinetics (99, 232, 425).

A small but important finding in the Morais-Cabral study was the observation that following patch excision, the recombinant PAS domain remained tightly bound to the D2–373 channels, suggesting that binding and unbinding
of the PAS domain cannot be directly responsible for deactivation gating which takes place over tens to hundreds of milliseconds. Recently, Gustina and Trudeau (232) confirmed the importance of the PAS domain by showing that a genetically encoded PAS domain restored wild-type-like slow deactivation kinetics to a “core” Kv11.1 construct missing the entire NH2-terminal cytoplasmic domain (Δ2–354), while mutant PAS domain
The PAS domain commences at residue 26. The preceding NH$_2$-tail 25 residues also play an important role in regulating Kv11.1 deactivation. Deletion of just the 25 residue NH$_2$-tail region results in a very similar phenotype to that seen for deletion of the entire NH$_2$-terminal cytoplasmic domain. Indeed, even deletion of just 9 (446) or 16 (659) residues can cause significant acceleration of deactivation. There are also numerous point mutants within this 25-residue tail domain that result in significantly faster rates of deactivation (431, 446). Wang et al. (659) have also shown that in inside-out macropatches, exogenous application of a peptide corresponding to residues 1–16, to “core” Kv11.1 constructs (Δ2–354) could substantially restore slow deactivation kinetics by stabilizing the open state. The authors noted, however, that the 1–16 peptide only slowed deactivation to an intermediate level, which they suggested could indicate that this peptide may be just one component of a more complex multidomain cytosolic arrangement that is needed for full restoration of function. Recently, three separate groups solved the structure of the hERG PAS domain using NMR spectroscopy (367, 431, 446), and each has noted that the NH$_2$-terminal tail formed by the first 25 amino acids contains a helical element (see Figure 18). Disruption of the α-helix, by substitution with a glycine/serine linker, whilst leaving the NH$_2$-terminal 14 residues intact, dramatically accelerated deactivation to a level comparable with the truncation of the entire 25 residue tail. This highlights the importance of this helical element in positioning the NH$_2$-terminal tail at its appropriate site of action (446). Li et al. (367) and Muskett et al. (431) reported broadly similar results.

From the foregoing discussion it is clear that the NH$_2$-terminal domain, comprising both the PAS domain as well as the NH$_2$-terminal tail, is critically involved in slow deactivation of Kv11.1 channels. A plausible hypothesis to explain these data would be that the PAS domain forms a stable interaction with the core of the channel, bringing the flexible NH$_2$-terminal tail close to the central conduction axis where it is in an appropriate position to regulate gating of the activation gate. Where then do the PAS domain and the NH$_2$-tail interact with the channel?

Gustina and Trudeau (231) have shown that deletions in the COOH-terminal region of the channel, specifically the cNBD, resulted in rapid deactivation kinetics similar to the deleted PAS domain construct. They also showed that when both the NH$_2$-terminal amino acids 1–135 and the cNBD were deleted, addition of a recombinant EAG domain could no longer restore slow deactivation. These data strongly suggest that the PAS domain binds to the cNBD. In 2009, Al

![Figure 18](http://physrev.physiology.org/)

**Figure 18.** Structure and function of hERG NH$_2$-terminal domain. A: solution structure of hERG PAS domain (residues 26–135) shown in blue (445) superimposed on the crystal structure of the PAS domain shown in red (425). B: 20 lowest energy structures of the NH$_2$-terminal 25 residues, superimposed on residues 12–23, which forms an amphipathic α-heli. C: putative models of role of PAS domain and NH$_2$-tail in regulating Kv11.1 deactivation. In both the open and closed states, the PAS domain remains bound to the cNBD. In the S4S5 model, the flexible NH$_2$-tail transiently binds to the S4S5 linker to stabilize the open state directly (367). In the cNBD model, the NH$_2$-tail binds to the “cAMP binding pocket” of the cNBD and regulates deactivation allosterically (431). [A and B from Ng et al. (445).]
G. Molecular Basis of Inactivation Gating

The rapidity and voltage-dependence of inactivation is perhaps the most important kinetic component of gating in regard to the role of Kv11.1 channels during the cardiac action potential (see sect. IID). Inactivation in Kv11.1 is most analogous to C-type inactivation in Shaker, yet it also has several unique features, most notably much faster and voltage-dependent kinetics (558, 583, 668).

1. Role of selectivity filter in inactivation

The importance of the selectivity filter in fast inactivation of Kv11.1 was first demonstrated in 1996, when Smith et al. (583) showed that the double mutation S631C-G628C abolished inactivation and Schonherr et al. (558) showed that mutation of Ser631 to alanine (the equivalent residue in the noninactivating Kv10.1 channel) largely eliminated inactivation. Two years later, Herzberg et al. (254) showed that transfer of a region encompassing the pore helix and selectivity filter between Kv11.1 and Kv10.1 channels conferred rapid inactivation to Kv10.1 and abolished it in Kv11.1 channels. The authors also showed that the S620T mutation in Kv11.1 (i.e., converting it to the equivalent residue in Kv10.1) removed inactivation. Ficker et al. reported similar findings for the S620T Kv11.1 mutant (178) and later showed that the replacement of Thr432 and Ala443 in Kv10.1 channels with serine (equivalent to Ser620 and Ser631 in Kv11.1) was sufficient to introduce fast inactivation (177).

In the last decade, our understanding of the molecular basis of gating at the selectivity filter has been revolutionized by the use of X-ray crystallography. First, Doyle et al. (150) revealed a network of hydrogen bonds and van der Waals forces to maintain the selectivity filter in a conformation relevant for selecting K\(^+\) over Na\(^+\). More recently, Perozo and co-workers (116, 127) identified residues Glu71 and Asp80 as critical for C-type inactivation in KcsA. The authors also suggest that this mechanism was likely conserved in voltage-gated channels since introducing glutamate at position Val370 in Kv1.2, a noninactivating channel in the absence of its \(\beta\)-subunit, recapitulated slow C-type inactivation. Further weight is added to this theory when considering that similar mutations in the selectivity filter and the proximal pore domain in several voltage-gated and inward rectifying potassium channels also have considerable effects on their gating properties (12, 178, 702).

Such diversity in the predictions for how the EAG domain may interact with the remainder of the channel simply highlights that the structural basis of slow deactivation gating is one of the least understood aspects of Kv11.1 gating. While it may be some way off, a crystal structure of the full-length Kv11.1 channel, including these intracellular assemblies, would help resolve these discrepancies and help guide the future direction of study in this area.

Owais et al. (11) identified a hydrophobic patch predicted to be on the surface of the cNBD (residues V794-I798) where introduction of charge mutants resulted in up to a sixfold increase in the rate of deactivation. They also noted that a similar hydrophobic patch had previously been identified on the surface of the PAS domain (425) and so suggested that these patches may provide a site for a stable interaction, although this remains to be verified experimentally.

There has also been extensive investigation of the role of the S4S5 linker in slow deactivation. Numerous studies have shown that mutations in the S4S5 linker can affect deactivation (642, 659, 661). Notably, Wang et al. (661) showed that NEM modification of a cysteine introduced at position Gly546 in the S4S5 linker accelerated deactivation in a similar manner to deletion of the NH2 terminus (\(\Delta 2\)-354). Furthermore, the effects of the NEM modification and the NH2-terminal deletion were not additive, indicating they likely disrupt the same process (661). More recently however, van Slyke et al. (648) used voltage-clamp fluorometry to show that the rate of VSD return during deactivation was altered by other mutations at position Gly546 (most notably G546V). The effect of the G546V mutation was not dependent on any NH2-terminal interaction with the S4S5 linker. Interestingly in the functional channel; however, it does not show that the rate of VSD return during deactivation was altered by other mutations at position Gly546 (most notably G546V). The effect of the G546V mutation was not dependent on any NH2-terminal interaction with the S4S5 linker (\(\Delta 2\)-354) Kv11.1 channels (648). In an alternative experimental approach, Li et al. (367) noted that titration of the PAS domain protein in the presence of a nine residue peptide corresponding to the S4S5 linker, shifted peaks in the HSQC spectrum. This change in chemical shift was taken to indicate specific interactions between the S4S5 peptide and several PAS domain residues. Yet another model for sites of interaction between the NH2 terminus and remainder of the channel has been proposed by de la Pena et al. (133). Using cysteine mutagenesis, they demonstrated that V3C in the NH2-tail could interact with Y542C in the S4S5 linker. This interaction appeared to preferentially occur when the channel was in the closed state. The fact that these residues are close enough to form disulfide bridges is evidence of proximity in the functional channel; however, it does not show whether this is a physiologically and functionally relevant interaction. Furthermore, the preference for interaction in the closed state is at odds with the data from Wang et al. indicating that the 16-residue peptide preferentially binds to the open state of NH2-terminally truncated (\(\Delta 2\)-354) channels (659).

Such diversity in the predictions for how the EAG domain may interact with the remainder of the channel simply highlights that the structural basis of slow deactivation gating is one of the least understood aspects of Kv11.1 gating. While it may be some way off, a crystal structure of the full-length Kv11.1 channel, including these intracellular assemblies, would help resolve these discrepancies and help guide the future direction of study in this area.
The equivalent residues in Kv11.1 are Tyr616 (Trp67 in KcsA), Phe617 (Trp68), Ser620 (Glu71), Phe627 (Tyr78), and Asn629 (Asp80) (see FIGURE 19). It has been postulated that the lack of these hydrogen bond networks in Kv11.1 contributes to the selectivity filter being more inclined to "collapse" leading to a faster rate of inactivation (167).

Molecular dynamic simulations of the pore helix and selectivity filter regions of Kv11.1, based on homology model of KcsA, have provided some insights into the molecular basis of Kv11.1 inactivation (592). In wild-type Kv11.1, the backbone carbonyl of the selectivity filter residue Phe627 often flips away from the central axis of the conduction pathway, disrupting the S0 K⁺ coordination site and so perturbing conduction. Conversely, in the presence of the S620T mutation, a water molecule stabilizes the backbone of the selectivity filter by sitting at the center of a network of hydrogen bonds between the pore helix and selectivity filter residues, similar to that previously identified in the crystal structure of KcsA (116). Specifically, the water molecule bridges Ser620 and Asn629. The equivalent residues in KcsA, Asp71 and Glu80, have been shown to be very important for C-type inactivation in KcsA (178, 254, 357).

A point worth considering here is the relationship between ionic selectivity and inactivation. With the process of inactivation seemingly so closely tied with the conformation of the selectivity filter, it is unsurprising that the two processes overlap. Several mutations that have been shown to alter inactivation gating in Kv11.1 have also shown to alter ionic selectivity (295, 357, 378, 644, 645). Gang and Zhang (197) examined this relationship in Kv11.1 channels, invoking the concept of separate P- and C-type steps to inactivation, where P-type refers to the initial closure of the selectivity filter and C-type refers to a stabilization of the inactive conformation (387). This multistep process has been associated with a decrease in selectivity for K⁺ over Na⁺ in other voltage-gated channels (593, 594) that can be observed as Na⁺ currents when recorded in K⁺-free conditions. In Kv11.1 channels, the fast transition to the P-type
state usually manifests as the termination of $K^+$ conductance, but can be detected as a transient $Na^+$ conductance in $K^+$-free conditions. The second slower transition to a stable C-type inactivated state, impermeable to either $K^+$ or $Na^+$, can be detected in $K^+$-free conditions as a slow decay in the $Na^+$ conductance. These experiments illustrate the tight interplay between inactivation gating at the selectivity filter and permeability. Given that in wild-type channels, the P-type and C-type inactivated states can only be separated in nonphysiological solutions, that is in the absence of $K^+$, most groups still continue to use the term C-type inactivation as a general description of the overall process.

2. Role of the pore outer mouth

In early studies of C-type inactivation in Shaker $K^+$ channels, Thr449 in the outer mouth region was identified as a key regulator. The equivalent residue in Kv11.1, Ser631, had been identified in early studies as important (see above). Heinemann et al. (558) initially suggested that the mutation S631A abolished inactivation. However, a subsequent study from Zou et al. (739) showed that the S631A mutation does not abolish inactivation, but results in a shift of the $V_{0.5}$ for inactivation by approximately +100 mV. A more in-depth investigation of the S631 position in Kv11.1, carried out by Fan et al. (167), identified some additional distinctions in the role of this position between Kv11.1 and Shaker channels. For example, mutation of this residue to either glutamate or lysine in Kv11.1 disrupted inactivation, while mutation of the equivalent residue in Shaker (Thr449) to either of these residues facilitated inactivation. Furthermore, in Shaker, Thr449 is an important determinant of sensitivity to TEA and has been shown to interact directly with the TEA molecule (252, 474). Conversely, in Kv11.1, TEA block is insensitive to mutations at this position, (474) and indeed, the mechanisms of block by TEA are likely to be quite different between Shaker and Kv11.1 (167, 573). Lastly, cysteine mutants at Ser631 in Kv11.1 form disulfides across the mouth of the pore much more readily than T449C in Shaker, suggesting that the outer mouth region in Kv11.1 is either narrower (167) or more flexible.

3. Role of S5P domain in inactivation

Beyond the subtle changes in structure of the outer mouth region of Kv11.1 compared with Shaker, there is of course a much more significant difference in the turret region between the EAG subfamily and other members of the VGK channel family. Kv11.1 has a much longer linker between the outer helix of the pore domain and the pore helix (i.e., the S5P linker, ~40 residues in Kv11.1) than in VGK channels (typically 12–15 residues).

Jiang et al. (294) first suggested that the longer S5P linker may be involved in Kv11.1 inactivation when they discovered that mutations of the two histidine residues in this region (His578 and His687) altered inactivation characteristics (294). In a subsequent paper, the authors examined the individual roles of these positions and noted that while His578 tolerated mutation to proline, cysteine, or lysine without affecting Kv11.1 gating properties, similar mutations at His587 altered inactivation as well as ion selectivity (159). This begged the question, how do mutations in the S5P linker, which is relatively far from the pore and selectivity filter in the primary sequence, impact inactivation and selectivity?

To examine the role of the S5P linker in more depth, Liu et al. (378) performed a cysteine scan of the entire region. Based on the accessibility of substituted cysteines to MTS modification, Tseng et al. suggested that the middle part of the linker (from Ile583 to Tyr597) forms a helical structure, which runs parallel to the membrane and is exposed to the extracellular environment along its whole length. The authors also proposed that the helix was orientated such that its NH$_2$ terminus was sitting close to the pore, since MTS modification of G584C caused a similar phenotype to modification of two residues near the pore entrance (T613C and S631C). In addition, many of the cysteine mutant channels could form intersubunit disulfide bonds (295), with disulfide bonds forming more readily for mutants in the NH$_2$-terminal half of the helix. They interpreted these data as indicating that the NH$_2$ terminus pointed towards the central pore (and therefore each other). However, introduction of many of these disulfides disrupted selectivity, and while this may reflect the previously discussed link between inactivation and selectivity, it is also possible that these channels may have been locked in nonnative conformations, so conclusions about native structure drawn from these experiments should be made with that caution in mind.

The prediction of a helical component in this region was confirmed in NMR studies from Torres et al. (641) who solved the structure of a 42-amino acid peptide corresponding to the S5P linker using two-dimensional NMR spectroscopy. They also showed that this helical region was amphipathic and was only seen in the presence of the membrane mimetic SDS micelles, but was unfolded in aqueous solutions. Interestingly, when CHO cells expressing wild-type Kv11.1 channels were superfused with exogenous S5P peptide, inactivation of the channels was disrupted. Furthermore, the interaction was voltage-dependent, with the off rate seemingly more voltage sensitive that the on rate. However, binding of the exogenous S5P peptide also resulted in disruption of selectivity and so again some caution needs to be applied to the interpretation of these experiments. Subsequently, Jiang et al. (295) used a combination of circular dichroism and NMR studies to show that the structure of the S5P domain was quite dynamic and suggested that it may switch between helical and unstructured conformations depending on its interaction with hydrophobic or...
aqueous environments. They also proposed that the S5P helical domains themselves were physically involved in terminating conduction during inactivation, either through stearic hindrance or though a local electrostatic potential formed as a result of the NH2-terminal positive helical dipoles being orientated towards the ion conduction pore preventing K+ conduction. While the S5P linker is clearly important, whether it is involved directly or is an allosteric regulator of the structure of the selectivity filter remains to be finalized.

4. Voltage sensitivity of inactivation

One of the most intriguing features of Kv11.1 inactivation gating is the origin of the voltage-dependence (547, 658, 668). Two main hypotheses have been considered. First, the voltage-dependence of inactivation arises from coupling to the S4 voltage sensor (502), and second, there is an inactivation voltage-sensing domain that is distinct from the activation voltage sensor (110).

As discussed in section II E, the major component of voltage sensor motion in Kv11.1, as detected by gating current measurements, is slow and, moreover, is proposed to be the rate-limiting step for slow activation (502). There is, however, also a fast component of voltage sensor movement (see FIGURE 16), which could couple to inactivation. In wild-type channels, this fast component is first detected at \(-80\) mV, well before the apparent threshold for channel opening, but consistent with the equilibrium voltage-dependence of inactivation. However, gating currents in wild-type and S631A Kv11.1 channels (a mutant that shifts the \(V_{0.5}\) of inactivation by \(+100\) mV) were indistinguishable, suggesting that either the voltage-dependence of inactivation was not derived from this fast component of the S4 gating charge or that mutations to Ser631 affect a later part of the inactivation process (638). Zhang et al. (720) also examined the contribution of S4 gating charge to inactivation voltage sensing, using the charge component of the Boltzmann equation as a reflection of the gating charge. In these experiments, neutralization of any of the six positive charges in the S4 transmembrane helix did not alter the apparent gating charge during inactivation.

Taking an alternative approach to monitoring voltage sensor motion, Smith and Yellen (584) used voltage-clamp fluorometry to simultaneously monitor ionic current and fluorescent changes were not affected by external application of TEA, which slows Kv11.1 inactivation (583), nor by the S631C-G628C double mutation that eliminates Kv11.1 inactivation. However, there are possible confounding factors in these experiments. Changes in the environment of the fluorophore (which lead to the observed changes in fluorescence) do not necessarily reflect movement of the S4 itself, but could report movement of other domains relative to this position. Even so, both the pharmacological and mutational disruptions of inactivation did not alter the fluorescent report, suggesting that the shared kinetics of the fluorescence and ionic inactivation may be purely coincidental and unrelated. More recently, Es-Salah-Lamoureux et al. (165) reexamined these fluorescent reports in the background of removal of endogenous cysteines and reported that the fast component of the signal actually related to fast VSD movement, with the slow component reporting opening of the activation gate but were unable to find direct evidence of a report of inactivation gating. The exact nature of the motion of the VSD of Kv11.1 and its role in inactivation is therefore unresolved.

In the absence of any concrete link between VSD movement and the voltage-dependent kinetics of the inactivation process, the extracellular S5P linker is a region that has been considered a possible candidate for the inactivation voltage sensor (110, 641). In their initial cysteine scanning mutagenesis experiments of the S5P linker, Tseng et al. (378) proposed that the S5P helical region may act as a bridge to couple the VSD and the outer mouth of the pore, i.e., upon depolarization, upward motion of the voltage sensors shift the S5P \(\alpha\)-helices toward the pore resulting in a physical and/or electrostatic barrier to ion conduction through the pore and hence inactivation of ion conduction. In 2006, Clarke et al. (110) showed that swapping the S5P domains between Kv11.1, Kv12.2 (hELK-2), and Kv10.1 (hEAG) had a large effect on the voltage-dependence of inactivation. They followed up on this observation by introducing different positive and negative charged residues at all the hydrophilic residues in the S5P \(\alpha\)-helix (His587, Asn588, Asp591, and Gln592) showing that the voltage range of Kv11.1 inactivation could be tuned over \(+150\) mV. Most dramatically, substitution of a lysine residue at either position 588 or 592 shifted the \(V_{0.5}\) of inactivation by 120 mV in the depolarized direction, whereas introduction of a glutamate at position Asn588 shifted inactivation \(-30\) mV in the hyperpolarized direction (110). Furthermore, the introduction of lysine residues into the S5P linker increased the slope of the Boltzmann fit to steady-state inactivation data, whereas introduction of negative charges decreased the slope. This would be consistent with the S5P being directly involved in voltage sensing. However, given the uncertainties of measuring changes in gating charge from Boltzmann fits to steady-state data, one cannot make definitive conclusions from these data.

Most recently, using voltage-clamp fluorometry studies of probes attached to R582C, which is located close to the NH2-terminal end of the S5P helix, Fougere et al. (187) reported a fast component of the fluorescent change that was coincident with rectification of the macroscopic
Kv11.1 current, i.e., between −20 and +60 mV (187). One problem with these data is that direct measurements of inactivation indicate that it is substantially completed by −20 mV (547, 583) even in the R528C mutant (187). Therefore, while these findings add more weight to the notion of the S5P helix contributing to Kv11.1 inactivation, perhaps as the voltage-sensing domain, this process is yet to be fully described.

5. Summary of voltage dependence

There is compelling evidence to suggest that voltage sensing for inactivation is distinct from the voltage sensing for activation. First, the two processes occur over quite distinct voltage ranges (668). Second, there are numerous mutations that have profound effects on the voltage sensitivity of activation but minimal effect on inactivation, such as mutations of charged residues in the S4 domain (500, 601). Vice versa, there are mutations that have profound effects on inactivation but minimal effect on activation, such as S631A (739) and N588K (110, 115). Third, changes in temperature have very different effects on the two processes, causing a hyperpolarizing shift in the midpoint of steady-state activation but a depolarizing shift in steady-state inactivation (649). It is important, however, to make the distinction between the differences in the range over which the voltage sensor operates and the molecular basis of the voltage sensor. It is possible that the S4 domain, in addition to being the voltage sensor for activation, could also be the voltage sensor for inactivation (either alone or in combination with other domains of the channel), despite the two processes occurring over different voltage ranges. An initial outward movement could contribute to activation gating, and a subsequent relaxation could contribute to inactivation. At this stage it seems most likely that both the S4 and S5P linker contribute to the voltage sensing for inactivation, but the specific mechanisms remain to be determined.

6. Macromolecular rearrangements in inactivation

Until recently, studies of C-type inactivation have focused on localized structural rearrangements in the vicinity of the selectivity filter. However, two recent crystallographic studies on KirBac (111) and KcsA (128) have shown that “collapse” of the selectivity filter may be linked to much more extensive macromolecular rearrangements involving domains throughout the channel protein. This has led to the suggestion that “collapse of the selectivity filter” may represent the final movement in a much more complex process. The concept that domains throughout the channel could be involved in inactivation came as no surprise to people working on Kv11.1 channels, given that mutations in so many disparate domains of the channel affected inactivation. In addition to the examples detailed above, there are also reports of deletions within the cytoplasmic COOH-terminal and NH2-terminal domains altering Kv11.1 inactivation (44).

In 2011, Wang et al. (658) reported an analysis of the contribution of different domains to the energetics of inactivation in Kv11.1, using Φ-value analysis (658). Φ-Value analysis compares the relative effects of an exogenous perturbation, such as a mutation, on the energetics of rates and equilibrium of a two-step reaction, to elucidate the relative temporal order with which different components (in this case domains of the channel) move during the transition between two stable end states. The authors showed that inactivation in Kv11.1 was initiated by exit of K+ from the selectivity filter, followed in order by conformational rearrangements of the S5 helix, extracellular turret region, S4 domain, S4S5 linker, and pore domain inner helix. They were not able to identify the final step but hypothesized that a collapse of the selectivity filter stabilized the final inactivated state. This seemingly complex allosteric process involving communication between extracellular, intracellular, and transmembrane domains is reminiscent of a Japanese puzzle box. Why the inactivation process is apparently so complex is an unresolved question, but one which would certainly open up multiple possibilities for regulation. If a similar mechanism is present in other channels, then there would be ample opportunity for kinetic fine-tuning, explaining why the rates of C-type inactivation vary by many orders of magnitude between different channels.

H. Models of Kv11.1 Gating

Kinetic modeling of ion channel activity serves two purposes. First, it provides a formal, quantitative mechanism for testing hypotheses about how channels work. Second, by building up models for all the different ion channels expressed in a cell, one can reproduce the electrical activity of an entire cell and ultimately build cells into models of organs and organisms. These models can then be used to interrogate the link between molecular defects and whole organ phenotypes. Cell and organ models, however, are only as good as the individual components that they are based on.

The biophysical accuracy of Kv11.1 models in reproducing gating kinetics is particularly important for several reasons. While simpler models may be able to approximate the global characteristics of the current, they are less effective in reproducing more complex time- and voltage-dependent effects (323, 390). It is also now widely accepted that binding of drugs to Kv11.1 channels (overwhelmingly the most common cause of drug-induced QT prolongation; see sect. VIII) is state dependent. In each of these scenarios, the accuracy of the model in predicting voltage-dependent changes in state occupancy is critical.

Over the past 25 years, models of I_Kr/Kv11.1 behavior have developed from Hodgkin-Huxley type descriptions (524),...
via relatively simple linear Markov schemes (668), to more complex Markov descriptions containing multiple closed, open, and inactive states (323, 390) as well as subunit cooperativity (502). While this increase in complexity has clearly arisen in parallel with a more in depth understanding of Kv11.1 gating, it is also a result of the availability of more powerful computer hardware that has facilitated the fitting of such models in a realistic time frame. This technological development is allowing more and more complex and realistic in silico simulations, meaning the coming years hold a huge amount of promise for this research field both in terms of how it drives our understanding of how ion channels work and in terms of clinical benefit felt from applied use of models.

The earliest models of $I_{Kr}$ were based on experimental data obtained for $I_{KCL}$ in cardiac myocytes (448, 572). However, in these early studies, researchers were still grappling with technical difficulties such as dissecting the multiple components to $I_{KCL}$ and trying to tease out the unique kinetics of $I_{Kr}$. As a result, these models are not commonly used today and are not discussed in detail here.

The simplest, and perhaps most used, model of voltage-gated ion channel behavior is based on the formalism introduced by Hodgkin and Huxley 60 years ago (263). In these formulations, the current passed through the channel is simply a function of two gating variables, an activation gate and an inactivation gate. These models can incorporate pseudo second-order kinetics by including power functions for each rate constant. The parameters used for simulation in Figure 20 are taken from ten Tusscher et al. (620). While there are earlier instances of Hodgkin-Huxley descriptions of $I_{Kr}$ (119, 506), this is the first that is based on fits to expressed Kv11.1 current. The authors note that their implementation is dramatically different from previous uses, with shifts of up to 60 mV in its steady-state gating characteristics (620).

In 1997, Wang et al. (668) developed a simple linear Markov scheme based on experimental data obtained from Kv11.1 currents expressed in oocytes. In contrast to the Hodgkin-Huxley type models, Markov schemes can allow incorporation of multiple open, closed, and inactive states, with transitions between each individual state determined by a voltage-dependent rate constant. To determine the number of pre-open closed states, the authors used an envelope of tails protocol to describe the onset of current activation (see sect. IVD) with depolarizations to the activating potential of +50 mV taken from −120 mV to ensure that the resting potential of each step reflected the fully deactivated state. The activation time course was fitted with a series of activation models ($C_0 \rightarrow C_1 \ldots C_n \rightarrow O$) with a varying number of pre-open closed states, and it was found that a minimum of three closed states was required to achieve good fits to the experimental data (668).

As the rates of activation reach a plateau at positive potentials, Wang et al. (668) included a voltage-independent step in the Kv11.1 activation pathway. The rationale for choosing the $C_1-C_2$ transition to be voltage independent was based on the fact that rates of deactivation are strongly voltage dependent, meaning that the final $C_2-O$ transition had to be voltage-dependent. And second, the duration of the sigmoidal phase in activation time courses continues to shorten at the most positive depolarization steps, which they interpreted as the first $C_0-C_1$ transition being weakly voltage-dependent. This model for activation was then fitted to activation time courses for multiple voltages, steady-state activation data, and deactivation time constants. Finally, an inactivation state was included in this linear gating scheme. Since the authors were able to fit their measured forward and reverse rate constants for inactivation with first-order voltage-dependent models, this is included as a simple single state transition from the open state.

Two years later, Kiehn et al. (323) published an expansion of this model that included inactivation from the final pre-open closed state (see Figure 20). The authors proposed that this transition was necessary to explain 1) the presence of channel openings upon repolarization when no channel openings had occurred during the preceding depolarization step and 2) the voltage-dependence of the magnitude of the transient peak upon depolarization. The authors evaluated several Markov model structures by fitting to macroscopic Kv11.1 currents and showed that a closed to inactive transition was necessary to accurately reproduce the transient peak observed experimentally upon depolarization. The model, however, was only used to simulate a few simple voltage protocols.

The “closed state inactivation model” was not parameterized fully, or used to simulate more physiologically relevant action potential waveforms until two years later when an adaptation of the model proposed by Kiehn et al. was used in an in silico evaluation of long QT syndrome (108, 403) and in evaluating the effects of premature stimulation on Kv11.1 gating (390). In these cases a five-state model with inactivation between both the closed and open states was employed (Figure 20). Each of these groups took different approaches to constraining the parameters in the model. Lu et al. fitted the model to activation, deactivation, and inactivation data recorded from Kv11.1 currents recorded in CHO cells at 37°C (390), Mazhari et al. (403) fitted their model to similar data acquired at 22°C and scaled the transition rates with a $Q_{10}$ of 3.3, whilst Clancy and Rudy (108) used data obtained from guinea pig cardiac myocytes to constrain their models. As a result, the models in each of these publications, despite having the same structure, have different rate constants and hence different current outputs during simulation.

In 2003, Piper et al. (502) proposed a more complex model based on measurement of gating currents in relation to activa-
tion and inactivation gating (see **Figure 20**). In particular, this model includes an extra closed state as well as transitions for individual VSDs between the up and down configurations. As a result, the first two closed state transitions were treated independently for each of four subunits of the channel with a statistical factor for both steps (S0 $\rightarrow$ S1 and S1 $\rightarrow$ S2) and positive cooperativity included in the S1 $\rightarrow$ S2 transition. For each of the first two transitions, $S_n \rightarrow S_{n+1}$ the transition sequence is considered as

$$
S0000 \xleftarrow{4\alpha} S0001 \xrightarrow{1-\beta} S0001 \xrightarrow{3\alpha-c} S0011 \xleftarrow{2\beta-c^{-1}} S0111 \xrightarrow{1\alpha-c^3} S1111
$$

The four steps represent the four individual subunit transitions. For the first step, the “four” multiple reflects the availability of four subunits while in the second transition, this drops to three and a cooperativity factor, $c$, is included. Under this scenario, the model predicts that the fast component of the gating charge (see discussion in sect. IV) is derived from the S0 $\rightarrow$ S1 subunit transition, and not inactivation. The remaining transitions were all considered concerted rearrangements involving all of the subunits. This model also incorporates two open states based on single-channel data previously reported (323, 738), as well as closed state inactivation (323). In this regard, based on their transition rates, the C2 $\rightarrow$ O1 transition is dominant over the C2 $\rightarrow$ O2 transition at depolarized potentials.

The final model summarized here is that presented by Smith and Yellen (584) that has its roots in a very different data-set, and hence has a different structure (see **Figure 20**). The
authors developed this model to specifically represent changes in conformational state of the VSD based on fluorescent measurements reporting the movement of this domain in response to voltage (see sect. IV.E). For illustration we have only shown the structure of the model they suggest reproduces ionic current more faithfully, although both of their original models describe the fluorescent datasets equally well. In this model the VSD is supposed to have four conformational states: q_r, q_R, r_Q, and Q_R and two types of conformational change q→Q and r→R, where the first of these is fast and the second slow. Upon depolarization, the VSD quickly changes conformation between q_r and Q_R before slowly transitioning to Q_R. Conversely, upon repolarization, the VSD quickly transitions from Q_R to q_R before slowly transitioning to q_r. In the original paper, these fast and slow transitions, occurring in parallel, account for the fast and slow components of the fluorescent report of VSD movement (see FIGURE 20). Based on prior knowledge of Kv11.1 kinetics, the authors suggest that slow q→Q transitions reflect slow activation/deactivation while fast r→R transitions reflect fast inactivation/recovery from inactivation as annotated in the model. For the purpose of simulation of ionic current, the occupancy of q_R is considered proportional to the open state. However, since this is solely a model for VSD movement, and does not include any coupling to gates in the conduction pathway, this model cannot be considered a true description of channel gating and is not routinely used as such.

1. Comparison of model outputs

$I_{K_r}$ currents and corresponding ventricular action potential waveforms simulated using each of the models discussed above are shown in FIGURE 20. The $I_{K_r}$ profiles described by the different models are quite diverse, and as a result, the action potential waveforms have significantly different durations and shapes. It should be noted that in these examples, an identical conductance value for $I_{K_r}$ was used in each case; hence, the magnitudes of the currents could potentially be scaled to be more similar. The kinetics, however, are largely unaffected by this parameter, except indirectly via altered contribution to the cellular membrane potential. The important consequence of these varied current profiles is that in interrogating physiological and pathophysiological questions, each of these models would be expected to make different predictions, but clearly not all of the models can be correct. Recent advances in computational hardware are making organ level simulations incorporating more complex biophysically accurate cellular models possible on practical time scales. Simulations at this level of scale and complexity have the potential to give us an unprecedented level of insight into the electrical system of the heart in the coming years. However, before we can take advantage of these technological gains in relation to the role of Kv11.1 channels in arrhythmogenesis, there is clearly a need for an examination of these kinetic models to provide accurate descriptions of Kv11.1 gating under both physiological and pathophysiological conditions.

V. PHARMACOLOGY OF Kv11.1 CHANNELS

The pharmacology of Kv11.1 has become a subject of intense interest following the discovery that this channel is the molecular target for the vast majority of drugs associated with drug-induced arrhythmias (see sect. VIII). In this section we will discuss the pharmacology of Kv11.1 channels and review how understanding the gating of these channels has provided insights into the molecular basis of drug-induced QT prolongation.

A. Drug Binding to Kv11.1 Channels

Voltage-gated ion channels are not static structures but instead undergo substantial conformational changes as they open, close, and inactivate. Determining how drugs bind to ion channels and how the affinity or kinetics of drug block are influenced by the gating state of the channel has been of significant interest for nearly half a century. Many of the classical principles of state-dependent drug block originate from studies examining the action of quaternary ammonium (QA) compounds on the delayed rectifier $K^+$ current of squid giant axons (32–36) or local anesthetic block of the sodium current in frog myelinated nerve or muscle fibers (120, 258, 259, 268, 561, 597). Insights gained from these studies have had a significant influence on how people think about drug block of Kv11.1 channels. There are, however, some subtle differences between how drugs block Kv11.1 compared with other voltage-gated ion channels as discussed below.

1. Drug block requires channel opening

Spanning a decade (1965–74), Armstrong published a series of seminal papers investigating the block of delayed rectifier $K^+$ current ($I_{K_r}$) by QA compounds (32–36). The key findings were as follows: 1) block by QA from the intracellular side requires channel opening by membrane depolarization (33, 36); 2) the onset of voltage-dependent block by hydrophobic QA compounds can be directly observed by a decrease in outward $I_{K_r}$ (32, 34, 35); and 3) at membrane potentials more negative than the reversal potential for potassium, a rapid dissociation of QA ions from open channels is observed because the inward flow of $K^+$ ions helps remove QA ions from the permeation pathway, an effect that is accelerated by increasing the external $K^+$ concentration (32–34). In a study using positively charged derivatives of local anesthetics (namely QX-314), which do not easily cross the lipid membrane, Strichartz (597) demonstrated a form of open channel block of $Na^+$ current that, like the QA block of $I_{K_r}$, is strongly voltage-dependent. Consistent
with these findings, Armstrong (33) and Strichartz (597) proposed simple models which assert that blockers, acting from the intracellular side, must pass through an internal gate to gain access to their receptor site within the ion conducting pathway of the channel pore. Moreover, the blockers are prevented from exiting through the external side by a narrowing of the pore which allows only the passage of permeant ions (33, 34). Subsequently, these models of the pore have been validated by crystal structures of multiple K+ channel proteins (111, 150, 244, 297, 337, 384, 386, 619, 682), as well as a bacterial voltage-gated Na+ channel (479).

Similar to QA block of \( I_K \) or local anesthetic block of Na current, the vast majority of drugs which target Kv11.1 channels require channels to open before they can gain access to the receptor site within the inner cavity of the channel pore, between the selectivity filter on the external side and the internal activation gate (86, 325, 420, 587, 698, 738). Two exceptions to this rule are drugs that inhibit trafficking of Kv11.1 channel protein (discussed in sect. VC) and Kv11.1 channel toxins (sect. VF).

2. Modulated receptor hypothesis for drug block

In 1977, Hille (258) extended the open channel block model by proposing the modulated receptor hypothesis for local anesthetic block of sodium current in frog axons. The hypothesis centered around earlier findings that the binding of local anesthetics promoted inactivation gating of sodium channels and that block was reduced by procedures that alleviated inactivation, i.e., membrane hyperpolarization (120, 258, 259, 321, 680) or pronase treatment (83). In the modulated receptor hypothesis, which is analogous to the model for allosteric modulation of enzyme activity proposed by Monod et al. (424), local anesthetics preferentially bind to the inactivated state of sodium channels and, in turn, local anesthetic binding promotes inactivation (258).

Whether Kv11.1 channel blockers preferentially bind to the open or the inactivated state has been the subject of many studies. Binding to the inactivated state was initially thought to be unfavorable because strong depolarizations actually reduced the affinity for dofetilide (324, 586, 697). However, reduced block at strong depolarizations could also occur if drug binding was voltage dependent, although this remains to be formally tested. Wang et al. (669) and Suessbrich et al. (604) showed that block by E4031 or LY97241 was reduced in mutant Kv11.1 channels which lack C-type inactivation. Subsequently, a variety of Kv11.1 mutations that impair or remove inactivation have been shown to alter the affinity of a multitude of drugs (178, 356, 452, 694), especially those of high affinity such as dofetilide (484). Other factors that alter inactivation, such as the addition of divalent cations (Cd\(^{2+}\)) or the removal of extracellular sodium, also reduce block (55, 452). Together, these studies provide evidence that inactivation plays a role in Kv11.1 channel block. Although it is important to remember that for some drugs the affinity for binding to the open and inactivated states is very similar (e.g., quinidine), the preference for binding to the inactivated state appears to be drug-dependent (484). An important difference between Kv11.1 channels and sodium channels with respect to drug binding to the inactivated state is that Kv11.1 channels undergo C-type inactivation rather than N-type inactivation (see sect. VC).

3. Drug trapping

To fully understand the relationship between drug binding and channel gating, we also need to consider the dissociation of the drug from its receptor. When examining recovery of \( I_K \) from QA block, two distinct phases were observed, a prominent rapid phase that was enhanced by increased extracellular potassium or membrane hyperpolarization, and an additional, much slower phase that was slower at hyperpolarized potentials (32–34). Armstrong (33) suggested that the initial rapid phase represents dissociation of QA compounds through the open gate of the channel, whereas the slower phase represents dissociation of drugs which had been retained within the pore of the channel by closure of the gate during repolarization, which was termed drug trapping. The smaller the side chain of the QA compound, the slower the second phase of recovery, meaning that smaller compounds are more easily trapped (33). Larger compounds may prevent closure of the activation gate, analogous to a foot-in-a-door effect (84, 258, 699). Local anesthetics too can be trapped within the pore of sodium channels at resting membrane potentials (i.e., –80 mV) (597), although this may also depend on the size of the compound (258). As a consequence of drug trapping, repetitive depolarizations, such as those associated with a train of action potentials, can cause block to accumulate because unbinding between depolarizations is minimal. This phenomenon was termed use-dependent block and is also observed with uncharged local anesthetics (120), although alternative pathways may also exist for more rapid recovery from block by more hydrophobic drugs (258, 259, 268, 561).

Recovery from block, at least for some Kv11.1 channel blockers, occurs relatively slowly compared with the rate of onset of block (86, 311, 420, 485, 596, 698). However, accurately assessing rates for recovery from block by different drugs is complicated by the use of different experimental protocols and the differences in state-dependent binding. It was noted by Yang and co-workers (698) that the slow recovery from block could mean that drugs are “trapped” within the inner cavity of the channel in the closed state following membrane repolarization. This would require closure of the activation gate while the drug remained bound within the cavity (420), which would be problematic for many of the larger Kv11.1 blockers. Studies utilizing a novel point mutation that allows Kv11.1 channels to open...
both with depolarization and again in response to strong hyperpolarization show that recovery from block by some drugs is augmented at negative potentials in these channels (311, 420, 596). If drug trapping in the closed state does exist, it may require reorientation of the drug compared with open or inactivated state binding modes (591, 705). Increasingly though, it is evident that trapping in the closed state is not necessarily true for all drugs (418, 485, 596). For example, the slow recovery from block by clofilium was not improved in D540K mutant Kv11.1 channels. This suggests that clofilium is held within the inner cavity of the channel even when the activation gate is open and membrane repolarization favors exit of the drug (485). One intriguing possibility is that the drug is held in the inactivated state via stronger binding to some residues (485). Further studies are required to further understand these phenomena.

B. Molecular Basis of Drug Binding

We now know that the majority of drugs bind within the inner cavity of Kv11.1 to block conduction of potassium ions through the central pore of the channel. In 2000, a mutagenesis study of four residues within the S6 helix, chosen based on homology differences with other Kv channels, reported the importance of a single aromatic residue (Phe656) for block by dofetilide (336). Alanine scanning mutagenesis subsequently revealed a more substantial binding site for the anti-arrhythmic agent MK-499 (419). This includes polar residues located at the base of the pore helix (Thr623 and Ser624), as well as aromatic residues on the S6 helix (Tyr652 and Phe656) both of which line the inner cavity of the channel (see FIGURE 21). The relative contribution of polar pore helix residues to drug binding appears compound-specific (419, 485). Indeed, mutation of polar residues can decrease the potency of ibutilide analogs between 30- and 1,000-fold depending on the para-substituent attached to the phenyl ring (489). In contrast, numerous studies have confirmed that aromatic S6 residues Tyr652 and Phe656 are crucial for high-affinity block by a range of different chemical entities (172, 356, 419). Systematic mutations at these two key positions indicate that high-affinity block by cisapride or terfenadine requires an aromatic side chain at position 652 and a hydrophobic side chain at position 656 (172). The aromatic side chain requirement at position 652 suggests that the π-electrons of the ring may form π-cation or π-π interactions with the drug molecule via charged nitrogen or aromatic ring structures, respectively (172, 591). Experiments using tandem dimers indicate that drugs such as cisapride can interact with Tyr652 residues on multiple subunits of the channel (432) and that the exact nature of these multisubunit interactions may be drug-specific (282). In silico modeling of drug-channel interactions using a homology model of Kv11.1 support these conclusions, and also suggest that individual drugs could adopt a multitude of binding conformations (168, 591). Certainly the concentric arrangement of aromatic side chains (Tyr652, Phe656) from each of the four subunits that line the cavity, together with the eight polar residues just below the selectivity filter, would allow for ample variability in the binding site of diverse drugs.

Whereas polar residues at the base of the pore helix are highly conserved among members of the VGK channel family, the aromatic residues (Tyr652, Phe656) on the S6 helices are not (568). These aromatic residues explain much of the extraordinary sensitivity of Kv11.1 channels to block by a diverse range of chemical entities. One problem with this hypothesis, however, is that the closely related Kv10.1
channel also possesses Tyr and Phe residues in analogous positions to Kv11.1, but the Kv10.1 channels are substantially less sensitive to block by most drugs (177, 254). One important difference between Kv10.1 and Kv11.1 is that the former do not exhibit the same rapid C-type inactivation process observed in Kv11.1 channels (177, 254). Indeed, transfer of the pore and upper S6 helix (Val612-Leu650) from Kv11.1 into Kv10.1 channels not only introduces rapid C-type inactivation it also increases the sensitivity to drug block such that it is now comparable with that of Kv11.1 channels (254). Indeed, mutation of just three residues in Kv10.1 (T432S/A443S/A453S) is enough to observe inactivation and drug binding phenotypes that are closer to Kv11.1 than wild-type Kv10.1 (177). Together with the earlier observations that Kv11.1 channel mutations that impair C-type inactivation also reduce sensitivity to block, these studies in Kv10.1 strongly suggested that rapid C-type inactivation was a requirement for high-affinity block. However, it is not quite as simple as that. First, not all high-affinity drugs favor binding to the inactivated state. Clofilium, for example, can block Kv10.1 channels with the same affinity as it blocks Kv11.1 channels (206, 208). Second, mutations that enhance inactivation can still reduce sensitivity to block (419). Third, and most important, the reduced sensitivity to block exhibited by mutant Kv11.1 channels with impaired inactivation is relatively minor compared with mutations to key binding residues such as Tyr652 or Phe656 (452, 484, 669). This would suggest that the predominance of inactivated state binding is not necessarily critical, and it may vary from drug to drug (484).

If, as seems likely, at least some drugs bind preferentially to the inactivated state, what is the mechanism that underlies this phenomenon? One possibility is that inactivation alters the side chain position of residues at the base of the pore helix (Thr623, Ser624), which then could facilitate drug binding. Two recent in silico studies have suggested that relaxation of the pore helix (282) or reorientation of pore helix polar residue side chains (592) is associated with inactivation. While this possibility is still valid, an important study by Chen et al. (97) demonstrated that repositioning of key binding residues, Tyr652 and Phe656, one position (100°) down the S6 helix, substantially increased sensitivity of Kv10.1 channels to cisapride even if inactivation was absent. This suggests that it is the positioning of the S6 aromatic residues and not the inactivation process itself that is important. Interestingly, the repositioning of residues in Kv10.1 did not confer sensitivity to block by MK-499 (97). One possible explanation is that the repositioning occurs relative to other important binding residues within the cavity, in particular the pore helix residues, which are important for binding MK499 but less so for cisapride. A subtle repositioning of the side-chains of Tyr652 and/or Phe656, which favors binding of some drugs, could occur naturally during transition from the open state to the C-type inactivate state of Kv11.1 channels (97). In support of this proposition, removal of inactivation by mutation is not additive to removal of Phe656, an important binding residue (391). Computer modeling using a Kv11.1 channel model suggests that rotation of the S6 helix from Gly648 downwards can reposition Tyr652 and Phe656 in a more favorable orientation for drug binding. A second in silico model, suggesting an alternative perpendicular binding mode, infers that the rotameric flexibility of Tyr652 side chains is critical during inactivation, and that rotation of at least one of the four Tyr652 side chains during inactivation could enhance binding (705). In either case, the dynamic nature of the drug-binding site of Kv11.1 offers even more possibilities for variations to drug binding conformations.

C. Drugs Can Alter hERG Protein Trafficking

The vast majority of drugs reduce $I_{Kr}$ via block of potassium conduction through the pore as outlined above. Another potential mechanism by which drugs can reduce $I_{Kr}$ is through a reduction in the number of Kv11.1 channels in the membrane. Several drugs that confer loss of function through reduced trafficking have recently been identified (179). Some drugs, including arsenic trioxide (179), pentamidine (117, 342), and probucol (226), used at concentrations known to cause QT prolongation and arrhythmia, disrupt hERG trafficking without direct channel block. Others, such as fluoxetine and ketoconazole, can acutely block Kv11.1 channels and reduce hERG protein at the cell membrane following long-term exposure (512, 614). It is worth noting that mutation of Phe656 abolished channel block but had no effect on the impaired trafficking of hERG protein by either drug (512, 614). This may reflect either alternative binding sites on the channel (663) or targeting of a distinct pathway that in turn regulates hERG protein trafficking (176). In any case, it is important to consider impaired trafficking as an alternative mechanism for drug-induced QT prolongation, especially as conventional compound screening procedures for Kv11.1 block liability may not detect reductions in current through this mechanism.

D. In Silico Modeling of Kv11.1 Drug Block

To determine a drug’s liability for causing prolongation of the QT interval, the pharmaceutical industry uses an initial nonclinical multtier approach to screen all new chemical entities as laid out by the ICH (International Conference on Harmonization of technical requirement for registration of pharmaceuticals for human use) guideline S7B (375). However, prior to this, in silico modeling can be used to assess the likelihood that any given drug will block Kv11.1 channels. Most of the modeling approaches to date have exploited ligand-based approaches, like (QSAR) and/or classification models, to build pharmacophores that highlight chemical moieties on a drug that positively or negatively correlate with block (39).
In 1992, Morgan and Sullivan published a pharmacophore model, based on a limited number of class III antiarrhythmic agents which are now known to preferentially block Kv11.1 channels (426). At the core of this pharmacophore lies a basic amine core attached by a short linker (1–4 atoms) to a phenyl ring. The nature of a para-substituent attached to the phenyl ring, in addition to two lipophilic substituents of the amine (one or more of which may be aromatic), were also acknowledged as important determinants of function. Remarkably, these key features are in general agreement with three pharmacophore models published 10 years later using 3D-QSAR modeling of known Kv11.1 channel blockers (89, 162, 481). Subsequent 2D- and 3D-QSAR models developed based on much larger and more diverse training sets did not dramatically improve their predictive capacity (201, 562), and one model exhibited lower prediction accuracy as new compound sets of diverse class and structure were added over time (201). One explanation is that structurally diverse compounds may preferentially bind to the channel during distinct gating states (open or inactivated). A rigid pharmacophore model may therefore not be the best solution, despite the apparent homogenous nature of the binding site (146, 320, 336, 617, 703). Recent studies have attempted to address the problem of multiple binding modes for different drugs (146, 320, 336, 617, 703). One approach taken by Kramer et al. (336) was to produce a composite model of two pharmacophores for high-affinity Kv11.1 blockers, as well as a third model for compounds that did not fit either of the first two pharmacophores (labeled nonspecific). This multimodel approach contrasts that of Tan et al. (617) who produced an ensemble pharmacophore derived from 5 best in class models distilled down from an initial 47. Both methods offer promising approaches to overcome the problems with static pharmacophore models.

A second approach, statistical classification, aims to predict the potency of compounds based on a variety of parameters such as fragmental partition coefficient and hydrophobicity. Various classification methods have now been used to examine parameters associated with Kv11.1 block potency (40, 156, 320, 368, 453, 523, 606, 627, 638). In general, classification models appear to have greater accuracy for inactive (nonpotent) than active (potent) compounds (40, 156, 320, 368, 453, 523, 606, 627, 638). This is not surprising as most studies use training compound datasets that contain many more inactive than active compounds, so skewing the statistical analysis. Recent support vector machine based classification models using large compound datasets exhibit much improved prediction power (291, 569).

Overall, the pharmacophore models generated by either method highlight some key physicochemical features of high-affinity Kv11.1 channel blockers: 1) hydrophobicity, in the form of aliphatic chains or aromatic rings, probably due to strong hydrophobic and/or π-stacking interactions with Tyr652 and Phe656 on the S6 helix of the channel (156, 523, 569, 617, 627, 638); 2) flexibility (562, 617, 638), which could reflect the ability of small molecules to take a variety of conformations within the inner cavity of the channel (105, 168, 399, 705); 3) increasing the number of aromatic rings has a positive correlation with block potency (447, 569, 606, 617); and 4) the presence of a charged amine shows strong correlation with high potency but is not necessarily crucial (38, 617). In contrast, molecular features that in general negatively correlate with block include the presence of polar entities (156, 447, 569, 638, 703) and hydrophilic groups close to hydrophobic regions of the drug (562, 569). On this note, distances between features (such as proximity between nonpolar atoms or between hydrogen bond donors and polar groups) may also be significant factors (569, 599).

One of the principle challenges in understanding Kv11.1 block using in silico modeling is interpreting the wealth of ligand-based modeling data within the context of a receptor model. Part of this challenge is due to the absence of direct structural information for the Kv11.1 channel. Instead, researchers must rely on homology models based on potassium channels for which there are crystal structures but where the degree of homology can be highly questionable for some regions of the protein potentially important for drug block (378, 641). Even when accurate alignments can be made, homology models based on crystal structures are a static picture of the channel in a single state and do not provide information regarding structural rearrangements that occur during gating transitions that likely contribute to state dependent drug binding (591, 592). A further complication is the inclusion of lipid membranes into these models using molecular dynamics simulations, which may be important for a stable Kv11.1 channel model (399, 595). Despite these significant problems in obtaining an accurate receptor model of Kv11.1, several sophisticated in silico models of drug binding exist (74, 160, 168, 282, 399, 591, 595, 705). The different docking strategies and diverse test structures used in these studies makes a comparison of binding conformations difficult. However, a few key points can be made. First, the predicted orientation of drugs within the inner cavity of the channel is variable. Relative to the conduction axis, there are three principle conformations: “curled” (168, 591), parallel (399, 591), and perpendicular (705). This variation may stem from the different homology models used for docking simulations (591, 705). Second, all studies highlighted the importance of multiple π-stacking and hydrophobic interactions with the aromatic side chains of two S6 helix residues, Tyr652 and Phe656. Furthermore, the simulations suggest that drugs can form aromatic and hydrophobic interactions with more than one subunit of the channel (74, 168, 282, 399, 591, 705). This fits well with ligand-derived models which indicate that multiple aromatic and/or aliphatic chains are critical for high-affinity...
block (156, 523, 569, 617, 627, 638). Positioning the side chains of Phe656, and particularly Tyr652, is then critical for drug interaction (591, 705). This may corroborate suggestions that repositioning of these residues during inactivation allows for a higher affinity interaction between drug and channel (97, 591, 705). Finally, some of the docking simulations noted the absence of a cation-π interaction between protonated nitrogen on the drug and an aromatic side chain of Tyr652 (74, 168, 282). Although ligand-based models suggest that this charged nitrogen is not crucial, its presence does correlate well with high-affinity block (447, 569, 606, 617). Docking models have suggested other potential roles for this positively charged group, including interaction with pore helix residues (168, 705), interaction with water molecules within the cavity in place of a potassium ion (74), and attraction to the overall negative electric field within the electric field (168).

It is important to note at this stage that accurate predictions for the arrhythmogenic profile of a compound require a multitude of considerations beyond just Kv11.1 block liability. Simple simulations of Kv11.1 channel block (approximated by reducing I_{Kr} conductance) in models of human ventricular cells have recapitulated some of the pro-arrhythmic biomarkers that are associated with drug-induced prolongation of the QT interval (219, 286, 454, 621). However, these models do have some problems such as the relative contributions of I_{Kr} and I_{Ks} to AP repolarization, especially in regard to adrenergic tone, and the lack of adequate incorporation of calcium handling mechanisms. A further consideration is the nonspecific actions of drugs. Verapamil for example blocks Kv11.1 with relatively high affinity but has little arrhythmogenic risk due, at least in part, to its effects on other cardiac ion channels (7). In this regard, Mirams et al. (416) recently used a human cardiac myocyte model to correctly characterize drugs into one of four categories of arrhythmogenic risk based on their modulatory effects on I_{Kr}, the fast sodium channel (I_{Na}), and the L-type calcium channel (I_{Ca,L}). Interestingly, the only drug that did not fall into any of the categorizations was amidarone, which is known not only to directly block Kv11.1 but also to impair trafficking of the channel to the cell surface (416). This acts as a reminder that direct channel block is not the only mechanism by which drugs can reduce I_{Kr} and prolong the QT interval, and we know very little regarding which types of structures can mediate these alternative effects.

Given these problems, the development of a computational model that accurately predicts the arrhythmogenic potential of a chemical entity will likely require a wider and more integrative approach that includes all levels of the system. To this end, a recent study used 3D-QSAR and docking simulations to predict block of both I_{Kr} (Kv11.1) and I_{Ks} (Kv7.1), before incorporating this information into a guinea pig ventricular tissue model (455). This integrated model then allowed the simulation of individual action potentials, pseudo-ECGs, and 2D-maps of action potential propagation through simulated ventricular tissue. The generation of even more complex integrative models will be extremely challenging but may in future provide an in silico screen for the arrhythmogenic potential of drugs.

### E. High-Throughput Screens for Kv11.1 Drug Block

The development of lead compounds in any pharmaceutical program involves screening large numbers of chemical entities. The mandated need to ensure that any potential therapeutic does not have an unacceptably high affinity for Kv11.1 therefore requires a medium- or preferably high-throughput screening method for Kv11.1 channel block. The full gamut of high-throughput screening technologies have been applied to this problem. These include radioligand binding, ion efflux, and fluorescence-based assays that indirectly measure channel function, as well as automated parallel patch-clamp electrophysiological assays that allow direct measurement of ionic current.

1. **Radioligand binding assays**

Competitive radioligand binding assays are one of the most common in vitro screening tools used within the pharmaceutical industry. Several radiolabeled Kv11.1 blockers have been characterized, including [3H]dofetilide (92, 143, 182, 183), [3H]astemizole (103), [35S]-MK-499 (509), and [123I]-BeKm1 (21). A nonradioactive fluorescent tracer polarization assay, which also works through competitive binding, has been reported to produce similarly accurate results, albeit using a small test drug dataset (499). Competitive binding assays can provide reasonably accurate estimations of Kv11.1 block liability, although it is important to note their limitations. Importantly, as these assays rely on competitive binding with high-affinity blockers, they cannot be used to identify drugs that bind outside of the channel cavity. For example, alternative binding sites have been proposed for drugs that impair hERG protein trafficking (512, 614), Kv11.1 agonists (488), and Kv11.1 toxins (646). The assays also do not take into account relative differences in state-dependent binding for the test drug compared with the drug being displaced. Finally, the kinetics of binding, which could be important when it comes to predicting proarrhythmic risk, are also not accounted for. It is clear therefore that this type of assay cannot be used in isolation when assessing action of a drug.

2. **Rubidium (Rb⁺) efflux assay**

Potassium channels like Kv11.1 are able to conduct Rb ions, so decreased Rb⁺ flux in the presence of a drug allows an indirect measure of channel block (618). While this technique can accurately predict relative potency between
drugs, it tends to substantially underestimate the IC_{50} of most drugs (78, 430, 518, 618). At least some of this underestimation can be attributed to impaired inactivation caused by Rb⁺ (518).

3. Fluorescence-based assays

Fluorescence-based dyes that measure changes in membrane potential can be used to assess Kv11.1 channel function indirectly (149, 430, 618). Three commercially available dyes have been assessed using stable Kv11.1-expressing cell lines and a fluorometric imaging plate reader (FLIPR, Molecular Devices, Sunnyvale, CA), with all three dyes giving IC_{50} values that showed relatively poor correlation with those obtained by patch-clamp analysis (149, 430). Two of the three studies reported a high number of false negatives in the fluorescence assay (618), while the third reported a number of false positives (149, 430, 618). Two of the main reasons for the less than satisfactory results with this technique are the low signal-to-noise ratio and a substantial quenching of the fluorescent signal by many of the test compounds that bind to the fluorescent dyes. Hopefully, some of these problems may be overcome by the generation of more accurate dyes and better fluorometric plate readers. Recently, Tian et al. (634) reported use of the dye di-8-ANNEPS and a genetically encoded fluorescent voltage sensor (Mermaid) to measure action potentials in rat cardiomyocytes. Addition of the drug E4031 prolonged action potential duration, suggesting that this type of technique could be used as a screen for drug-induced QT prolongation.

A combination of ion flux and fluorescence-based approaches forms the basis of newly proposed thallium flux assay (635). On one hand, this works similarly to the rubidium flux assay in that thallium can permeate through the channel once opened. Channel activity is indirectly measured using a dye (FluxOR, Life Technologies, Carlsbad, CA), trapped in the cell, which is excited in the presence of thallium. This technique can be ultra high-throughput if used in conjunction with a plate reader that enables fast (≈10 min) detection of fluorescence in 1,536-well plates. In initial studies, the accuracy of IC_{50} values was highly variable, with underestimations of potency by more than 1,000-fold for some drugs compared with the IC_{50} values obtained using automated patch clamp (77, 278, 635). However, small alterations to the protocol of thallium flux studies, such as increasing the external KCl concentration used to open the channels, appears to improve these inaccuracies, at least for high-affinity compounds (557). One major benefit of flux assays compared with competitive binding assays is the possibility of identifying Kv11.1 channel agonists (278). Moreover, by incubating cells with drug for a longer time period, these assays may also detect compounds which impair trafficking of Kv11.1 channels to the cell membrane (278).

4. hERG-Lite

A specific assay named hERG-Lite, which measures cell surface expression of hemagglutinin (HA)-tagged hERG protein in HEK293 cells, has been developed to detect inhibitors of hERG trafficking (683). In this assay, Kv11.1 channel block can be indirectly assessed at the same time by measuring the capacity of a drug to rescue a trafficking defective mutant hERG protein. A total of 26 of 100 compounds were shown to induce hERG trafficking inhibition, of which 20 also exhibited channel block (683). This assay though cannot measure IC_{50} values directly and at present is relatively low throughput.

5. Automated patch-clamp techniques

The major problem with high-throughput assays for Kv11.1 channel block discussed above is the lack of direct voltage control and hence inability to accurately assess the state dependence of drug binding. At the present time, only electrophysiological techniques allow for direct control of the membrane potential, and these assays are considered the “gold standard” for assessing Kv11.1 block liability (238). Traditionally though, electrophysiological screens do not have sufficiently high throughput to be considered as primary screening tools. The development of automated planar patch-clamp systems that allow parallel recordings from multiple cells has significantly improved the screening potential of such systems. Several systems exist including Ionworks Barracuda and PatchXpress 7000A (both Molecular Devices), Patchliner and SynchroPatch 96 (Nanion), QPatch HTX (Sophion Biosciences), and IonFlux (Fluxion). These systems are now being extensively used in the pharmaceutical and biotechnology industries. Furthermore, the data for large numbers of drugs screened for hERG binding are now publically available (see, e.g., www.hergcatalogue.org; Ref. 155).

6. In vivo screening assays

While high-throughput screens like those discussed above are important tools for measuring Kv11.1 block by drugs in vitro, it is important that potential new drugs are subsequently tested for liability to cause QT interval prolongation and arrhythmias in an in vivo system, as per the ICH guidelines. Isolated ventricular wedge preparations (693) and Langendorff-perfused heart preparations (266) are commonly used for this purpose. These are, however, by their very nature more expensive and much lower throughput and have been reviewed in detail elsewhere (210, 313). More recently, the use of zebrafish as an in vivo screening assay for arrhythmic potential has been explored (54, 349, 414, 422). When coupled with medium- to high-throughput screening techniques for the assessment of cardiac function (82), zebrafish may provide an interesting in vivo model for this purpose, although its efficacy requires further evaluation (422).
F. Toxin Binding to Kv11.1 Channels

1. ERG specific toxins

Several short peptide toxins isolated from various species of scorpion are high-affinity blockers of Kv11.1 K⁺ channels (118, 528). Despite sharing little amino acid homology, both BeKm-1 (334) and ErgTx-1 (also known as CnErg1; Refs. 229, 473) specifically target the ERG subfamily of K⁺ channels with nanomolar affinity. Together with their various analogs, BeKm-1 and ErgTx-1 form a subfamily of scorpion toxins termed γ-KTx (528). A sea anemone toxin APETx1 (148) also demonstrates specificity for ERG channels over other channel types, but this toxin has been less extensively studied. Although less potent than the peptide toxins, the organic quandine-based alkaloid saxitoxin (STX) can also reduce the function of Kv11.1 channels (660).

The venom of most venomous animals contains a wide range of toxins, many of which specifically target different ion channels. These toxins presumably subserve different tasks, from rapidly immobilizing their prey (e.g., through inhibition of neuronal/muscle sodium channels) to killing the prey. One would not expect an ERG-specific toxin to cause rapid immobilization of a small animal, but induction of a cardiac arrhythmia would certainly contribute to rapid cardiac arrest.

2. Mechanisms of block

Ion channel toxins typically exhibit either one of two modes of action. Pore blockers bind to a region of the channel where they directly prevent conduction of ions through the pore (212), whereas gating modifiers alter channel function by modifying the kinetics and/or voltage dependency of one or more gating transitions (611). There are several common features of Kv11.1 inhibition by γ-KTx-subfamily toxins BeKm-1 and ErgTx-1, which allude to their mechanism of action. Both toxins inhibit Kv11.1 in a concentration-dependent manner with an apparent toxin-channel stoichiometry of 1:1 (229, 334). Contrary to drug-induced pore block, binding of BeKm-1 or ErgTx-1 shows reverse state dependence, with reduced affinity at more depolarized potentials (229, 415, 718). The rapid onset and reversibility of action (229, 334) indicates that both toxins bind to an external site on the channel and crucially, their inhibitory effect can be attenuated by outer pore mutations and external TEA, both of which strongly implicate direct pore block (473, 474, 718).

Direct pore block of other voltage-gated potassium channels by KTx-family toxins is sensitive to changes in the permeant cation concentration. Charybdotoxin, for example, blocks deep within the pore of Shaker channels to “plug” the selectivity filter and prevent conduction of potassium ions (212). In this case, a positively charged lysine residue, which together with a hydrophobic patch forms a functional dyad group on the toxin, plugs the pore by substituting for a potassium ion at the outermost coordination site of the channel selectivity filter (212). A high external potassium concentration leads to increased occupancy of the outermost potassium coordination site and thereby reduces the affinity for toxin binding (212). In contrast, the inhibition of Kv11.1 by γ-KTx-subfamily toxins, BeKm-1 and ErgTx-1, was unaffected by elevated external potassium concentration (474, 718). Further, Kv11.1 inhibition by either toxin was incomplete, even at concentrations 100-fold greater than the IC₅₀ (334, 474, 718). At first glance, the lack of sensitivity to potassium and incomplete block suggest that γ-KTx act as gating modifiers (718). However, while the residual current (~10% of total) following maximal inhibition exhibits altered gating parameters (256, 718), these are insufficient to account for the inhibition of Kv11.1 by γ-KTx (256, 718). Neither is there a significant alteration to single-channel conductance, at least in the case of ErgTx-1 (256, 718). An alternative explanation is that the primary mechanism is one of pore block rather than gating modification, but Kv11.1 toxins may not bind as deep within the pore as occurs in other KTx-family scorpion toxins (see FIGURE 22). In support of this, a point mutation (S631A) in the outer mouth of the Kv11.1 pore introduced sensitivity of toxin binding to external potassium concentration (255). It is possible that the S631A mutation alters the conformation of the outer mouth, which allows the toxin to bind deeper within the pore, possibly through a dyad binding motif (255). A “weaker” binding mechanism for Kv11.1 toxins may also underlie their fast dissociation kinetics from the channel. This is important because a fast dissociation rate (relative to binding rate) from the Kv11.1 pore can account for the incomplete block by ErgTx-1 (256).

APETx1 may act more as a gating modifier of Kv11.1 rather than a direct pore blocker (148, 721). Unlike the more direct pore blockers, APETx-1 exhibits a much higher affinity for Kv11.1 over Kv11.2 or Kv11.3 K⁺ channels (517). This specific inhibition of Kv11.1 current by APETx-1 occurs through a concentration-dependent depolarizing shift in the voltage dependence of activation and a reduction in maximal conductance (148, 721). As with γ-KTx-subfamily toxins, the inhibition of Kv11.1 current by APETx-1 is incomplete even at high concentrations (148, 721).

The organic molecule saxitoxin also reduces Kv11.1 current via a mechanism that is reminiscent of APETx-1 (660). One important difference though is that saxitoxin also induces a depolarizing shift in the voltage dependence of C-type inactivation, which paradoxically causes an enhancement of Kv11.1 function at very depolarized potentials where activation is maximal (660). This effect is not observed with APETx-1, and it is likely that these toxins have...
distinct binding sites on the hERG protein. Interestingly, several naturally occurring small molecule agonists of Kv11.1 channels also reduce inactivation by shifting the voltage dependence to more depolarized potentials but do not produce the concomitant depolarizing shift in voltage dependence of activation (see sect. VGG).

3. Binding site for erg toxins

The rapid onset and reversibility of γ-KTx-subfamily toxins clearly indicates an external binding site on the hERG protein (229, 334). Mutagenesis studies of Kv11.1 identified the outer mouth of the pore, as well as the four S5-P linkers of the channel as the likely binding regions for both BeKm-1 (646, 718) and ErgTx-1 (474), with at least partial overlap in binding sites for these toxins (718).

Mutant cycle analysis and NMR spectroscopy have highlighted the importance of residues with hydrophobic (Tyr11 and Phe14) and positively charged (Lys18 and Arg20) side chains in γ-KTx binding to Kv11.1 channels (333, 646). In particular, the positively charged Lys18 and Arg20 appear to play a key role in BeKm-1 toxin binding.

It has been suggested that binding of ERG toxins to Kv11.1 is mediated by interactions with hydrophobic residues in the amphipathic helix of the S5P linker (474). Given that mutations of the S5P linker hydrophobic residues resulted in significant perturbations to inactivation gating and selectivity (474), one must be cautious with assuming that they have maintained the normal tertiary structure. Conversely, mutation Q592C within the S5P linker exhibits reduced affinity for CnErg1 but still has normal inactivation and selectivity (474). Thus there is no doubt that the S5P linker is important for CnErg1 (and BeKm1) binding, although the precise site of binding remains to be determined. Nevertheless, various models predicting the binding conformation of both γ-KTx-subfamily toxins have been postulated, and a general picture of γ-KTx binding to Kv11.1 channels is emerging. This consensus appears to involve binding to the outer mouth of the pore and the S5-P linker through hydrophobic interactions, but with the positively charged lysine or arginine residues interacting with the hydroxyl group of Ser631 (255, 646). This is distinct from other KTx-family toxins (like charybdotoxin) that bind into the selectivity filter of Kv channels to plug the pore. This can explain why Kv11.1 block by γ-KTx-subfamily toxins is incomplete and lacks sensitivity to external potassium concentration.

Unlike the pore blocking γ-KTx-subfamily of toxins outlined above, the gating modifier toxin APETx-1 appears to impair activation of Kv11.1 channels through an interaction with the voltage sensor paddle (721). Crystal structures of other voltage-gated potassium channels indicate that the voltage sensor paddle is comprised of S3b to S4 helices, which play a critical role in opening the channel in response to membrane depolarization. Targeted binding to the S3b appears to be a common mechanism for gating modifiers of a range of ion channels (610). Cysteine scanning mutagenesis of residues within the outer S3b region of the Kv11.1 channel highlighted a negatively charged residue (Glu518) as important for binding of APETx-1, probably through an interaction with a basic residue (Lys18) on the toxin (721).
In addition, several hydrophobic residues on APETx-1 may help stabilize this interaction (93, 721). The binding site for another gating modifier, saxitoxin, has not yet been identified but is likely separate from that of APETx-1 due to their distinct effects on C-type inactivation of the channel (660, 721).

G. Kv11.1 Activators

High-throughput screening techniques used to test compound libraries for Kv11.1 block have led to the serendipitous discovery of small molecules that enhance current passed through Kv11.1 channels. In principle, an increase in ventricular repolarization currents such as \( I_{K_S} \) or \( I_{Kr} \) could provide a useful treatment for ventricular arrhythmias associated with both congenital LQTS and acquired QT interval prolongation. Moreover, this mechanism for shortening action potential duration (APD) would be favorable over the use of calcium channels blockers as it would not be expected to alter contractility of the myocardium.

Several partial agonists of Kv11.1 have been identified since 2005 (88, 205, 240, 241, 312, 600, 729). The exact mechanistic profile of each appears to be subtly different and may reflect specialized binding interactions for each agonist with the channel. This seems in direct contrast to Kv11.1 channel blockers that show a remarkable degree of conformity in blocking conduction by binding within the inner cavity of the channel (see sect. VB). Based on the primary mode of action, Kv11.1 activators can be separated into two groups, types 1 and 2.

The first reported Kv11.1 activator was RPR260243 ([3R,4R]-4-[3-(6-methoxyquinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluoro-phenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid), a small molecule that primarily slows the rate of channel deactivation and is designated a type 1 activator (312, 487). Secondary effects on channel gating include an attenuation of C-type inactivation and a slowing of activation but promote channel opening by accelerating the kinetics of activation and shifting the voltage dependence of activation (88, 205, 240, 241, 600, 729). These small differences in mode of action could reflect subtle differences in binding interactions of type 2 activators with the channel protein. For example, a combination of mutagenesis and molecular modeling suggests that binding of PD118057, a type 2 activator that attenuates inactivation but has no effect on deactivation, occurs within a small hydrophobic pocket formed between the pore helix and S6 helix of adjacent subunits (486). Another type 2 activator, NS1643, that does slow deactivation, is proposed to bind in a similar region but shares only some binding residues with PD118057 (namely Leu622 on the pore helix and Leu646 on the S6 helix) (222). Subtle differences in binding residues within this pocket have also been identified for a more potent activator, ICA105574 (200). Further studies to map the binding sites of other type 2 activators may reveal the exact nature of these activator specific effects in more detail. In any case, the primary effect of impaired inactivation is likely mediated through drug interaction with the pore helix, a region proposed to stabilize the inactivation gate of the channel (592).

Other Kv11.1 activators have been identified that fit neither type 1 nor type 2 categories. For example, mallotoxin and KB130015 (a derivative of amiodarone) do not affect inactivation but promote channel opening by accelerating the kinetics of activation and shifting the voltage dependence of activation in the hyperpolarizing direction (207, 709). As yet their site of interaction with Kv11.1 channels is unclear, but it is known that the effects of these two drugs are synergistic, suggesting that they occupy separate but functionally coupled binding sites (207, 709). Similar effects on activation are observed with some class III antiarrhythmics (Almkalant, azimilide, nifekalant), although only after a strong depolarizing prepulse (85, 272, 293). In this case “facilitation” of Kv11.1 current is only observed at potentials less than −30 mV due to the voltage-dependent block that concomitantly occurs at more positive potentials. Facilitators are considered distinct from activators like mallotoxin and KB130015 due to the prerequisite depolarizing prepulse (85, 272, 293).

VI. REGULATION OF Kv11.1 CHANNELS

There are dozens of reports in the literature looking at regulation of Kv11.1/\( I_{Kr} \) by pathological stimuli such as oxi-
dative stress, acidosis, and altered electrolytes as well as acute and chronic stimulation of signaling pathways. There are many disparate and, in some cases contradictory, findings in these studies. Rather than critiquing each study one by one, discussion of these studies is focused on what will happen to cardiac $I_{Ks}$ activity during 1) acute adrenergic regulation (such as occurs during exercise), 2) acute ischemia (oxidative stress, acidosis, hyperkalemia), and 3) heart failure (chronic stimulation of multiple signaling pathways). Studies that have specifically focused on regulation of Kv11.1/$I_{Kr}$ in noncardiac tissue are covered in section X. In the last section some miscellaneous regulatory pathways including the effects of lipid messengers, temperature, and steroid hormones are reviewed.

A. Adrenergic Tone and Circulating Catecholamines

Exercise is the prototypic example of the fight-or-flight response resulting from activation of the sympathetic nervous system. During exercise, in addition to circulating catecholamines, there is a significant release of catecholamines from local sympathetic nerve terminals (121) which activate adrenergic receptors resulting in activation of adenylate cyclases, increases in cAMP, and activation of PKA. The increase in intracellular cAMP stimulates HCN channels directly resulting in an enhanced rate of diastolic depolarization and hence increased heart rate in sinoatrial node cells (144). The increased PKA activity also results in phosphorylation of numerous proteins involved in calcium handling, including plasma membrane L-type calcium channels and ryanodine receptors, resulting in enhanced calcium cycling and hence contractility of the myocardium (555).

During exercise, the increase in heart rate demands that repolarization duration shortens so that there is still a sufficient diastolic interval for the heart to refill with blood before the next contraction. To a large extent, this is achieved by enhanced activity of $I_{Kr}$. $I_{Kr}$ has a very strong adrenergic response (624, 657) and represents one of the best examples of a well-characterized macromolecular complex governing phosphorylation (398, 625). In addition to contributing directly to shortening of APD, the enhanced $I_{Kr}$ is also sufficient to counteract the enhanced $I_{Ca}$ activity, which contributes to increased contractility but also tends to lengthen the APD.

$\beta$-Adrenergic and/or PKA stimulation of isolated guinea pig ventricular myocytes has been reported to cause no change in $I_{Kr}$ activity (549), a decrease (72% reduction in tail current amplitude after 12 min application of isoproterenol; Ref. 316), or a small increase that was dependent on a rise in intracellular Ca$^{2+}$ and activation of PKC (251). Given that these three studies were undertaken in guinea pig ventricular myocytes, one cannot evoke species differences as a possible explanation. There were, however, slight differences in protocols used, such as differences in the level of calcium buffering in the patch pipette. The studies are also complicated by difficulties in completely isolating the $I_{Kr}$ and $I_{Ca}$ components, which is problematic given that $I_{Kr}$ is very sensitive to activation by both PKA and PKC (657). Additionally, guinea pig myocytes contain a robust cAMP-activated chloride current (46, 247) that can complicate analyses. More recently, Harmati et al. (246) have provided evidence for $\beta$-adrenergic/PKA-mediated stimulation of $I_{Kr}$ in canine ventricular myocytes. Whereas 100 nM isoprenaline caused a 293% increase in $I_{Kr}$, it caused only 37% increase in $I_{Kr}$. Thus, based on studies in isolated myocytes, it appears that $I_{Kr}$ can be modulated by PKA, although there may be some species variation. Perhaps more importantly though, the modulation of $I_{Kr}$ by PKA is relatively modest, and it is certainly not as important as changes in $I_{Kr}$ for shortening APD during exercise.

To overcome some of the problems of overlapping currents and inadequacy of pharmacological tools for separating different channel activities, a number of groups have investigated the effects of PKA on Kv11.1 channels (278, 766) in heterologous expression systems. When expressed in Xenopus oocytes, Kv11.1 currents are modestly reduced following activation of PKA by the PDE IV inhibitor Ro-20–1724 (100 $\mu$M) or forskolin (400 $\mu$M), and this is associated with ~10 nM depolarizing shift in the $V_{0.5}$ of steady-state activation (632). These effects were largely abrogated by mutation to alanine of all four of the putative PKA phosphorylation sites (Ser283, Ser890, Thr895, and Ser1137). Similarly, Cui et al. (130) showed that Kv11.1 channels expressed in CHO cells are modestly inhibited by PKA activation, while cAMP could have a direct stimulatory effect, presumably via binding to the cAMP-binding domain of the channels. The overall effect of this inhibition caused by phosphorylation and cAMP-mediated activation is a small decrease in current amplitude (130). Conversely, when Kv11.1 channels are coexpressed with either KCNE1 or KCNE2, the overall effect of adrenergic stimulation was an overall increase in current amplitude (129). A further complicating factor is that whilst Cui et al. were clearly able to show that cAMP bound to Kv11.1 channels, the affinity was as high as 40 $\mu$M, are more than an order of magnitude greater than the concentrations of cAMP determined in cardiac myocytes (280). The low affinity for cAMP has been attributed to the lack of a critical arginine residue in the cAMP binding pocket that coordinates binding of the phosphate moiety (76). Whilst it is possible that there may be compartmentalization of cAMP production (114), it is difficult to imagine that one could get local concentrations of cAMP exceeding a few micromolar. More recently, the Zagotta group has determined the crystal structure of the cyclic nucleotide binding homology domain (cNBHD) of the zebrafish ether-a-go-go like (zELK) channel and found that the “cAMP binding pocket” was occupied by a short $\beta$-sheet strand at the COOH-terminal end of the domain.
which they suggested acted as an endogenous ligand for the channel (75).

In recent years there has been increasing awareness that ion channels do not function in isolation but rather exist as part of macromolecular complexes. One of the best-studied examples of this is the KCNQ1 channel, which forms a complex with A-kinase adaptor proteins, PKA, and phosphatases (625). The net effect is that signaling process can be effectively localized to specific regions in the cell and is not dependent on diffusion of second messengers and/or effector proteins across significant distances. Another corollary of this arrangement is that the local concentration of signaling molecules such as cAMP may be much higher in the vicinity of the effector protein than in the general cytoplasm (363). Although not as extensively investigated as $I_{Ks}$, there is evidence to suggest that components of PKA signaling complexes are attached to hERG proteins. McDonald and co-workers (309) have shown that the 14–3-3 protein can bind to hERG but only if Ser283 and Ser1137 have been phosphorylated (104). Binding of 14–3-3 results in a hyper-activation of hERG but only if Ser283 and Ser1137 have been phosphorylated (104). Binding of 14–3-3 results in a hyper-polarizing shift in $V_{0.5}$ of steady-state activation (thus counteracting the effect of PKA alone) and prolongs the effect of PKA stimulation. More recently, McDonald and co-workers (370) have also shown that hERG proteins in porcine cardiac membranes cosediment with a range of PKA RI and RI domains, although they have not been able to confirm these interactions by coimmunoprecipitation; thus any interactions may require additional partners (370).

Another complicating factor when considering acute regulation of Kv11.1 by PKA is that the common polymorphism (L897T, minor allele frequency ~23%) results in introduction of an additional PKA consensus phosphorylation site. Numerous groups have investigated the effect of the K897T polymorphism on gating, with reports of very modest loss (22, 468) or gain of function (66). Similarly, in clinical studies, the K897T polymorphism has been associated with slight lengthening of the QT interval (496), shortening of QT interval (397, 444, 493), or no statistically significant change (510). The larger studies suggest a 1–3 ms shortening for each copy of the Thr allele (397, 444, 493). This suggests that the Thr allele may result in a slightly enhanced $I_{Kr}$. Recently, Gentile et al. (204) have shown that Thr897 is phosphorylated following PKA stimulation, resulting in reduced channel activity. If the overall effect of K897T is to increase $I_{Ks}$ function when nonphosphorylated, but decrease it when phosphorylated, then the population studies (397, 444, 493) suggest that under the conditions in which they made their ECG measurements, the increased activity of the nonphosphorylated K897T is relatively more important than the reduced activity of the phosphorylated K897T. From the studies in heterologous expression systems, one can conclude that it is possible for Kv11.1 channel activity to be influenced by PKA. However, whether such modulation occurs in native cells is still not known for certain. To help resolve these issues, more needs to be known about the macromolecular complexes hERG proteins are part of in native cells and whether the level of adrenergic activation that occurs in vivo is sufficient to modulate Kv11.1 activity within the context of its native macromolecular environment. Irrespective of whether the overall effect under in vivo conditions is a small increase, small decrease, or no change, what is certain is that the relative balance between $I_{Kr}$ and $I_{Ks}$ is very different, with $I_{Ks}$ being the major repolarizing current during exercise, whereas $I_{Kr}$ is much more important at rest.

Another possible interaction between adrenergic stimulation of the heart and $I_{Kr}$ function is that ERG proteins are expressed in rat chromaffin cells and blockade of $I_{Kr}$ in these cells leads to enhanced epinephrine (but not norepinephrine) release (225).

### B. The Alarm Clock Stimulus

One of the arguments used to support the hypothesis that $I_{Kr}$ is regulated by acute sympathetic nerve stimulation is that patients with LQTS type 2 are particularly prone to arrhythmias triggered by loud noises, such as being awoken from sleep by an alarm clock (684). There is no doubt that unexpected auditory stimuli are associated with activation of the sympathetic nervous system and that this leads to an acute increase in heart rate (433). However, it is important to bear in mind that following sympathetic stimulation the increase in heart rate occurs relatively rapidly (as it only requires production of cAMP which binds directly to HCN channels), whereas there is a significant lag between activation of HCN channels and activation of channels that require phosphorylation (363). More recently, Liu et al. (376) have also shown that there is a significantly longer lag in the increase in $I_{Ks}$ compared with $I_{Ca}$ following adrenergic stimulation in rabbit cardiac myocytes. Thus, in the first 5–10 s after an alarm clock going off, one would expect to see significant changes in heart rate but minimal changes in APD. This is indeed what is observed. However, after correcting for the change in heart rate, there is up to a 20% prolongation of the corrected QT interval (QTc) in the 5–10 s after an alarm clock goes off (433). This time frame is important, as in cases where arrhythmias have been recorded on Holter monitors following an alarm clock going off, the arrhythmia is initiated within 5–10 s (684). At rest, one would expect there to be minimal sympathetic tone such that $I_{Kr}$ would make a minimal contribution to repolarization. Conversely, $I_{Kr}$ is relatively more important for...
repolarization at slower heart rates, so one would expect that an alarm clock might cause an exaggerated QT_{c} prolongation in patients with LQTS type 2 but not in LQTS type1 (i.e., LQTS caused by loss of I_{Kr} function). Clearly sympathetic stimulation is an important component of the stimulus, such that β-blockers would still be useful therapy (211); however, this need not be because there is direct modulation of I_{Kr} by sympathetic nerve stimulation.

Overall, the accumulated data in the literature suggest that if I_{Kr} is modulated by sympathetic nerve activity it is only modestly so (perhaps a maximum ~30% change in current magnitude), compared with the effects observed for I_{Kr} (246). Furthermore, the sensitivity of patients with LQTS type 2 to arrhythmias triggered by adrenergic stress does not necessarily support a direct role of regulation of I_{Kr} by adrenergic activity. Rather, there are multiple mechanisms, via actions on other channels, by which adrenergic stress can trigger arrhythmias in patients with LQTS type 2. For example, simple prolongation of the action potential and increased duration of SR Ca^{2+} release coupled with the sensitivity of Ca^{2+} release channels to adrenergic stress (360, 507) could increase risk of arrhythmias in patients with LQTS type 2.

C. Myocardial Ischemia

Acute ischemia, with or without reperfusion, is associated with many metabolic changes that result in altered electrical activity and in increased risk of arrhythmia. Many of these metabolic changes can influence I_{Kr} activity, which consequently increases arrhythmia risk.

1. Oxidative stress

Generation of reactive oxygen species (ROS) using hydrogen peroxide (62) results in an acceleration in rates of both activation and deactivation, with the changes in activation occurring more quickly than the changes in deactivation. Xanthine plus xanthine oxidase (662), hyperglycemia (723), TNF-α (662), and ceramide (47) have all been reported to increase ROS and decrease Kv11.1 channel activity. In contrast to these studies, Tagliatela et al. (612) showed that extracellular application of FeSO_{4} and ascorbate, requires two histidine residues in the extracellular S5P linker (His_{578} and His_{587}). This mechanism, however, does not account for the reduced current density seen with production of intracellular ROS (331). Conversely, Kolbe et al. (331) showed that cysteine residues in the cytoplasmic COOH-terminal domain of Kv11.1, in particular Cys_{723} in the COOH-linker domain, play a role in the acute regulation of Kv11.1 currents by intracellular ROS. Cysteine residues are commonly associated with responses to oxidative stress as they can react with glutathione to form glutathionylated adducts or react with other cysteine residues to form disulfide bonds. The reactivity of thionyl side chains is promoted by having neighboring basic residues (650), which lower the pK_{a} of the thionyl group. Cys_{723}, however, is surrounded by a triad of acidic residues (Glu_{722}, Asp_{727}, and Asp_{767} from a neighboring subunit); thus it is unlikely that Cys_{723} would be directly modulated by oxidative stress.

Oxidative stress is also a major component of the diabetic heart. Acute hyperglycemia has been shown to reduce Kv11.1/I_{Kr} function (723) and prolonged hyperglycemia to reduce Kv11.1/I_{Kr} density (726). Furthermore, insulin has been shown to reduce some of these effects, and thus it has been postulated that ROS regulation of Kv11.1/I_{Kr} function may be an important component of the electrical remodeling that occurs in diabetic hearts and makes them more susceptible to arrhythmias in the context of ischemic heart disease (303).

2. Acidosis

Kv11.1 currents, whether expressed in mammalian cells or oocytes, are reduced by extracellular acidosis (26, 154, 262,
294), whereas selective alteration of intracellular pH does not affect gating (154). Although there are subtle differences between studies, all have reported an acceleration of the rate of deactivation (262, 294). A range of other effects have also been reported including suppression of $G_{\text{max}}$ (26, 64, 262), slowing of activation (26, 623, 730), a depolarizing shift in steady-state activation (26, 64, 262), and a modest increase in rate of recovery from inactivation (294). Multiple groups have also reported that the changes in deactivation and suppression of $G_{\text{max}}$ had different pH sensitivities (26, 64, 262), and this likely explains some of the discrepancies between studies in which different pH ranges were used. Nevertheless, the overall effect is to cause a reduction of the amount of $I_{Kr}$ that will flow during the action potential (152), which contributes to the action potential prolongation observed during acidosis (63).

The observation that intracellular acidosis does not affect Kv11.1 gating is consistent with the suggestion that extracellular acidosis alters Kv11.1 gating by modifying extracellular residues (294). The pKs for changes to the rate of deactivation, $-6.2$ (294), and modification of the voltage-independent step in activation, $-6.4$ (730), are similar to the pKs of histidine. However, when the two extracellular histidines in Kv11.1 (His578, His587) are mutated to glutamate, the extracellular pH effects on deactivation remained (294). It should be noted though that the pKs of amino acid side chains in proteins can be very different to those measured in free solution, e.g., the active site aspartate in Escherichia coli thioredoxin is buried in a hydrophobic environment and has a pK of 7.5 (350). It is possible that charged residues within the transmembrane region of Kv11.1 could have pK values closer to 6.5. Consistent with this, Tseng and co-workers (377) showed that mutating aspartate residues in the S1 (Asp411), S2 (Asp460, Asp466), or S3 (Asp501, Asp509) of Kv11.1 largely abrogated the effects of extracellular pH on accelerated deactivation (377). Two recent voltage-clamp fluorometry studies (165, 648), showing that extracellular acidosis slows voltage sensor return during deactivation, are also consistent with the primary site of action of extracellular protons being within the voltage sensor.

3. Hyperkalemia

$I_{Kr}$/Kv11.1 activity is very sensitive to changes in extracellular K$^+$ (547), primarily due to effects on inactivation (658, 668, 670). In contrast, hyperkalemia does not affect rates of activation nor steady-state activation (668, 670). Increasing extracellular K$^+$ from 5 to 100 mM increases the single-channel conductance [$\sim10–12$ pS in symmetrical high K$^+$ (324, 738) compared with $1–2$ pS at physiological K$^+$ (256, 738)]. There are relatively few studies that have examined the effect of changes in K$^+$ within the physiologically relevant range. Wang et al. (658) showed that changes in extracellular K$^+$ between 2 and 10 mM caused dramatic changes in rates of inactivation but minimal changes in rates of recovery from inactivation, with a consequent modest shift in steady-state inactivation. Overall, mild hyperkalemia will lead to an increase in Kv11.1 current flow during the cardiac action potential, and this would counteract the reduced current flow caused by acidosis and oxidative stress.

4. Summary

During myocardial ischemia, accumulation of extracellular K$^+$ will result in an increase in $I_{Kr}$ that would likely counteract any decrease caused by extracellular acidosis and oxidative stress. It is also worth noting that the accumulation of extracellular K$^+$ occurring during myocardial ischemia is predominantly the result of activation of $K_{ATP}$ channels (198), and the magnitude of these fluxes would overwhelm any changes in Kv11.1/$I_{Kr}$ activity. Conversely, during reperfusion, changes in extracellular K$^+$ and acidosis are rapidly corrected, whereas oxidative stress will be exacerbated by the reintroduction of oxygen. Thus, during early reperfusion, there is likely to be a suppression of $I_{Kr}$.

That $I_{Kr}$ still makes significant contributions to cardiac repolarization during ischemia is confirmed by findings using guinea pig ventricular muscle strips showing that low doses of dofetilide (5 nM) can prevent APD shortening during early ischemia (534). Conversely, dofetilide, at doses ranging from 5 to 50 nM, did not alter the incidence of reperfusion-induced arrhythmias (534). These results suggest that either reduced $I_{Kr}$ contributes to reperfusion-induced arrhythmias (and therefore reducing it further does not prevent them) or that the magnitude of $I_{Kr}$ during reperfusion is insufficient to modulate the occurrence of reperfusion-induced arrhythmias. In a more recent study, Gerard et al. (157) found that when extracellular K$^+$ was increased during simulated ischemia (and reperfusion), a low dose of dofetilide caused significant action potential prolongation and, either had a neutral or protective effect against reperfusion-induced arrhythmias. This later study indicates that the effects of hyperkalemia can have a significant impact on $I_{Kr}$ function, although one should probably be cautious in extrapolating the results from the in vitro model used by Gerard et al. to the clinical environment where ischemic insults are likely to be much more heterogeneous than in well-controlled in vitro models.

D. Heart Failure

Heart failure is associated with activation of numerous signaling pathways (48). Many groups have investigated the effects of stimulants these pathways on Kv11.1 channels (see sect. III). Almost invariably, these studies have focused on the effects of acute stimulation. In general, acute stimulation has resulted in reduced Kv11.1 function (see sect. IIIIE) with the exception being the PIP2/PIP3 pathway that can significantly upregulate Kv11.1 function (see below).
More recently, the McDonald group has started to look into the effects of chronic (24 h) stimulation. Interestingly, both chronic β-adrenergic (activating PKA) and α-adrenergic stimulation (activating PKC/PLC/PKA) resulted in significantly increased levels of hERG protein at the plasma membrane (96, 98). These changes are primarily mediated by an increase in the rate of synthesis of protein with no change in the rate of degradation of channels. In the case of β-adrenergic stimulation, the increased protein synthesis could be prevented by transfection of cells with a protein kinase A inhibitory (PKI) peptide. Furthermore, when the PKI peptide was targeted to the mitochondrial outer membrane, it was ineffective but, when it was targeted to the ER membrane it was effective and completely suppressed the enhanced protein synthesis in both HEK cells and neonatal rat ventricular myocytes (590).

In the two studies to date that have looked at KCNH2 mRNA expression in human heart failure samples, no change in mRNA levels was found (221, 307). This does not, however, preclude the possibility that there are changes in the level of hERG protein or Kv11.1 current density. In a rat model of cardiac hypertrophy, which is a precursor to heart failure, it has been reported that KCNH2 mRNA and protein levels are decreased (277). This is not necessarily incompatible with the data from McDonald et al. showing that chronic (24 h) neurohormonal stimulation of myocytes leads to increased hERG protein synthesis, as in heart failure chronic stimulation usually leads to downregulation of signaling pathways (348). Indeed, it is thought that one of the benefits of β-adrenergic blockers in heart failure is to reverse the downregulation of the intracellular signaling pathways induced by chronic stimulation.

Patients with heart failure are prone to develop hypokalemia, both as a result of the activation of neurohormonal pathways that regulate renal K\(^+\) handling and as a consequence of diuretic therapy. Hypokalemia in the setting of heart failure is known to increase mortality (362). Indeed, Leier et al. (362) have suggested that “effective potassium management with properly targeted serum potassium concentrations... probably represents the most effective and safe antiarrhythmic intervention” in heart failure. Recently, Zhang et al. have shown that hypokalemia is a potent stimulus for proteasomal degradation of hERG protein, and this contributes to the prolongation of APD seen in hypokalemia (see sect. IIIF). It is important to note that the changes seen in cultured cells after 24 h were much more dramatic than those seen in vivo. Nevertheless, rabbits treated with a low K\(^+\) diet for 4 wk (sufficient to reduce K\(^+\) from 4.88 to 2.4 mEq) resulted in a marked reduction of fully glycosylated hERG protein and an ~30% prolongation of QT interval, clearly sufficient to markedly increase the risk of lethal arrhythmias (227).

E. Miscellaneous Regulation of \(I_{Kr}\) Function

1. Temperature

The cardiac action potential is very sensitive to changes in temperature, with the duration at 95% repolarization approximately doubling as temperature is dropped from ~34 to ~24°C (329). This can be largely explained by the observation that repolarizing K\(^+\) currents during the action potential are more sensitive to changes in temperature than the depolarizing current through L-type calcium channels (329). Noble et al. noted that \(I_K\) was particularly sensitive to temperature with a Q\(_{10}\) value of 4.4, i.e., its magnitude changed 4.4-fold for every 10°C change in temperature. This large temperature sensitivity was confirmed for Kv11.1 channels heterologously expressed in CHO cells (649). The origin of the very high temperature sensitivity for Kv11.1 current magnitudes measured during depolarizing pulses (see FIGURE 23) can be primarily attributed to the opposing effects of temperature on steady-state activation and inactivation. As temperature increases, the \(V_{0.5}\) for activation shifts to more negative potentials (i.e., it is activated more easily), whereas the \(V_{0.5}\) for inactivation shifts to more positive potentials. As a consequence, there is a very large in-
crease in the range of potentials where the channels are open, i.e., the so-called window current (649). This result has two important implications. First, it suggests that patients with loss of $I_Kr$ caused by mutations or drug-block may be particularly prone to arrhythmias when they have high fevers (17, 228). Second, when constructing kinetic models of Kv11.1 based on gating parameters derived from recordings at room temperature, it is advisable to use a single temperature correction factor to obtain predicted outputs at 37°C.

2. **Sex hormones**

Adult females have longer QTc (288, 514, 724) and are at higher risk for developing life-threatening torsades de pointes ventricular arrhythmias, especially after taking medications that block Kv11.1 channels (394). Recent epidemiological studies indicate that QTc in men is significantly correlated with testosterone levels (724). Such studies do not, however, provide insight into the molecular mechanism. Animal models provide strong evidence for male sex hormones causing an increase in $I_Kr$ and a shorter QT interval (189, 381, 688). In rabbits, the increase in $I_Kr$ was not associated with any changes in KCNH2 mRNA (381); rather, dihydrotestosterone causes an increase in r-bERG protein stability at the plasma membrane which is likely to involve an ERK1/2-dependent mechanism (688). Female sex hormones do not appear to have significant effects on Kv11.1/$I_Kr$ levels (189), although progesterone increases basal $I_Kr$ activity and this may contribute to the variation in QT interval during the menstrual cycle (438). The Koren group have also shown that in the Rabbit LQTS2 model, progesterone reduces the incidence of arrhythmias whilst estrogen increases the risk of arrhythmias, although these effects are likely mediated by changes in calcium current density (456).

Recently, it has been shown that $\beta$-estradiol can inhibit Kv11.1 channels expressed in HEK293 cells (20). If this were to occur in native cells, then it may contribute to the greater sensitivity of women to drug-induced arrhythmias. On the other hand, Shuba et al. (576) have shown that testosterone can reduce the sensitivity of Kv11.1 channels to drug block. Overall, these studies suggest that it may be a combination of females being slightly more susceptible and males slightly less susceptible that leads to the marked gender divide with respect to susceptibility to drug-induced arrhythmias.

3. **Lipid second messengers**

Phosphatidylinositol 4,5-bisphosphate (PIP2) is a minor component of the plasma membrane but serves many important functions. It is the substrate of phospholipase C (PLC), leading to the production of IP3 and DAG, two important second messengers. PIP2 also directly modulates the function of many proteins and a number of ion channels (for recent review, see Ref. 605) including Kv11.1 (71). In most cases, as a result of activation of PLC, depletion of PIP2 acts on the target ion channels in concert with PI3 kinase and PKC (which are activated in response to IP3 and DAG, respectively) to exhibit synergistic effects. Elevation of PIP2 results in an increase in current amplitude, as well as enhancing the rate of activation and decreasing the rate of inactivation of Kv11.1 channels (69). Bian et al. (69) also showed that exposing Kv11.1 channels in excised inside-out patches to PIP2 largely abrogated channel rundown, a phenomenon that has dogged attempts to study Kv11.1 channels in this configuration. The effect of PIP2 is independent of Ca2+ and PKC and is thought to involve a cluster of basic amino acid residues just distal to the cNBD domain in the COOH terminus of Kv11.1 (70).

Kv11.1 is localized in cholesterol- and sphingolipid-enriched membrane microdomains of cardiomyocytes (49). Depletion of membrane cholesterol causes a positive shift in the voltage dependence of activation and an acceleration of the rate of deactivation (49). These effects are opposite to that observed with PIP2, and it has been suggested that increasing cholesterol may activate PLC resulting in reduced levels of PIP2 (107). Probucol, a cholesterol-lowering agent, also reduces Kv11.1 activity in heterologous cell lines and native cardiomyocytes (226). Probucol also decreases cell membrane caveolin, a Kv11.1 interacting protein found in cholesterol- and sphingolipid-rich lipid rafts. Thus it has been suggested that the increased degradation of cell surface Kv11.1 channels in the presence of probucol may be related to altered cholesterol metabolism (226). An argument against this hypothesis, however, is that statins, which are very effective cholesterol-lowering drugs, result in shortening of QT intervals rather than a lengthening (654).

Ceramide, another minor component of phospholipid membranes, has been shown in some studies to modulate Kv11.1 kinetics (196). In contrast, other studies suggest that ceramide does not affect kinetics (47, 94), but prolonged exposure leads to increased degradation, although the specific mechanism of this decreased protein half-life is debated (47, 94, 196).

VII. **Kv11.1 CHANNELS AND CONGENITAL LONG QT SYNDROME TYPE 2**

A. **Historical Perspective**

“Wenigstens hatten die Aeltern des Kindes, nachdem ihnen möglichst schonend das unglückliche Lebensende ihrer Tochter mitgetheilt worden war sich gar nicht darüber gewundert sondern geradezu geantwortet dass diese Nachricht sie durchaus nicht befremdet habe, da schon einige solche Zufälle in ihrer Familie früher vorgekommen seien ein Kind war nehmlich nach einem heftigen Schreck, ein
zweites nach heftigem Zorn plötzlich todt niedergefallen” (410).

The parents of the child were given the unfortunate news of the death of their daughter, but they were not surprised, as this had happened twice before in their family: one child had died suddenly during a sudden shock and another during a violent rage.

Writing in 1856 on the education of the “deaf-mute,” Friedrich Ludwig Meissner recounted the case of a young girl who died suddenly during an emotional upset. His short account, including details of the untimely deaths of her brothers, captured key features of our current understanding of the congenital LQTS: its genetic basis; an association, in some cases, with deafness; its lethality; and symptoms during times of acute emotion (410). However, 100 years passed before a synthesized description of the condition was made.

Anton Jervell and Fred Lange-Nielsen reported, in 1957, the “combination of deaf-mutism and a peculiar heart disease” in three girls and a boy among six children of a family (290). Each suffered congenital deafness and fainting spells in association with prolongation of the QT interval on the electrocardiogram. Three of the four died before the age of 10. The appellation, Jervell Lange-Nielsen was attached to this evidently autosomal recessive disorder. A short time after, Romano (1963) (529) and Ward (1964) (677) described a syndrome characterized by a long QT interval and episodes of syncope or sudden cardiac death. However, in such families, the mode of inheritance was autosomal dominant, and no child suffered from a hearing deficit. It is now understood that the Romano-Ward form of congenital LQTS is considerably more common than the Jervell Lange-Nielsen form.

While QT prolongation was a necessary component for diagnosis of the condition, the underlying cardiac arrhythmia responsible for syncope and sudden death was not recorded. Dessertenne, in 1966, published the case of an 80-year-old woman presenting with complete atrioventricular block, prolongation of the QT interval, and a unique form of polymorphic ventricular tachycardia that appeared to twist around the isoelectric line, “torsades de pointes” (Tdp) (141). His complete and careful analysis ensured the survival of this eloquent description. A few years later, this arrhythmia was shown to be the cause of symptoms in congenital LQTS (429).

A landmark in LQTS research occurred in 1979 with the establishment of the LQTS registry (427). It provided the first long-term, prospective follow-up of families with well-defined clinical phenotypes. It has also enabled molecular discoveries made in subsequent years to be understood immediately in their clinical context, and strong genotype-phenotype relationships established in short time. The first genetic locus for congenital LQTS was identified on chromosome 11 in 1991 by the Keating group (318), and they suggested that the affected gene was the Harvey ras-1 gene, although this was later shown to be incorrect (see below). Later in 1991, the Keating group identified a further six families with linkage to the same locus on chromosome 11 and suggested that the syndrome may be genetically homogeneous. However, in 1994, a LQTS family with linkage to chromosome 7 (LQTS type 2) and another with linkage to chromosome 3 (LQTS type 3) were identified (292), confirming the genetic heterogeneity of the syndrome. In the short space of a year, the three genes responsible for >90% of congenital LQTS were identified: KCNH2, the cause of LQTS type 2 (131); SCN5A, the cause of LQTS type 3 (667); and KCNQ1 (not the previously suspected Harvey ras-1 gene, which is located in a very similar region of chromosome 11), the cause of LQTS type 1 (666).

Douglas Zipes (737) had remarked that just as Wolf-Parkinson-White was the Rosetta Stone of reentrant arrhythmia, LQTS might be the Rosetta Stone of ventricular tachyarrhythmias dependent on sympathetic simulation. This prediction has very much proved to be correct; molecular insights into LQTS have become the paradigm for understanding the normal processes that underscore repolarization in the heart and which, in their dysfunction, predispose to sudden cardiac death in a host of common cardiac diseases (396).

Mutations in KCNH2 account for ~40% of cases of genetically confirmed congenital LQTS. As will be described, the risk for sudden cardiac death, the efficacy of therapy, the triggers for symptomatic episodes, the ECG appearance, and the phenotypic response to exercise are individual to this genotype.

B. Loss of Function Mutations in hERG

From the discussion of the crucial role of Kv11.1 channels in cardiac repolarization (see sect. IID), it is easy to understand how mutations that reduce Kv11.1 channel function may have a harmful effect on cardiac electrical activity. Over 459 putative disease-causing mutations in KCNH2 have been identified (http://www.fsm.it/cardmoc/; Ref. 315; see Figure 24). However, very few of these have been characterized at an in vitro level, and it is quite possible that at least some of these putative mutations may not be the cause of disease. The magnitude of current (I) passing through a given ion channel type is determined by four parameters:

\[ I = N \cdot \gamma \cdot P_{o} \cdot V \]  

(6)

Where \( N \) is the total number of channels on the membrane, \( \gamma \) is the single-channel conductance, \( P_{o} \) is the open probability, and \( V \) is the transmembrane voltage. Theoretically, then, mutations in KCNH2 may result in a loss of function.
by four mechanisms: 1) reduced or defective protein synthesis (\( \downarrow N \) in Eq. 1), 2) defective trafficking (\( \downarrow P_o \)), 3) defective channel gating (\( \downarrow P_a \)), and 4) reduced ion permeation (\( \downarrow \gamma \)) (139).

1. Reduced synthesis

Around 25% of KCNH2 mutations (http://www.fsm.it/cardmoc/) result in premature stop codons (see FIGURE 24). A relative absence of truncated protein in the cell is likely the result of nonsense-mediated mRNA decay (344) (see sect. III B). Truncated KCNH2 transcripts resulting in mutations R1014X and W1001X have been shown to undergo nonsense mediated decay (218), and it is reasonable to assume that this will also apply to the vast majority of other mutants that result in premature stop codons.

2. Defective trafficking

In the most comprehensive survey of mutants to date, Anderson et al. (19) showed that 28 of 34 missense mutants (i.e., \( \sim 80\% \) of the mutants studied) result in a hERG trafficking defect. For hERG trafficking mutants there are examples that exert a dominant negative suppression of wild-

3. Abnormal gating

Abnormal gating can lead to reduced Kv11.1 current by one of two mechanisms: reduced activation (i.e., slower activation kinetics/accelerated deactivation kinetics, or shift in the voltage dependence of activation to more depolarized voltages) (61, 99, 545) or enhanced inactivation (435, 552, 728). Many mutations affect the gating of Kv11.1 channels when assayed in Xenopus oocytes (545). However, as Xenopus oocytes are incubated at low temperatures (typically \( \sim 17^\circ C \)), mutant proteins that would be misfolded and consequently degraded in mammalian systems maintained at \( 37^\circ C \) will often reach the cell membrane. This problem is

FIGURE 24. Location of LQTS type 2 mutations. Missense mutations (closed diamonds), nonsense mutations (includes deletion/insertion/frameshift; open diamonds), and splice site mutations (S). Note the high incidence of mutations in the PAS domain and pore domain regions.
most clearly exemplified by the study of the R534C mutant Kv11.1 channel. When expressed in *Xenopus* oocytes, the mutation results in an increased open probability, i.e., a gain of function, yet clinically the mutant causes loss of function (434). Subsequently, it was shown that the R534C mutant when expressed in mammalian cells is retained in the ER, explaining the clinical loss of function (19). The most important implication of these results is that it is essential when characterizing mutant channels to perform assays in mammalian cells. This is not trivial as studying ion channels in mammalian systems has a much lower throughput than studies in *Xenopus* oocytes. Nevertheless, a number of mutations that result in gating defects have been characterized in mammalian cells (61, 552, 728). The Berecki study of the R56Q mutant is especially noteworthy for the use of the dynamic action potential clamp technique that is a particularly elegant means of characterizing the effect mutant channels will have on the cardiac action potential.

4. Abnormal conduction

Mutations in proximity to the selectivity filter of Kv11.1 may result in altered ion selectivity and/or altered single-channel conductance (321). In 2000, it was reported that the mutation N629D resulted in altered ionic selectivity and proposed that an inward current during terminal repolarization was the cause of prolonged repolarization in these patients (357). However, these studies were performed in *Xenopus* oocytes, and a subsequent study showed that the N629D mutation resulted in defective trafficking (19). More recently, it has been shown that the G628S mutant channel trafficks normally and gates normally, as assessed by voltage-clamp fluorometry (166), but does not conduct channel conductance (521). In 2000, it was reported that mutations in proximity to the selectivity filter of Kv11.1 channel. When expressed in *Xenopus* oocytes, the mutation results in an increased open probability, i.e., a gain of function, yet clinically the mutant causes loss of function (434). Subsequently, it was shown that the R534C mutant when expressed in mammalian cells is retained in the ER, explaining the clinical loss of function (19). The most important implication of these results is that it is essential when characterizing mutant channels to perform assays in mammalian cells. This is not trivial as studying ion channels in mammalian systems has a much lower throughput than studies in *Xenopus* oocytes. Nevertheless, a number of mutations that result in gating defects have been characterized in mammalian cells (61, 552, 728). The Berecki study of the R56Q mutant is especially noteworthy for the use of the dynamic action potential clamp technique that is a particularly elegant means of characterizing the effect mutant channels will have on the cardiac action potential.

4. Abnormal conduction

Mutations in proximity to the selectivity filter of Kv11.1 may result in altered ion selectivity and/or altered single-channel conductance (321). In 2000, it was reported that the mutation N629D resulted in altered ionic selectivity and proposed that an inward current during terminal repolarization was the cause of prolonged repolarization in these patients (357). However, these studies were performed in *Xenopus* oocytes, and a subsequent study showed that the N629D mutation resulted in defective trafficking (19). More recently, it has been shown that the G628S mutant channel trafficks normally and gates normally, as assessed by voltage-clamp fluorometry (166), but does not conduct channel conductance (521). In 2000, it was reported that mutations in proximity to the selectivity filter of Kv11.1 channel. When expressed in *Xenopus* oocytes, the mutation results in an increased open probability, i.e., a gain of function, yet clinically the mutant causes loss of function (434). Subsequently, it was shown that the R534C mutant when expressed in mammalian cells is retained in the ER, explaining the clinical loss of function (19). The most important implication of these results is that it is essential when characterizing mutant channels to perform assays in mammalian cells. This is not trivial as studying ion channels in mammalian systems has a much lower throughput than studies in *Xenopus* oocytes. Nevertheless, a number of mutations that result in gating defects have been characterized in mammalian cells (61, 552, 728). The Berecki study of the R56Q mutant is especially noteworthy for the use of the dynamic action potential clamp technique that is a particularly elegant means of characterizing the effect mutant channels will have on the cardiac action potential.

C. Rescue of Trafficking Defective Mutant Channels

Many mutant Kv11.1 channels can give rise to channels with normal or near normal gating properties, if they reach the plasma membrane (192, 434). This has led to considerable interest in the possibility of developing pharmacological chaperones to rescue trafficking defective mutant channels (174, 317, 522), similar to what has been shown for trafficking defective CFTR channels (202). Broadly speaking there are three classes of compounds that can rescue misprocessed Kv11.1 channels. First, there are small molecules, such as glycerol and DMSO, that are thought to help stabilize correctly folded proteins, i.e., act as chemical chaperones, and have been shown to improve trafficking for multiple different proteins, including CFTR (553), aquaporin-2 (616), and Kv11.1 (734). Second, many Kv11.1 blockers including E-4031, astemizole, cisapride, terfenadine, and fexofenadine (180, 511, 734) can rescue trafficking by binding to the inner vestibule of the channel pore, i.e., the same site as drugs that block the channels (180). As such this would therefore not appear to be clinically useful as the rescued channels would be nonconducting (317). However, fexofenadine is an exception to this rule, in that it can rescue trafficking at a dose more than two orders of magnitude lower than the dose that causes channel block (180, 511, 734). The mechanism underlying this particular property of fexofenadine, however, remains to be determined. Third, there are a series of non-protein specific drugs such as the sarcoplasmic/ER Ca$^{2+}$-ATPase inhibitor thapsigargin that can improve trafficking of many types of mutant channels including Kv11.1 (138). To date there have been no whole animal or clinical studies to determine whether any of these drugs could be useful in vivo.

An interesting feature of the studies looking at pharmacological rescue of trafficking defective Kv11.1 channels is that the efficacy of different drugs to rescue mutant proteins appears to be domain specific. For example, pore-blocking drugs are more effective at rescuing channels with mutations in transmembrane domains, whereas thapsigargin does not rescue N470D but is effective at rescuing channels with mutations in the cNBD (180). More recent studies, however, suggest that these differences may not be quite as clear-cut, with both drugs showing more similarities than differences in terms of the mutant channels they can rescue (19). Nevertheless, the differences that do occur may well be telling us something about how different mutant channels fold as it is possible that different conformational states of the channel (e.g., open versus inactivated) are more stable than others, and this warrants further investigation.

D. Genotype-Phenotype Relationships in LQTS Type 2

The International Long-QT Syndrome Registry has been an important resource for investigating genotype-phenotype relationships in the three most common forms of the disorder (LQTS type 1 caused by mutations in KCNQ1, LQTS type 2 caused by mutations in KCNH2, and LQTS type 3 caused by mutations in SCN5A). There are some common features in all genotypes, for example, an early age of onset and a long baseline QT interval carry an increased risk of sudden cardiac arrest (SCA) irrespective of genotype (508). There are also many differences between genotypes.

Each LQTS subtype manifests an idiosyncratic T-wave morphology on the surface electrocardiogram (ECG).
These are as follows: LQTS type 1, low amplitude and broad; LQTS type 2, notched or bifid; LQTS type 3, late onset and peaked (428, 715) (see FIGURE 6 above). A refined subdivision of these general descriptions into 10 “typical” T-wave appearances (4 for LQTS type 1, 4 for LQTS type 3, and 2 for LQTS type 3) is accurate for identifying genotype from T-wave morphology (715). An affected individual’s ECG may not show a typical T-wave morphology; however, ECGs of affected family members often reveal a predominant, typical form. Furthermore, individuals with LQTS type 2 and normal T-waves at rest may develop the typical bifid or notched appearance during exercise (615). It is, at present, uncertain why reduced Kv11.1 function manifests with a bifid or notched T wave. An arterially perfused wedge preparation modeling LQTS type 2 has been advanced to explain the appearance based on an increase in transmural dispersion of repolarization with reduced Kv11.1 current (574). However, the whole animal applicability of such experiments is controversial (see Ref. 463 for discussion).

In LQTS type 2, standing from the supine position prolongs the QT interval despite tachycardia; in contrast, the QT interval shortens in LQTS type 1 (653). The QTc in LQTS the QT interval despite tachycardia; in contrast, the QT discussion).

bility of such experiments is controversial (see Ref. 463 for

bility of such experiments is controversial (see Ref. 463 for

delayed in onset. Kv11.1-mediated repolarization, then, is critical during sudden increases in heart rate and upon exercise inception. This insight informs our understanding of the common triggers for cardiac events in LQTS type 2: sudden sympathetic surge (loud noises/emotion), and exercise (see sect. VI.B).

In congenital LQTS, triggers for syncope and SCA show significant genotype specificity (560). In LQTS type 1, exercise was the predominant risk factor for cardiac events (62% of total) and SCA (68%), with swimming being a particularly notable risk factor. In LQTS type 2, arousal (e.g., loud noises or sudden emotion) was the major trigger for cardiac events (43%), although exercise and rest/sleep were also common. Interestingly, in LQTS type 3, exercise was never a trigger for SCA, which was frequently in the setting of arousal (29%) or rest/sleep (49%). In each genotype, a low but significant percentage of cases had no obvious antecedent for the cardiac event.

Pregnancy is associated with a reduction in arrhythmic risk in LQTS type 1 and LQTS type 2, but the postpartum period is a time of very high risk. This increase is especially pronounced in LQTS type 2 compared with LQTS type 1 (322, 566). The cause is not known but stress, change in sex hormone levels, reduced sleep, and the intensity of auditory stimuli (crying babies) are possible contributors.

1. Mutation specific phenotypes

There have been numerous case reports of KCNH2 mutations with a malignant phenotype (310, 545, 728). However, this hypothesis had not been thoroughly tested until quite recently. Kim et al. (327) studied 634 patients with LQTS type 2, from 158 proband-identified families; each subject was followed from diagnosis to the age of 40. During this time period, 204 patients had a first cardiac event; the trigger to this event was mutation-site specific: mutations in the pore domain had the highest risk for arousal triggers, and a high risk for exercise triggers; while mutations in non-pore transmembrane domains had a strong predilection to exercise-triggered events, mutations in the PAS domain were significantly associated only with nonarousal/nonexercise triggered events. Events were more common in those with long QTc intervals, and in women, regardless of mutation site (327).

A full understanding of mutation-specific phenotype would require the in vitro characterization of each mutant, an exercise of considerable time and resource. However, some general insights may be gleaned from the existing data. First, mutations causing defects in synthesis, i.e., premature truncation mutations that undergo nonsense-mediated decay, would be expected to result in a ~50% reduction in Kv11.1 current, assuming that the wild-type allele is unaffected. Conversely, trafficking mutants that result in misfolded monomers, which can then target the PAS and targeted for degradation, could result in up to 93% reduction in Kv11.1 current (175); these mutants would be expected to cause severe disease. At this stage it is not known how many trafficking defective mutants result in dominant negative suppression of current, but based on the data of Anderson et al. (19), one would expect most trafficking mutants to be dominant negative, although not necessarily causing complete dominant negative suppression. Almost all mutants within the transmembrane core of the channel are trafficking defective, (19), although there is at least one in the extracellular SSP linker that results in a gating defect (728) and another mutant close to the selectivity filter that results in abnormal conduction (166). Fewer mutants in cytoplasmic domains have been studied, but they are likely to contain a mixture of defective synthesis (218), trafficking (340), and gating (61) phenotypes (see FIGURE 24 above). Given the overlap of phenotypes defined by mutation site, it is quite possible that the mechanism of Kv11.1 current reduction is of more importance than the mutation site per se.

Considerable progress has been made in refining our understanding of genotype-phenotype associations in LQTS type 2, in particular in regard to risk profiling. Risk is now understood as a function of the patient’s clinical history and baseline ECG, as well as their age, gender, pregnancy status, and most intriguing of all, mutation site. Further work is required to understand the influence of an individual’s “ge-
VANDENBERG ET AL.

E. Animal Models of LQTS Type 2

Despite impressive progress in the characterization of LQTS type 2 in humans, the absence of an animal model has hampered efforts to understand the complex interplay of genetic and environmental modifiers of phenotype expression. The first animal model developed was that from Colatsky et al. (45) who bred transgenic mice overexpressing the Kv11.1 pore mutant G628S. In Xenopus oocytes, G628S exerts a dominant-negative effect on channel function (349). Correspondingly, transgenic mice showed absent \( I_{Kr} \) and, at slow cycle lengths and 20°C, a prolonged APD. However, recordings from strips of ventricular muscle were unchanged between wild-type and G628S mice, and there was no change in QT interval. Furthermore, no mice developed cardiac arrhythmia. Given the much higher heart rates in mice (500–600/min in the unanesthetized mouse) compared with humans (60–90/min), and consequently very different repolarization characteristics, the mouse may not be a good model system to use for studying arrhythmias related to abnormalities of repolarization. Furthermore, it is worth noting that \( I_{Kr} \) is relatively unimportant in adult mice (664, 665), so one would not expect to see any significant change in the QT interval of G628S Kv11.1 mice.

ZERG, the zebrafish ortholog of hERG, is expressed in the atrium and ventricle of zebrafish; the zebrafish heart has only two chambers and has very similar amino acid sequence in the pore and drug-binding regions (349). Coupled with ease of breeding, rapid development, and straightforward generation of genetic knockdowns, this makes zebrafish a very attractive model for the investigation of LQTS type 2. Additionally, the heart rate, QT interval, rate-adaptation of QT interval, and action potential duration recorded from zebrafish hearts are all similar to those measured in humans (37). Zebrafish Kv11.1 expressed in Xenopus oocytes also shows similar characteristics to human Kv11.1. Consequently, reduced \( I_{Kr} \) in zebrafish displays a similar electrophysiological phenotype to human \( I_{Kr} \) block: markedly prolonged action potential duration, to the extent of producing 2:1 conduction; and a prolonged QT interval on the surface ECG (37). Complete absence of \( I_{Kr} \) results in a “silent ventricle,” with a depolarized membrane near 0 mV perhaps explaining the apparent rarity of live human births with homozygous LQTS type 2, i.e., embryonic/fetal lethality (67). These results suggest that zebrafish may be a useful animal model system for the investigation of LQTS type 2 and the genetic milieu that shift its phenotype. Langheinrich et al. (349) have also demonstrated that zebrafish may be used to screen for drugs, which block Kv11.1. Drug application commonly produced 2:1 atrioventricular conduction; however, several false-negative results were obtained, including sotalol, quinidine, and erythromycin, all important causes of TdP in humans, perhaps as a result of poor drug penetration to its site of action.

A transgenic rabbit model of LQTS type 2 expressing G628S has been described (81). Half of rabbits with this mutation died suddenly from polymorphic ventricular tachycardia within 12 mo of birth. Optical voltage mapping demonstrated that susceptibility to arrhythmia was correlated with an increase in the spatial heterogeneity of epicardial action potential duration across the anterior wall of the heart. Interestingly, many of the female rabbits died during lactation, a correlate of the increased risk of LQTS type 2 arrhythmia in postpartum women (see above). Transgenic rabbits expressing KvLQT1:Y315S (a model of LQTS type 1) showed prolonged QT, but did not develop arrhythmia under resting conditions. Thus several distinct features of LQTS type 2 and LQTS type 1, and their phenotypic differences, are reproduced in these transgenic animal models.

VIII. DRUG-INDUCED QT PROLONGATION AND KV11.1 CHANNELS

In clinical practice, prolongation of the QT interval on the surface electrocardiogram is most commonly seen in patients taking medications that block the Kv11.1 channel and/or electrolyte abnormalities that alter repolarizing currents. This scenario, sometimes referred to as acquired long QT syndrome (aLQTS), encompasses any noninherited form of QT prolongation beyond the clinically defined normal range (>440 ms in men, >460 ms in women). Patients with so-called aLQTS do not have any of the noncardiac features seen in some patients with congenital long QT syndrome. Accordingly, it is more accurate to refer to this condition as drug-induced prolongation of the QT interval. However, in keeping with common practice, the term aLQTS is used in this review. More common than the congenital form, aLQTS is similarly associated with the development of life-threatening arrhythmias such as torsades de pointes (TdP). A variety of medical conditions including myocardial infarction, as well as electrolyte abnormalities such as hypomagnesemia and hyokalemia, can lead to QT prolongation. However, drug administration is by far the most commonly identified cause of aLQTS and will be the focus of this section.

Congenital long QT syndrome is genetically heterogeneous (see sect. VII.A). In contrast, the overwhelming majority of cases of aLQTS are caused by drug block of \( I_{Kr} \). Drug-induced QT prolongation can occur as a direct consequence of Kv11.1 channel block and/or impaired trafficking of Kv11.1 channels to the cell membrane.
**A. Historical Perspective**

Levy (364) reported the first cases of syncope and sudden death linked to treatment of patients with the antimalarial drug quinidine, in 1922. The clinical basis for these phenomena was revealed in 1964, when Selzer and Wray (363) observed polymorphic ventricular tachycardia on electrocardiograms from patients with quinidine-related syncope. This observation clearly demonstrates TdP arrhythmia associated with use of a drug that is now known to block Kv11.1 channels.

In 1970, Vaughan-Williams (579) introduced a classification system for antiarrhythmic drugs, which, as the name implies, are used to restore normal heart rhythm and contraction. It was triggered by the finding that amiodarone, an antiarrhythmic drug, caused considerable prolongation of the action potential duration in isolated rabbit atrial or ventricular muscle fibers (579). Newly identified drugs like amiodarone, which delayed repolarization and thereby prolonged both action potential duration and the effective refractory period, were categorized as class III antiarrhythmic drugs (580). Quinidine, on the other hand, was identified as a class I antiarrhythmic due to its reduction in the magnitude of APD and slowing of conduction velocity (298). However, as early as 1957 it was suggested that quinidine could slow repolarization by reducing potassium conductance in isolated rabbit heart and atria (31). Subsequent studies showed that quinidine prolonged repolarization of the action potential in a manner similar to class III antiarrhythmic drugs (527). It is now well known that a significant overlap exists between all four classes of the Vaughan-Williams system, and much of this is due to the high susceptibility of Kv11.1 channels to block by antiarrhythmic drugs.

The first noncardiac drug associated with ventricular tachycardia was the antipsychotic thioridazine (559). Subsequently, a large number of non-cardiac-related medications, spanning a number of therapeutic classes and with a wide variety of chemical structures, have been demonstrated to induce life-threatening arrhythmias through QT prolongation (listed at www.torsades.org). As a consequence of this potentially fatal unwanted side effect, several noncardiac medications have been severely restricted in their use, or removed from the pharmaceutical market altogether (525). Predicting whether new chemical entities carry the risk of drug-induced QT prolongation and TdP before substantial time and expenditure has been spent on their development has been, and remains, an important scientific goal.

**B. Predicting Risk of Drug-Induced TdP**

In theory, the relationship between Kv11.1 channel block, QTc prolongation, and TdP offered an attractive approach to identify the proarrhythmic risk of new and existing drugs. High-throughput assays for detecting Kv11.1 drug block are discussed in section VE. However, due to a complex interplay of factors, these relationships are not as straightforward as initially thought. Drugs, for instance, can target more than one molecular entity that underlies the complex depolarization-repolarization relationship of an action potential. This means that Kv11.1 channel block does not necessarily always lead to prolongation of the action potential duration and QT interval. One example of this is the Kv11.1 channel blocker verapamil, which also blocks L-type calcium channels and reduces depolarization current thereby preventing QT interval prolongation (170, 697). Block of L-type calcium channel current \([I_{Ca,L}]\) will also severely restrict the formation of EADs and could explain why verapamil very rarely results in TdP (7). The relationship between QT prolongation and the generation of arrhythmia is even less certain. It is true that drug-induced TdP most often results from Kv11.1 block and QT interval prolongation, but QT interval prolongation alone is not sufficient to cause the development of TdP in patients. In fact, it has been estimated that most antiarrhythmic drugs that prolong the QT interval carry only a 1–3% risk of TdP over a 2-year exposure and that this risk is even less for non-cardiac-related drugs (313, 525). Indeed, some class III antiarrhythmic drugs, such as amiodarone, which prolongs the QT interval by high-affinity block of Kv11.1 channels, have almost no propensity to be proarrhythmic (265, 697). An even further level of complexity is added by the suggestion that drug-induced ventricular tachyarrhythmias which fit the description of TdP can occur without QT prolongation, but are not labeled TdP for this very reason (567).

Despite this uncertainty, progress has been made in the development of a predictive model for the proarrhythmic risk of drugs. In particular, a number of interlinked electrophysiological biomarkers for TdP have been identified using an automated Langendorff-perfused rabbit heart preparation called SCREENIT (266, 267, 567). Known by the acronym TRIaD these biomarkers are: triangulation, reverse use-dependence, instability, and dispersion. Drug-induced prolongation of action potential duration by slowing phase 3 repolarization (defined as APD_{30-90}) results in a triangulation of action potential morphology. As discussed previously, this occurs predominantly though reduced outward \(I_{Kr}\), but can also occur through enhanced inward sodium or calcium currents. Triangulation is proarrhythmic because it both increases the propensity for arrhythmogenic triggers such as EADs (due to increased time in calcium and sodium window currents) and for substrates of arrhythmia like re-entry and transmural dispersion of repolarization (TDR) (266, 267, 567). Clinically, triangulation manifests as wider, flatter, and often notched T-waves that precede TdP, although caution must be taken in using T-wave morphol-
ogy as an indicator of TdP as there may be other causes for this phenotype (451, 467).

Reverse use dependence refers to the tendency of most class III antiarrhythmic drugs to prolong the APD to a greater degree during bradycardia (slower heart rates) when it is least required (269). Several explanations for reverse use dependence have been postulated, but the exact molecular mechanism underlying this phenomenon has not been resolved (50, 306, 687, 696). One intriguing possibility is that the inherent reverse rate dependence of currents that constitute the cardiac action potential (50), in particular the late sodium current, favors a greater degree of action potential prolongation with \( I_{Kr} \) block at slow heart rates (687). This would explain why the \( I_{Kr} \) blocker amiodarone, which also blocks the late sodium current, shows little reverse use dependence (540). In addition to being a highly predictive preclinical marker for arrhythmia, reverse use dependence also causes beat-to-beat variation in repolarization that is known as instability (266, 267, 567). This cyclic phenomenon results in alternate long-short lengths of action potential duration and QT interval. Although some degree of instability is normal, due to intrinsic reverse rate dependence of currents, its proarrhythmic potential is greatly enhanced with \( I_{Kr} \) block (267). On an ECG, instability is represented by T-wave alternans prior to arrhythmia, thereby making it a powerful predictive biomarker for TdP (186).

One of the most important biomarkers for TdP is dispersion of repolarization (24). Essentially, dispersion refers to gradients in the action potential duration that exist between different areas of the cardiac muscle including from apex to base, from right to left ventricle, and in regions of scar tissue. Transmural dispersion between the epicardium (shortest APD) and the mid-myocardium (longest APD) appears to be of particular importance (23). An imbalance of depolarizing and repolarizing ionic conductances underlies these transmural differences, i.e., midmyocardial cells (M-cells) have a reduced \( I_{Ks} \), repolarizing conductance and enhanced depolarizing conductances, both of which contribute to a longer action potential duration (24, 443). Block of \( I_{Ks} \), therefore produces larger alterations to M-cell action potential duration than in epicardium or endomyocardium, which creates a strong substrate for reentry arrhythmia (23, 24).

Since repolarization of the epicardium coincides with the peak of the T-wave on an ECG, while midmyocardial repolarization coincides with the end of the T-wave, prolongation of the distance between T-peak and T-end can be a powerful biomarker for increased transmural dispersion of repolarization (25, 691). These studies have been largely conducted in arterially perfused isolated wedges of canine heart. Other studies using intact pig and canine hearts have added a note of caution, in that T-peak to T-end may represent dispersion of repolarization across the entire ventricle, rather than being a direct measure of transmural dispersion (464, 690). It is also important to note that none of the biomarkers listed is an absolute predictor of the arrhythmogenic potential of a drug. Further studies are required to examine the predictive abilities of these and other possible biomarkers of drug-induced QT prolongation and TdP.

Marked variations in QT prolongation and proarrhythmic risk are observed not only for different drugs but also between patients taking comparable doses of the same drug. At least some of this variation can be attributed to drug-drug interactions. Inadvertent prescriptions for multiple QT-prolonging drugs may be a fairly common problem that could lead to increased clinical manifestations of drug-induced QT prolongation (133). Other problems may occur in relation to impaired metabolism of a QT-prolonging agent. A common example is the antihistamine terfenadine that is metabolized by cytochrome P-450 3A4 (CYP3A4) to its active agent, which at standard doses has little proarrhythmic risk (239). Inhibition of CYP3A4 by grapefruit juice or a number of other commonly used drugs can significantly elevate serum concentrations of terfenadine and increase the incidence of Kv11.1 block and QT prolongation (60, 151, 731). Such increased arrhythmic risk is unacceptable for a drug used in treatment of non-life-threatening conditions, and for which safer alternatives are available, so terfenadine was withdrawn from the pharmaceutical market in 1998.

Various patient specific factors can also influence susceptibility to drug-induced QT prolongation and the onset of TdP (525). A concept known as “repolarization reserve” may help explain the basis of this individual variation (526). In essence, repolarization is coordinated by a number of mechanisms so a natural redundancy exists. As such, there is little substrate for arrhythmia to occur. In this context, block of \( I_{Kr} \), may not, on its own, represent a significant risk for QT prolongation. However, if combined with other stressors that reduce the repolarization reserve, then a significant increase in risk is expected. Genetic factors, such as gender or common polymorphisms in LQTS causing genes, are likely common stressors. Pathophysiological conditions including various forms of heart disease, renal failure, and hepatic insufficiency have also been identified as risk factors.

C. Clinical Management

Incidence rates for drug-induced QT prolongation are hard to accurately evaluate, although estimations suggest that 2–3% of drug prescriptions may carry some risk (136). Perhaps the best study in this regard is that from Ray et al. (515) looking at the incidence of sudden cardiac death (SCD) in patients taking antipsychotic medications. The incidence of SCD was closely correlated with the dose of drug used, and in those patients taking higher doses of drugs, the incidence of SCD was up to three times higher.
that are known to induce SQTS (80, 115, 608). However, compared with the inherited mutations (N588K or T618I) shortening of the QT interval (389). Kv11.1 agonists pro-
some of these agents could induce arrhythmia through
One concern is that by enhancing repolarization current
may be proarrhythmic in some conditions (389, 476, 482).
rabbit model of TdP (147). A note of caution is that agonists
beats and tachycardic episodes in a methoxamine-sensitized
Kv11.1 agonists (205). In vivo, NS3623 can prevent E4031-
ity for block). In this regard, both type 1 and 2 agonists have
agonists are able to displace blockers from their binding
remaining unblocked channels can be activated) or if the
prolongation. Reversal of drug-induced reductions in
native pharmacological treatments for drug-induced QT
question is whether Kv11.1 agonists have potential as alter-
G
The discovery of a series of Kv11.1 channel agonists (see
same protein change, N588K (80). The N588K mutation
were different in the two families, they both resulted in the
In 2004, Brugada et al. (80) identified mutations in
ms in males (477). Inherited SQTS, however, is likely to be
A. Genetic Basis
In 2004, Brugada et al. (80) identified mutations in KCNH2
in two families with SQTS. Although the gene mutations
were different in the two families, they both resulted in the
same protein change, N588K (80). The N588K mutation
shifts in the voltage dependence of inactivation similar to
the level of Kv11.1 agonists (∼+20mV) suggests that such
drugs could cause sufficient shortening of the QT interval to
induce SQTS (<360 ms) (59). Whether agonist-shortened
QT intervals could result in arrhythmia is therefore uncertain and requires further exploration. A second problem that may inhibit the therapeutic use of Kv11.1 channel agonists is their relative low potency (low micromolar range). Indeed, most are partial agonists that also block Kv11.1 at high concentrations (88, 486, 487). Specificity of action may also be a problem. For example, agonists may not show sufficient specificity for Kv11.1 over other ether-a-go-go family members (163) or ion channels (223). Additional unwanted side effects may arise from targeting of noncardiac Kv11.1 channels (see sect. X). Despite these potential problems, potassium channel agonists (either Kv11.1, KCNQ1, or Kir6) still present a potentially interesting pharmacological alternative for the treatment of LQTS. Increased knowledge regarding their mechanisms of action, binding sites, and therapeutic potential may in the future allow us to tailor the use of these compounds to specific LQTS phenotypes (223).

There are also a few reports of noncardiac drugs that result in shortening of the QT interval. In a recent study, Schimpf et al. (556) reported that the antiepileptic drug rufinamide caused ∼20 ms shortening of corrected QT interval in a sample of 19 patients. There were, however, no adverse events (cardiac arrhythmias or sudden cardiac arrest) observed in this group over an average 3-yr follow up. Nevertheless, given the risk of sudden death in patients with short QT intervals (see below), it is reasonable to sound a note of caution with the use of drugs that shorten the QT interval (556).

IX. SHORT QT SYNDROME
People with short QT intervals (<400 ms) on the electrocardiogram have as high a risk of SCD (∼2.4 increase risk of SCD in the subsequent 2 yr) as do people with long QT intervals (>440 ms) (15). It was not until 2000, however, that Gussak et al. (230) suggested a new inherited arrhythmia syndrome characterized by shortened QT intervals and atrial fibrillation, which they termed short QT syndrome (SQTS). Today the consensus for how short the QT interval needs to be to define STQTS is <360 ms in females and <350 ms in males (477). Inherited SQTS, however, is likely to be very rare with relatively few families identified worldwide.

A. Genetic Basis
In 2004, Brugada et al. (80) identified mutations in KCNH2 in two families with SQTS. Although the gene mutations were different in the two families, they both resulted in the same protein change, N588K (80). The N588K mutation

Regulatory agency approval and clinical use of any drug with suspected liability to cause QT prolongation is clearly dependent on the benefits of the primary therapy and the availability of alternatives. In addition, clinical evaluation of risk factors that increase susceptibility to arrhythmia is important. If assessed prior to treatment, at least some of these risk factors, such as electrolyte imbalances, could be reduced. Computer algorithms that combine analysis of patient- and drug-specific risk factors could be an important tool for clinicians in TdP risk avoidance (525).

Current therapies for acute episodes of drug-induced QT prolongation are limited to intravenous administration of magnesium sulfate (647) or in extreme cases cardiac pacing (95). Magnesium therapy prevents recurrence of TdP without correction of the QT interval, even in patients with serum concentrations within the normal range (647). The underlying mechanism for the effectiveness of magnesium remains unclear, although one plausible hypothesis is that it suppresses EADs by blocking L-type calcium channels (27). Discontinued use of the suspected problematic medication appears an obvious concomitant step to alleviate TdP risk. However, if the primary use of the medication is for an otherwise fatal condition and there is no alternative therapy available, continued use of the drug with adequate supervision may be a necessity (525).

The discovery of a series of Kv11.1 channel agonists (see sect. VG) has raised the possibility that these drugs may be used as antiarrhythmic drugs (223). Another interesting question is whether Kv11.1 agonists have potential as alternative pharmacological treatments for drug-induced QT prolongation. Reversal of drug-induced reductions in \( I_{Kr} \) may occur if only a portion of channels are blocked (so the remaining unblocked channels can be activated) or if the agonists are able to displace blockers from their binding sites (possibly by inhibiting inactivation and reducing affinity for block). In this regard, both type 1 and 2 agonists have been shown to reverse drug-induced APD prolongation in vitro (312, 729), although this effect is minimal for other Kv11.1 agonists (205). In vivo, NS3623 can prevent E4031-induced QT prolongation in conscious guinea pigs (243), while NS1643 substantially reduced the number of ectopic beats and tachycardic episodes in a methoxamine-sensitized rabbit model of TdP (147). A note of caution is that agonists may be proarhythmic in some conditions (389, 476, 482). One concern is that by enhancing repolarization current some of these agents could induce arrhythmia through shortening of the QT interval (389). Kv11.1 agonists produce only a moderate effect on Kv11.1 channel inactivation compared with the inherited mutations (N588K or T618I) that are known to induce SQTS (80, 115, 608). However, computational modeling of Kv11.1 mutations that induce
results in reduced inactivation and hence greater current flow during the plateau potentials of the cardiac potential (see Figure 25). As a consequence of the greater current flow at plateau potentials, the ventricular (and atrial) action potential has a shorter duration and thence a shorter QT interval (see Figure 25). Recently, Sun et al. (608) reported another KCNH2 mutation, resulting in a mutation T618I that also results in loss of inactivation, although the phenotype is less severe than that seen for N588K. The only other KCNH2 mutation reported to be associated with SQTS is R1135H (284). R1135H channels display significantly slower deactivation than wild-type channels without significant changes in any other gating parameters (284). Such a phenotype would not be expected to cause significant shortening of the action potential at low heart rates, but it is possible that at high rates the accumulation of Kv11.1 current could contribute to a significant shortening of the action potential.

Recently, McPate et al. (409) have shown that the in vitro phenotype of the SQTS mutation N588K was more severe when coexpressed with hERG1b subunits rather than hERG1a subunits. Given that the midpoint of the voltage dependence of inactivation of Kv11.1 channels composed of hERG1b subunits is shifted by ~+20 mV compared with channels composed of hERG1a subunits (542), it is reasonable to presume that coexpression of N588K, in either the hERG1a or hERG1b background, with hERG1b subunits would exacerbate the loss of inactivation seen with the N588K mutant subunits.

Since 2004, a total of five genetic loci associated with SQTS have been identified. These include mutations in three K+ channel subunits: KCNH2 (SQTS1), KCNQ1 (SQTS2), and KCNJ2 (SQTS3) as well as two Ca2+ channel subunits: CACNA1C (SQTS4) and CACNB2b (SQTS5). A more comprehensive review of these SQTS subtypes has been reviewed elsewhere (477).

B. Pharmacological Treatment of SQTS1

Given the large number of drugs that can inhibit Kv11.1 K+ channels, intuitively one would think that it would be relatively easy to treat patients with SQTS1. As noted earlier (see sect. V), however, the N588K mutation results in a marked reduction of channel inhibition by a wide range of drugs (408, 484). Nevertheless, there have been some promising results in small clinical trials. For example, Gaita et al. (195) showed that hydroquinidine was effective in prolonging the QT interval to normal levels and eliminating inducibility of ventricular fibrillation in patients with SQTS.

C. Models of SQTS

In 2008, Hassel et al. (248) identified a zebrafish mutation, reggae (reg), which displays clinical features of SQTS. The
A reg mutation was found to be located in the voltage sensor of zERG (248) and resulted in a mutation equivalent to L532P in human Kv11.1. Characterization of both the zERG mutant (248) as well as the equivalent human mutation (727) revealed a complex gating phenotype resulting in a marked increase in the window current, i.e., the voltage range at which the channels would be constitutively open. The Kv11.1 agonists, PD-118057 (476) and NS3623 (352), have also been used to mimic SQTS in cardiac tissues. It is interesting to note that NS3623 was also found to impair cardiac conduction in guinea pig hearts, consequent to reduced sodium channel availability. Whether this is due to a direct effect on sodium channels or an indirect effect caused by the altered K⁺ conductance remains to be determined.

An alternative to animal models is to use in silico models of the N588K mutation (283, 681, 712). These models have reproduced the shorter action potential duration and QT interval; however, the earlier models did not reproduce the altered dispersion of repolarization or the taller T-waves typical of SQTS1. In a more recent study, Adeniran et al. (4) found that these features could only be reproduced if they incorporated a heterogeneous distribution of I_{Kr} among the subtypes of ventricular myocytes (epicardial:mid-myocardial:endocardial in ratio 1.5:1:1 or greater). Whether such a gradient really exists is uncertain (193). Nevertheless, the Adeniran study clearly illustrates the importance of combining tissue heterogeneity into any cardiac electrophysiology studies.

**X. DISTRIBUTION OF KV11.1 CHANNELS IN DIFFERENT TISSUES**

Although Kv11.1 channels have been most extensively studied with respect to cardiac function, they are also quite widely expressed in brain regions, smooth muscle cells of the gastrointestinal and genitourinary tracts, as well as a range of endocrine cells (see **TABLE 2**).

### A. Nervous System

Most of what is known about Kv11.1 in the central nervous system has come from studies in rats. In addition to ratERG-1 (Kv11.1), adult rat brain expresses two closely related members of the EAG superfamily, ERG2 (Kv11.2) and ERG3 (Kv11.3) (571) (see **FIGURE 4**, sect. II). ratERG2 and ratERG3 appear to be exclusively expressed in neuronal tissue. All three ratERG subtypes are strongly expressed

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Species</th>
<th>Isoforms</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous tissue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F11 DRG neuron x neuroblastoma hybrid cell line</td>
<td>Mouse x rat hybrid</td>
<td>Unknown</td>
<td>102</td>
</tr>
<tr>
<td>Hippocampus/prefrontal cortex</td>
<td>Human, primate</td>
<td>hERG1a+b, hERG 3.1</td>
<td>279</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>Rat</td>
<td>rERG1a+b, rERG2, rERG3</td>
<td>224</td>
</tr>
<tr>
<td>Developing ventral horn GABAergic neurons</td>
<td>Mouse</td>
<td>mERG1a+b, mERG2, mERG3</td>
<td>190</td>
</tr>
<tr>
<td>Glomus cells (carotid body)</td>
<td>Rabbit, rat</td>
<td>Unknown</td>
<td>326, 465</td>
</tr>
<tr>
<td>Astrocytes</td>
<td>Rat, mouse</td>
<td>ERG1a+b, ERG2, ERG3</td>
<td>184, 224, 470</td>
</tr>
<tr>
<td>Taste buds (young β2/M5 cells)</td>
<td>Rat</td>
<td>Unknown</td>
<td>457</td>
</tr>
<tr>
<td>Smooth muscle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>Opossum</td>
<td>Unknown</td>
<td>8</td>
</tr>
<tr>
<td>Stomach smooth muscle</td>
<td>Rat</td>
<td>rERG1, rERG2</td>
<td>458</td>
</tr>
<tr>
<td>Small intestinal smooth muscle</td>
<td>Mouse, human, rabbit</td>
<td>Unknown</td>
<td>347, 371</td>
</tr>
<tr>
<td>Colonic smooth muscle</td>
<td>Human, rabbit</td>
<td>ERG1</td>
<td>575</td>
</tr>
<tr>
<td>Gallbladder smooth muscle</td>
<td>Human, mouse, guinea pig</td>
<td>ERG1*</td>
<td>475</td>
</tr>
<tr>
<td>Portal vein</td>
<td>Mouse</td>
<td>mERG1b &gt; mERG1a</td>
<td>459</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>Guinea pig</td>
<td>Unknown</td>
<td>281</td>
</tr>
<tr>
<td>Myometrium</td>
<td>Mouse</td>
<td>mERG 1a, 1b</td>
<td>220</td>
</tr>
<tr>
<td>Epididymal duct</td>
<td>Bovine</td>
<td>bERG1b &gt; bERG1a</td>
<td>412</td>
</tr>
<tr>
<td>Endocrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic beta-cells</td>
<td>Human</td>
<td>hERG1 found, hERG2+3</td>
<td>530</td>
</tr>
<tr>
<td>Pituitary</td>
<td>Rat</td>
<td>ln lactotrophs: rERG1, rERG2, rERG3</td>
<td>52, 56, 554</td>
</tr>
<tr>
<td>Cromaffin cells</td>
<td>Rat</td>
<td>rERG1</td>
<td>225</td>
</tr>
<tr>
<td>Lactotroph cells</td>
<td>Rat</td>
<td>rERG1, rERG2, rERG3</td>
<td>554</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney (proximal tubule, distal tubule, collecting duct)</td>
<td>Rat</td>
<td>rERG1a+b (rERG2&amp;3 not tested)</td>
<td>87</td>
</tr>
</tbody>
</table>

**TABLE 2. Tissue distribution of hERG outside the heart**

Physiol Rev • VOL 92 • JULY 2012 • www.prv.org 1455
in the olfactory bulb, while ratERG1 is the only isoform present in brain stem nuclei, and ratERG3 is the dominant isoform in cerebral cortex and hippocampal pyramidal cells (539). Subsequent RT-PCR, in situ hybridization, and immunohistochemistry studies confirmed and extended these results (224) and additionally detected expression of KCNH2 transcripts in hippocampal astrocytes (164, 470), cerebellar Purkinje cells (164, 470, 536), and vestibular nucleus neurons (490). Papa et al. (470) also found that KCNH2 transcripts appeared at very high levels in individual, scattered neurons throughout the cortex and speculated that these cells possibly represent inhibitory interneurons. A similar pattern of scattered, high levels of KCNH2 expression are also found in interneuron populations of the hippocampus (470, 539).

During a single neuronal action potential, only a small fraction of \( I_{Kr} \) channels will be activated, due to the slow activation and rapid inactivation properties of these channels (see sect. IV). Therefore, the effect of \( I_{Kr} \) on an individual neuronal action potential is minimal. However, during prolonged bursts of action potentials, the amount of \( I_{Kr} \) increases as a consequence of the slow deactivation kinetics. Chiesa et al. (102) have shown that current injection into F11 cells results in brief, self-terminating trains of action potentials, but after blocking \( I_{Kr} \) with WAY-123,398, these trains became long lasting and more regular. This indicates that the gradual increase in \( I_{Kr} \) during prolonged bursts can eventually counteract \( Na^+ \) influx and decrease spiking frequency or even terminate a burst (see FIGURE 26). This spike-frequency adaption has also been demonstrated in cerebellum Purkinje neurons (224, 536) and in neurons from the medial vestibular nucleus (490).

Another example of \( I_{Kr} \) channels influencing the membrane potential and firing rate has been shown in glomus cells of the adult rabbit carotid body (466). In whole cell current-clamped glomus cells, application of 150 nM dofetilide caused a significant 13 mV depolarizing shift of the membrane potential. Voltage-clamp experiments showed a concentration-dependent block of \( I_{Kr} \) by dofetilide with an \( IC_{50} \) of 13 ± 4 nM. In carotid sinus nerve preparations, dofetilide was also able to increase the basal sensory discharge. \( I_{Kr} \) has also been demonstrated in rat carotid body chemoreceptor cells (326). The current density in these cells decreases with age, and this could be implicated in increased sensitivity to hypoxia during maturation.

In addition to expression in neurons, \( I_{Kr} \) is also present in astrocytes (164). In hippocampal slices, E-4031 inhibited both hyperpolarization- and depolarization-activated glial currents resulting in impaired clearance of extracellular potassium (164, 736). From these results, Emmi et al. (164) concluded that Kv11.1 encoded \( I_{Kr} \) currents are important in the process of “spatial buffering” of extracellular potassium ions, which accumulate during high neuronal activity.

Mutations in KCNH2 have been linked to both LQTS type 2 and a high incidence of seizures (169, 461). In many cases, the “seizures” may be caused by cardiac arrhythmias. However, recent work has demonstrated that the incidence of true seizures is significantly higher in patients with LQTS type 2 than in patients with LQTS type 1 or LQTS type 3 (47% in LQTS type 2 vs. 22% in LQTS type 1 and 25% in LQTS type 3, sample size 343 patients; Ref. 299). While there is no definitive proof of the idea, one possible reason for this high incidence of seizures in LQTS type 2 could be the effect of Kv11.1 mutations on \( K^+ \) buffering properties of astrocytes (164) as discussed above.

Two recent studies have found a link between schizophrenia and KCNH2 (43, 279). A SNP in the chromosomal 7q36.1 region was linked to a novel KCNH2–3.1 isoform (see FIGURE 2), in which the first 102 NH2-terminal amino acids are replaced by 6 unique amino acids. In control patients, mRNA levels of the KCNH2–3.1 isoform and the KCNH2–1a isoform were comparable in the brain, while in the heart KCNH2–1a mRNA is three orders of magnitude lower than KCNH2–3.1 mRNA.
more abundant than mRNA of the KCNH2–3.1 isoform. In brains of some schizophrenia patients, however, the KCNH2–3.1 isoform expression levels were 2.5-fold higher than KCNH2–1a expression (279). Given the critical role that the NH2-terminal regions play in Kv11.1 deactivation (see sect. IVF), it is not surprising that the 3.1 isoform displays a significantly faster deactivation rate than channels composed of hERG1a subunits. Huffaker et al. (279) showed that expression of the 3.1 isoform in rodent cortical neurons results in high-frequency nonadapting firing patterns. This is precisely what one would expect for a channel that has rapid deactivation and so will show significant less accumulation during repetitive action potential firing. Kv11.1 channels have of course been of keen interest in the schizophrenia field for many years as almost all anti-psychotics used clinically have the unwanted side effect of blocking Kv11.1 channels in the heart, resulting in a significantly increased risk of sudden death (515). The discovery of an increased expression of a hERG isoform in the brains of at least some schizophrenia patients raises the intriguing question as to whether antipsychotic drug block of Kv11.1 in the brain may influence the clinical course of schizophrenia either in a beneficial or harmful way?

B. Smooth Muscle

Both full-length hERG1a and the COOH-terminally truncated hERG-USO variant have been identified in a range of smooth muscle tissue (see TABLE 2). HERG-USO has distinct biophysical properties compared with the cardiac Kv11.1 channels, in particular, a much accelerated rate of deactivation (169, 338). Smooth muscle Ik, channels contribute to regulation of the resting membrane potential as well as affecting either the force or frequency of contraction. Studies in human jejunum revealed that block of Ik, channels with 1 µM E-4031 and increase in the extracellular potassium to 45 mM caused very similar effects on phasic contractile amplitude (169). This suggests that Kv11.1 modulators may be related to a marked upregulation of KCNE2 and KCNE4 transcripts during pregnancy. These accessory subunits could alter the properties of smooth muscle strips from late pregnant mice and comparable to nonpregnant animals. However, preparations of smooth muscle strips from late pregnant mice show strong spontaneous contractions that are insensitive to either Kv11.1 blockers or activators (220). Greenwood et al. (220) suggested that the apparent insensitivity to Kv11.1 modulators may be related to a marked upregulation of KCNE2 and KCNE4 transcripts during pregnancy. These accessory subunits could alter the properties of Kv11.1 in a way that reduces its importance during late pregnancy (220). Given the marked effect that changes in microRNA expression can have on levels of protein expression independent of changes in transcript levels (see sect. IIB), it would be worth investigating whether changes to microRNA expression during pregnancy may explain the reduced role Kv11.1 channels play in the late stages of pregnancy.

In bovine epididymal duct, KCNH2–1a and KCNH2–1b transcripts are found throughout the length of the duct, with higher levels of KCNH2–1b relative to KCNH2–1a (412). Application of E-4031, dofetilide, or cisapride enhanced spontaneous contractions, while NS-1643 suppressed spontaneous contractions. Experiments with nifedipine (L-type Ca2+ channel blocker) and thapsigargin (SR Ca2+ reuptake inhibitor) suggest that Ca2+ influx and not internal Ca2+ release is responsible for the muscle contractions modulated by Ik, channels. Given the importance of correct epididymal duct contractile function for the male reproductive system, these findings raise the interesting possibility that Kv11.1 activators could have contraceptive effects.

C. Endocrine Cells

Blockade of Ik, channels in some endocrine cells has a similar effect as that seen in smooth muscle cells, i.e., depolarization of the resting membrane potential and/or an increase in the frequency of action potential firing leading to increased release of hormones. This has been shown in human pancreatic islet cells, where blockade of Ik, channels causes a 77% increase in insulin secretion (530). Similarly, in rat chromaffin cells, E-4031 causes increased release of epinephrine but not norepinephrine (225), and in rat lactotrophs, ERG block is associated with increased prolactin release (554). The corollary of each of these studies is that in patients with loss-of-function mutations in KCNH2, one might expect to see increased blood levels of insulin, epinephrine, and prolactin. In general, there are no clinical studies to corroborate this. However, it is well known that a side effect of many neuroleptic drugs that inhibit Kv11.1 channels is an increase in blood prolactin levels (554).
D. Kv11.1 Channels and Cancer

1. hERG in cell cycle regulation

VGK channels in general, and Kv11.1 channels in particular, have been implicated in the regulation of apoptosis and proliferation, both during normal development and in cancer. For example, in early embryonic stages, $I_{Kr}$ channels are expressed at high levels in quail neural crest and are replaced by inward rectifier currents during maturation (30, 122). Also, in mouse embryonic heart, mERG expression levels are high, but downregulated during development (664, 665). Interestingly, ERG protein reappears in tissue that has undergone dedifferentiation (112), and in tissue samples from tumors, KCNH2 transcript and hERG protein expression is usually found to be more frequent than in the noncancerous control tissue (101, 497). These findings correlate well with the fact that most terminally differentiated cells display a membrane potential more negative than $-60 \text{ mV}$, while nondifferentiated cells are usually more depolarized and have a membrane potential in the Kv11.1 window current range (8).

Arcangeli et al. (29) demonstrated that the recorded membrane potentials of unsynchronized mammalian neuroblastoma cells vary considerably from cell to cell, and that these variations correlate well with the cell-to-cell differences in the steady-state activation curves of “KIR” inward rectifier currents. After synchronization of the cells in the G1 phase with retinoic acid, the variation in steady-state activation curves as well as membrane potentials was much less. In the same publication, Arcangeli et al. (29) also first proposed that “KIR channels might be a relevant target in the transformation process” (29). At the time the group had no information about the molecular identity of the channels that carried the $K_{IR}$ current. In a later study, Crociani et al. (123) found that the hERG subunit mix varies at different points in the cell cycle of synchronized cells: the NH2-terminally truncated hERG1b isoform was dominant during the S phase, while hERG1a subunit was dominant during the G1 phase. This result provides a molecular correlate to the apparent differences of biophysical parameters of “KIR” at different phases of the cell cycle.

2. Evidence for hERG expression in cancer tissue

KCNH2 mRNA has been detected in numerous cancer cell lines (73, 472) (see Table 3). Smith et al. (582) also showed that, in various leukemia cell lines, incubation with E-4031 could reduce the rate of proliferation in these cells. This was the first demonstration of a functional effect of Kv11.1 in a cancer cell line (582).

3. Mechanism of hERG action in cancer

The emerging picture is that Kv11.1 has important implications for the invasiveness of cancers. In human colorectal cancer, Kv11.1 was found to regulate invasion of tumor cells, and Kv11.1 expression was observed more often in

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Cancer Type</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEM</td>
<td>Leukemia</td>
<td>582</td>
</tr>
<tr>
<td>U937</td>
<td>Leukemia</td>
<td>582</td>
</tr>
<tr>
<td>K562</td>
<td>Leukemia</td>
<td>582</td>
</tr>
<tr>
<td>SK-OV-3</td>
<td>Ovarian cancer</td>
<td>41, 42</td>
</tr>
<tr>
<td>SH-SY5Y</td>
<td>Human neuroblastoma</td>
<td>29, 73</td>
</tr>
<tr>
<td>N18TG2</td>
<td>Mouse neuroblastoma</td>
<td>29, 73</td>
</tr>
<tr>
<td>NG108-15</td>
<td>Mouse neuroblastoma</td>
<td>29, 73</td>
</tr>
<tr>
<td>TE-671</td>
<td>Human rhabdomyosarcoma</td>
<td>73</td>
</tr>
<tr>
<td>SK-BR-3</td>
<td>Human mammary adenocarcinoma</td>
<td>73</td>
</tr>
<tr>
<td>NCI-N592</td>
<td>Human lung microcytoma</td>
<td>73</td>
</tr>
<tr>
<td>FLG29</td>
<td>Human monoblastic leukemia</td>
<td>73</td>
</tr>
<tr>
<td>SK-N-BE</td>
<td>Human neuroblastoma</td>
<td>73</td>
</tr>
<tr>
<td>41A3</td>
<td>Mouse neuroblastoma</td>
<td>73</td>
</tr>
<tr>
<td>F11</td>
<td>Rat DRG x mouse N18TG2 neuroblastoma</td>
<td>73</td>
</tr>
<tr>
<td>NG108-15</td>
<td>Mouse-rat neuroblastoma x glioma</td>
<td>73</td>
</tr>
<tr>
<td>PC12</td>
<td>Rat pheochromocytoma</td>
<td>73</td>
</tr>
<tr>
<td>GLC8, H69</td>
<td>Small cell lung cancer</td>
<td>73</td>
</tr>
<tr>
<td>GH3, GH4, MMQ</td>
<td>Pituitary tumor</td>
<td>73</td>
</tr>
<tr>
<td>RIN, INS-1</td>
<td>Pancreatic beta-cell tumor</td>
<td>73</td>
</tr>
<tr>
<td>MCF-7</td>
<td>Human breast cancer</td>
<td>472</td>
</tr>
<tr>
<td>EF119</td>
<td>Breast cancer</td>
<td>472</td>
</tr>
</tbody>
</table>
metastatic cancers with a bad prognosis than in less aggressive cancers (354). This trend was also observed in human leukemia cases, in which patients with Kv11.1 positive tumors had a higher mortality and higher likelihood of relapse than patients with Kv11.1 negative tumors (498). It appears that interaction of Kv11.1 with integrins is an important factor in this phenomenon. Hofmann et al. (264) showed that in the leukemic osteoclastic cell line FLG29.1, fibronectin can transiently increase Kv11.1 current density and alter membrane potential via integrin action. Both mRNA and membrane protein levels appeared to be unchanged, so most likely a posttranslational mechanism was involved in the Kv11.1 current increase. Interestingly, the Kv11.1 activation in turn led to an increased expression of $\alpha_6\beta_3$ integrins, indicating that Kv11.1 is involved both in outside-in and inside-out signaling in these cells. The addition of G protein inhibitor pertussis toxin prevented both the current density increase and the upregulation of $\alpha_6\beta_3$ integrins. Later work added further evidence for the interaction of Kv11.1 channels with the $\beta_1$ subunit of the integrin receptor in leukemia and neuroblastoma cells, and that this complex could influence downstream signaling targets such as tyrosine kinases and GTPases (28, 100). Cherubini et al. (100) showed that $\beta 1$ integrin and Kv11.1 colocalize in close proximity to caveolin-1, indicating an involvement of lipid rafts/caveolae. They also showed that the focal adhesion kinase (FAK) associates with Kv11.1 and becomes tyrosine phosphorylated after exposure of the cell to fibronectin (100), an effect that could be blocked with Kv11.1 blockers. In a model of Kv11.1-transfected HEK-293 cells, cell migration after seeding on fibronectin was clearly impaired in mock-transfected cells compared with Kv11.1 transfected cells (100).

Currently the most plausible hypothesis for how Kv11.1 channels activate integrins is that Kv11.1 channels and integrins are conformationally coupled, i.e., gating transitions of the Kv11.1 protein could be directly transmitted to integrins in close proximity. While there are no data available that would support this hypothesis at present, in EAG channels there is evidence for ion-channel signaling that does not involve ion flux across the membrane, such as in fibroblasts and myoblasts where overexpression of EAG has a proliferative effect. This effect persists even when the nonconducting EAG mutant F456A is expressed instead of wild-type channels. Hegle et al. (253) were able to demonstrate involvement of p38 MAP kinase in this proliferative signaling. Furthermore, they showed that the conformational state of the EAG channels is important for signaling, since mutants with increased open-state occupancy inhibited proliferation (253). Another piece of evidence comes from work on melanoma cells. In these cells, block of Kv11.1 channels with E-4031 or cisapride disrupted proliferation and cell migration as does Kv11.1 knockdown with siRNA. Similar to the previous experiments, the signaling appears to go via mitogen-activated protein (MAP) kinase and expression of $c$-fos transcription factor. Block of Kv11.1 reduced MAP kinase phosphorylation and reduced $c$-fos levels (5).

Solid tumors are often characterized by a lack of oxygen, because growth of the cancerous tissue outpaces development of new vasculature. Kv11.1 channels might play a role here as well. First, it has been shown that Kv11.1 channel gating can be modulated by hypoxic conditions (185). The authors of this study speculated that the Kv11.1 PAS domain could be involved in sensing hypoxic conditions, but to date, no experimental evidence for this has been found. Second, in glioblastoma multiforme, Kv11.1 channels are overexpressed and modulate VEGF secretion, which is critical for angiogenesis (400).

4. hERG as a potential treatment target in cancer

Given its frequent expression and functional relevance in cancerous tissue, Kv11.1 appears to be a possible target for anticancer drugs. The antihistamine and known Kv11.1 blocker astemizole has been suggested as a possible candidate (199). This drug is particularly interesting, because it has been used in humans before, and it has two distinct properties that make it a good candidate: histamine favors proliferation of normal and cancerous cells, and astemizole is a strong Kv11.1 blocker. Both attributes combined have been shown to be antiproliferative both in vitro and in vivo (199). The use of Kv11.1 blockers in combating cancer is a novel and promising concept. Another example in this regard is the use of arsenic trioxide, which has been shown to induce apoptosis in MCF-7 cells via inhibition of Kv11.1 and activation of caspase-3 (675).

XI. CONCLUSIONS

In the first 12 months after Kv11.1 channels were identified there was some initial confusion as to how Kv11.1 channels gated. Were they inward rectifiers, canonical voltage-gated $K^+$ channels, or a hybrid of the two? It turns out that they are classical voltage-gated $K^+$ channels, but they have “upside-down” kinetics. The consequence of these unusual kinetic properties is that these channels are ideal for determining the repolarization duration of the cardiac action potential. The underlying basis of the unusual kinetic properties of Kv11.1 channels continues to fascinate physiologists. Conventional patch-clamp techniques, gating current measurements, voltage-clamp fluorometry, and phi-value analysis have all contributed to reveal significant insights into the molecular basis of gating of Kv11.1 channels. The next challenge will be to determine the structural basis of gating by combining high-resolution structural biology methods with electrophysiology studies. In the clinical sphere, Kv11.1 channels are also a topic of immense interest, as mutations in KCNH2 are one of the most common causes of congenital long QT syndrome. Most KCNH2 mutations
result in defective trafficking of the mutant channels. Consequently, there are considerable efforts underway to try and unravel the molecular basis of normal assembly and trafficking of these channels with the hope that one day it will be possible to restore trafficking in mutant channels. Perhaps the area of greatest interest is in the area of pharmacology. Kv11.1 channels are the most dreaded of “anti-targets,” and trying to predict the affinity with which drugs will bind to these channels continues to exercise the minds of pharmaceutical chemists everywhere. Hopefully, structural biology, and in particular X-ray crystallography, will open up the analysis of the structural basis of drug binding to Kv11.1 channels. However, the picture that is emerging is that drug binding to Kv11.1 is likely to be a highly dynamic process with multiple drug and channel conformations contributing to binding for any given drug. It is likely that the development of accurate computer models of drug binding kinetics combined with structural studies will be needed to fully understand and ultimately overcome this complex safety-pharmacology problem.

ACKNOWLEDGMENTS

Address for reprint requests and other correspondence: J. I. Vandenberg, Molecular Cardiology and Biophysics Division, Victor Chang Cardiac Research Institute, 405 Liverpool St., Darlinghurst, NSW 2010, Australia (e-mail: j.vandenberg@victorchang.edu.au).

GRANTS

J. I. Vandenberg is supported by a Senior Research Fellowship from the National Health and Medical Research Council (NHMRC; 459401, 1019693). A. P. Hill is supported by a Future Fellowship from the Australian Research Council (ARC; FT110100075). Work in the authors’ laboratory is supported by project grant funding from the NHMRC, ARC, National Heart Foundation of Australia, and the St. Vincent’s Clinic Foundation.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

REFERENCES


232. Gustina AS, Trudeau MC. A recombinant N-terminal domain fully restores deactiva-
tional guinea pig heart.

tional guinea pig heart.

234. Hackos DH, Chang TH, Swartz KJ. Scanning the intracellular S6 activation gate in the

235. Hackos DH, Chang TH, Swartz KJ. Scanning the intracellular S6 activation gate in the

236. Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and

237. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, Grunnet M. hERG potassium channel and

238. Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and

239. Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical

240. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, Grunnet M. hERG potassium channel and

241. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, Grunnet M. hERG potassium channel and

242. Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical

243. Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical

244. Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical

245. Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical


hERG K⁺ CHANNELS


hERG K⁺ CHANNELS


